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Abstract 
 
Introduction: Chronic Kidney Disease (CKD) is characterized as a silent epidemic 
and undoubtedly is one of the most severe chronic disease worldwide. It is 
accompanied by several comorbidities such as anemia, cardiovascular diseases, 
atherosclerosis and diabetes, which contribute to the reduced quality of life and to the 
mortality of the patients. Additionally CKD is accompanied by several skeletal 
muscle abnormalities, in part linked to hypokinesis and in part to uremic toxicity. 
Skeletal muscle’s weakness and metabolic imbalance, are components of functional 
and morphological alterations which are collectively termed uremic myopathy. It is 
suggested that oxidative stress heavily contribute to all the above pathologies 
encountered in CKD. Although the progression of CKD is associated with the harmful 
effects of oxidative stress, its role has not yet been fully clarified during pre-dialysis 
stages of the disease. 
Aims: The aim of this study, using an animal model of CKD, was to evaluate the 
systemic effects of CKD in redox status indices as reflected in blood levels (Research 
Paper 1). Moreover, the study evaluated the skeletal muscle specific effects of uremia 
on muscle redox status. Specifically two different types of skeletal muscle, the fast 
psoas and the slow soleus were analyzed (Research Paper 2). Also, the biochemical 
and hematological parameters in our early CKD model and its possible association 
with oxidative stress levels were evaluated (Research Paper 3). Last but not least it 
was examined whether the oxidative stress markers measured in blood adequately 
reflected redox status in skeletal muscle and whether redox status evaluated in psoas 
muscle reflected the redox status in soleus. (Research Paper 4).  
Methods: We used an animal model (partial nephrectomy) of renal disease in New 
Zealand white female rabbits. Surgery and euthanasia (after 3 months) protocols were 
approved by the ethic committee of the University of Thessaly. Renal insufficiency 
was induced by removal of the right kidney and partial nephrectomy of the left kidney 
(Uremic group, N=9). Control animals underwent sham operation (Control group, 
N=6). From both groups, blood and skeletal muscle (psoas, soleus) samples were 
collected and analysed for the Reduced Glutathione (GSH), Oxidized Glutathione 
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(GSSG), GSH/GSSG Ratio, Total Antioxidant Capacity (TAC), Thiobarbituric Acid 
Reactive Substances (TBARS) and Protein Carbonyls (PC) levels and for GR-
Reductase and Catalase (CAT) activities. Blood samples were also analyzed for the 
biochemical (lipid profile) indices Total Cholesterol, High-Density Lipoprotein 
(HDL), Low-Density Lipoprotein (LDL), Triglycerides, Triglycerides/HDL Ratio 
Glucose and Bilirubin and for the hematological parameters leukocytes, red blood 
cells (RBC), hemoglobin (Hb), hematocrit (Hct), Mean Corpuscular Volume (MCV) 
and Mean Corpuscular Hemoglobin (MCH). Urea, creatinine, and plasma total protein 
levels were also evaluated. 
Results: (Research Paper 1) GSH concentration was significantly higher in the 
Uremic group (17.50 ± 1.73 μmol/g protein) compared to Control (12.43 ± 1.01 
μmol/g protein), p=0.033. TBARS concentration tended to be higher in the Uremic 
group (7.03 ± 0.81 nmol/ml), compared to Control (5.12 ± 0.42 nmol/ml), p=0.060. 
No significant differences were found in the rest of redox status indices evaluated in 
blood of Control and Uremic groups (p>0.05). 
(Research Paper 2) Significant group main effects were found for PC in both muscle 
types with its concentration to be higher in the Uremic group (psoas: 1.086 ± 0.294, 
soleus: 2.52 ± 0.29 nmol/mg protein) compared to the Control (psoas: 0.596 ± 0.372, 
soleus: 0.929 ± 0.41nmol/mg protein). Significant muscle main effects were found for 
Total protein, PC, TBARS, GSH, TAC, CAT and GR-Reductase activity in both the 
Control and the Uremic group. Total protein and TAC concentrations were 
significantly lower in soleus compared to psoas muscle in both the Control and the 
Uremic group. Additionally, soleus demonstrated higher levels of TBARS and PC 
levels as well as higher GSH levels, Catalase and GR-Reductase activities compared 
to psoas muscle in both the Control and Uremic group. No interactions were found 
between the two examined muscle types (psoas, soleus) and two groups (Control, 
Uremic) for all the redox status indices (p>0.05).   
(Research Paper 3) We found no significant changes in the blood lipid profile of the 
Uremic group as compared to the Control group (p>0.05). However, the ratio of 
Triglycerides/HDL was 5.67, much higher than the Control group value, at 4.63. 
Moreover, RBC, Hematocrit and MCH were found to be significant decreased in the 
Uremic group (3.92 ± 0.29 × 106/mm3, 26.06 ± 1.85 %, 19.76 ± 0.67 pg/cell) as 
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compared to the Control (5.10 ± 0.17 × 106/mm3, 35.24 ± 0.79 %, 21.64 ± 0.44 
pg/cell), p<0.05, and MCV had a tendency to be lower in the Uremic group (65.40 ± 
1.89 mm3) as compared to the Control group (69.78 ± 1.36 mm3), p=0.087. 
(Research Paper 4) For each one of the redox status indices, statistical analysis didn’t 
show any significant correlation between blood and the two examined muscles’ levels 
neither in the pool of samples nor for each group separately (p>0.05). Regarding the 
correlation analysis between Urea, Creatinine and redox status in blood and skeletal 
muscle, while no relationship reached statistical significance it is noteworthy that in 
the pool data Creatinine levels tended to correlate with blood GSH (r=0.664, 
p=0.073). Likewise, Urea tended to correlate with blood GSH (r=0.655, p=0.078). 
Although in the Control group there was no significant correlation in redox status 
indices between the two different types of skeletal muscle (p>0.05), in the Uremic 
group there was significant correlation between psoas and soleus muscle in PC levels 
(r=0.913, p=0.002), in GSSG levels (r=0.766, p=0.027) levels and in CAT levels 
(r=0.743, p=0.035) respectively. 
Discussion: In the current PhD Thesis an increase in blood GSH levels of the Uremic 
group was found probably as an adaptive response to keep redox homeostasis stable. 
Indeed the tendency for increased lipid peroxidation (TBARS) constitutes an early 
sign of oxidative stress appearance in blood of our model of pre-dialysis stage of 
CKD. This is probably indicative of a premature development of cardiovascular 
problems and atherogenesis in pre dialysis patients (Research Paper 1). In addition 
increased PC levels in both muscle types of the Uremic group were observed. This is 
regarded as a very interesting finding for the time point of protein oxidation since it 
reveals the early emergence of oxidative damage to protein content. Regarding the 
two different types of skeletal muscle, soleus demonstrated higher TBARS levels, 
irrespective of group, consistent to the differences in mitochondrial content, as soleus 
has higher amount thus is more exposed to ROS. However we observed that soleus 
muscle developed an appropriate antioxidant capacity to withstand the oxidative load. 
Despite the reduced TAC levels in soleus muscle in comparison with psoas, the 
increased levels GSH, CAT and GR-reductase indicate that healthy soleus indeed 
demonstrates a higher antioxidant capacity than psoas, with uremic soleus appearing 
to have likewise further up-regulated its defenses (Research Paper 2). Regarding lipid 
profile, perhaps more time was needed for our model to develop disturbances since no 
Institutional Repository - Library & Information Centre - University of Thessaly
30/09/2018 04:54:58 EEST - 137.108.70.6
  
18 
 
changes were found between the two groups. However the tendency for increased 
plasma lipid peroxidation (TBARS) and for a higher Triglycerides/HDL ratio in the 
Uremic group fits well with a progressive atherogenic development due to CKD. On 
the other hand, an impairment in the hematological profile of the Uremic group was 
observed which constitutes early signs of anemia development (Research Paper 3). 
The current study also observed that there is no correspondence between blood and 
skeletal muscle redox status indices in CKD, demonstrating that tissue specific redox 
status changes do not cause corresponding changes that can be measured in blood. It 
is possible that factors like the animal model, the techniques differences and the stage 
of the disease may mask muscle’s contribution to blood levels of redox indices in our 
data. The significant correlations of redox status indices among the two types of 
skeletal muscle that were found only for the Uremic group, indicated that the 
experimentally induced CKD posed an appreciable redox challenge for skeletal 
muscle, whose samples presented with a coordinated variability in redox status levels 
(Research Paper 4). 
Conclusions: In conclusion, the results of this work demonstrate that even in the pre-
dialysis stages of CKD there is an emergence of oxidative stress in blood and as an 
adaptive response the antioxidant defense mechanisms are upregulated in order to 
preserve redox status homeostasis. Moreover in both types of skeletal muscle (psoas, 
soleus) carbonyl formation indicates an early stimulus of muscle protein degradation. 
However both oxidative damage and antioxidant response seem to be muscle type-
specific. Our model of CKD shows that the lipid profile in this stage of the disease 
development does not seem to be disturbed to a great extent. However, an atherogenic 
development cannot be excluded and should be addressed early on. Still, we found a 
severely disturbed hematological profile in experimental animals.  This highlights that 
early recognition of anemia, in pre-dialysis stage, could play a key role it its treatment 
and could probably delay the progression of CKD. Last but not least, it was found that 
blood levels of the redox status indices did not reflect muscle concentrations and more 
work is needed in the direction of less invasive monitoring of muscle related redox 
imbalances.Overall, our results highlight the need for interventions early during 
disease progression in order to protect skeletal muscle quality, maintain redox balance 
and correct anemia, and thus allow patients to reach the end-stage at the best possible 
status. 
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Περίληψη 
 
Εισαγωγή: Η Χρόνια Νεφρική Νόσος (ΧΝΝ) χαρακτηρίζεται ως μία σιωπηλή 
επιδημία και αναμφίβολα αποτελεί μία από τις πιο σοβαρές ασθένειες παγκοσμίως. Η 
ασθένεια συνοδεύεται από παθήσεις, όπως είναι η αναιμία, τα καρδιαγγειακά 
νοσήματα, η αθηροσκλήρωση και ο διαβήτης, οι οποίες συμβάλλουν στην μειωμένη 
ποιότητα ζωής και τη θνησιμότητα των ασθενών. Επιπρόσθετα, η ΧΝΝ συνοδεύεται 
από διάφορες παθήσεις των σκελετικών μυών που εν μέρει αποδίδονται στην 
υποκινητικότητα των ασθενών αλλά και στην ουραιμική τοξικότητα. Η αδυναμία του 
σκελετικού μυός καθώς και οι μεταβολικές διαταραχές του αποτελούν στοιχεία 
λειτουργικών και μεταβολικών αλλοιώσεων τα οποία συγκεντρωτικά ονομάζονται 
ουραιμική μυοπάθεια. Έχει προταθεί ότι το οξειδωτικό στρες συμβάλει σε μεγάλο 
βαθμό σε όλες τις παραπάνω παθολογικές καταστάσεις που εμφανίζονται στη ΧΝΝ. 
Αν και η εξέλιξη της νόσου σχετίζεται με τις επιβλαβείς επιδράσεις του οξειδωτικού 
στρες, ο ρόλος του δεν έχει πλήρως διαλευκανθεί σε προγενέστερα στάδια της νόσου 
πριν το τελικό στάδιο (αιμοκάθαρση). 
 
Σκοπός: Ο σκοπός της μελέτης ήταν να αξιολογήσει τις συστημικές επιδράσεις της 
ΧΝΝ στο οξειδοαναγωγικό προφίλ του αίματος, χρησιμοποιώντας ένα ζωικό μοντέλο 
προ-τελικού σταδίου ΧΝΝ (Μελέτη 1). Επίσης, στόχος ήταν να αξιολογηθεί η 
επίδραση της ΧΝΝ στο οξειδοαναγωγικό προφίλ του σκελετικού μυός. Συγκεκριμένα 
εξετάστηκαν δύο διαφορετικοί τύποι σκελετικού μυός, ο ψοΐτης (ταχείας συστολής) 
και ο υποκνημίδιος (βραδείας συστολής) (Μελέτη 2). Η μελέτη επίσης αξιολόγησε το 
βιοχημικό και αιματολογικό προφίλ του ζωικού μοντέλου και εξετάστηκε η πιθανή 
συσχέτιση τους με το οξειδωτικό στρες (Μελέτη 3). Τέλος, εξετάστηκε κατά πόσο οι 
δείκτες οξειδωτικού στρες που αξιολογήθηκαν στο αίμα αντικατοπτρίζουν επαρκώς 
την οξειδοαναγωγική κατάσταση στο μυ και αν η οξειδοαναγωγική κατάσταση που 
μετρήθηκε στον ψοΐτη μυ αντανακλά την οξειδοαναγωγική κατάσταση του 
υποκνημιδίου (Μελέτη 4). 
 
Μεθοδολογία: Χρησιμοποιήθηκε ένα ζωικό μοντέλο ΧΝΝ και συγκεκριμένα λευκοί 
θηλυκοί κόνικλοι Νέας Ζηλανδίας. Τα πρωτόκολλα της εγχείρισης και της 
ευθανασίας (μετά από 3 μήνες) εγκρίθηκαν από την Επιτροπή Βιοηθικής του 
Πανεπιστημίου Θεσσαλίας. Η νεφρική ανεπάρκεια προκλήθηκε με την αφαίρεση του 
Institutional Repository - Library & Information Centre - University of Thessaly
30/09/2018 04:54:58 EEST - 137.108.70.6
  
20 
 
δεξιού νεφρού και την μερική νεφρεκτομή του αριστερού νεφρού (ουραιμική ομάδα 
Ν=9). Η ομάδα ελέγχου υποβλήθηκε σε εικονική εγχείριση (ομάδα ελέγχου, Ν=6). 
Και από τις δύο ομάδες ζώων συλλέχθηκαν δείγματα αίματος  και σκελετικού μυός 
(ψοΐτης, υποκνημίδιος) και προσδιορίστηκαν οι συγκεντρώσεις της Ανηγμένης 
Γλουταθειόνης (GSH), της Οξειδωμένης Γλουταθειόνης (GSSG), του λόγου  
GSH/GSSG, της Ολικής Αντιοξειδωτικής Ικανότητας (TAC), των Ουσίων που 
αντιδρούν με Θειοβαρβιτουρικό Οξύ (TBARS), των Πρωτεϊνικών Καρβονύλίων  
(PC) καθώς και οι δραστικότητες της Ρεδουκτάσης της γλουταθειόνης (GR –
Reductase) και της Καταλάσης (CAT). Στα δείγματα του αίματος προσδιορίστηκαν 
επίσης οι συγκεντρώσεις των βιοχημικών δεικτών όπως η Ολική Χοληστερόλη, η 
Υψηλής-Πυκνότητας Λιποπρωτεΐνη (HDL), η Χαμηλής-Πυκνότητας Λιποπρωτεΐνη 
(LDL), τα Τριγλυκερίδια, ο λόγος Τριγλυκερίδια/HDL, η Γλυκόζη και η 
Χολερυθρίνη καθώς και τα επίπεδα των αιματολογικών παραμέτρων όπως τα 
Λευκοκύτταρα, τα Ερυθρά αιμοσφαίρια (RBC), η Αιμοσφαιρίνη (Hb), ο 
Αιματοκρίτης (Hb), ο Μέσος όγκος ερυθρών (MCV) και η Μέση περιεκτικότητα 
αιμοσφαιρίνης (MCH). Μετρήθηκαν επίσης η Ουρία, η Κρεατινίνη και η Ολική 
πρωτεΐνη πλάσματος. 
 
Αποτελέσματα: (Μελέτη 1) Η συγκέντρωση της GSH βρέθηκε σημαντικά 
υψηλότερη στην ουραιμική ομάδα (17.50 ± 1.73 μmol/g protein) σε σχέση με την 
ομάδα ελέγχου (12.43 ± 1.01 μmol/g protein), p=0.033. Η συγκέντρωση των TBARS 
παρουσίασε μία τάση για αύξηση στην ουραιμική ομάδα (7.03 ± 0.81 nmol/ml), σε 
σχέση με την ομάδα ελέγχου (5.12 ± 0.42 nmol/ml), p=0.060. Δεν βρέθηκαν άλλες 
σημαντικές διαφορές στους υπόλοιπους δείκτες οξειδωτικού στρες που μετρήθηκαν 
στο αίμα των δύο ομάδων (p>0.05). 
(Μελέτη 2) Σημαντική επίδραση της ομάδας παρατηρήθηκε για τα PC και στους δύο 
μύες με την συγκέντρωσή τους να είναι υψηλότερη στην ουραιμική ομάδα (ψοΐτης: 
1.086 ± 0.294, υποκνημίδιος: 2.52 ± 0.29 nmol/mg protein) σε σχέση με την ομάδα 
ελέγχου (ψοΐτης: 0.596 ± 0.372, υποκνημίδιος: 0.929 ± 0.41nmol/mg protein). 
Σημαντική επίδραση του μυός παρατηρήθηκε για τις συγκεντρώσεις των Total 
protein, PC, TBARS, GSH, TAC, και της δραστικότητες των CAT και GR-Reductase 
και στις δύο ομάδες με τα επίπεδά τους να είναι υψηλότερα στην ουραιμική ομάδα 
(ψοΐτης: 1.086 ± 0.294, υποκνημίδιος: 2.52 ± 0.29 nmol/mg protein) σε σχέση με την 
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ομάδα ελέγχου (ψοΐτης: 0.596 ± 0.372, υποκνημίδιος: 0.929 ± 0.41nmol/mg protein). 
Η συγκεντρώσεις των Total Protein και TAC ήταν σημαντικά χαμηλότερες στον 
υποκνημίδιο μυ σε σχέση με  τον ψοΐτη και στις δύο ομάδες. Επίσης ο υποκνημίδιος 
παρουσίασε υψηλότερα επίπεδα TBARS και PC όπως επίσης και υψηλότερα επίπεδα 
GSH, Catalase και GR-Reductase σε σχέση με  τον ψοΐτη τόσο στην ουραιμική όσο 
και στην ομάδα ελέγχου. Δεν παρατηρήθηκαν σημαντικές αλληλεπιδράσεις μεταξύ 
των δύο τύπων μυός και των δύο ομάδων για όλους τους δείκτες οξειδωτικού στρες 
(p>0.05).   
(Μελέτη 3) Δεν υπήρξαν σημαντικές αλλαγές στο λιπιδαιμικό προφίλ της ουραιμικής 
ομάδας συγκριτικά με την ομάδα ελέγχου (p>0.05). Ωστόσο ο λόγος 
Τριγλυκερίδια/HDL βρέθηκε 5,67, πολύ υψηλότερος από την τιμή 4 της ομάδας 
Ελέγχου. Επίσης οι συγκεντρώσεις των RBC, Hematocrit και MCH βρέθηκαν 
σημαντικά χαμηλότερες στην ουραιμική ομάδα (3.92 ± 0.29 × 106/mm3, 26.06 ± 1.85 
%, 19.76 ± 0.67 pg/cell) σε σχέση με την ομάδα ελέγχου (5.10 ± 0.17 × 106/mm3, 
35.24 ± 0.79 %, 21.64 ± 0.44 pg/cell), p<0.05, και το MCV παρουσίασε μία τάση για 
μείωση στην ουραιμική ομάδα (65.40 ± 1.89 mm3 ) σε σχέση με την ομάδα ελέγχου 
(69.78 ± 1.36 mm3, p=0.087). 
(Μελέτη 4) Για κάθε έναν από τους δείκτες οξειδωτικού στρες που αξιολογήθηκε, η 
στατιστική ανάλυση δεν έδειξε καμία σημαντική συσχέτιση μεταξύ των επιπέδων του 
στο αίμα και των επιπέδων του στους δύο τύπους μυός τόσο στο σύνολο των 
δεδομένων (pool data) όσο και σε κάθε ομάδα ξεχωριστά (p>0.05). Επίσης, ενώ δεν 
παρατηρήθηκε σημαντική συσχέτιση στα επίπεδα Ουρίας και Κρεατινίνης και των 
δεικτών του οξειοδαναγωγικού προφίλ στο αίμα και στο σκελετικό μυ, αξίζει να 
σημειωθεί ότι στο σύνολο των δεδομένων (pool data), τα επίπεδα της Κρεατινίνης 
παρουσίασαν μία τάση για συσχέτιση με τα επίπεδα της GSH στο αίμα (r=0.655, 
p=0.078). Αν και στην ομάδα ελέγχου δεν υπήρξε σημαντική συσχέτιση των δεικτών 
οξειοδαναγωγικού προφίλ μεταξύ των δύο διαφορετικών τύπων μυός (p>0.05), στην 
ουραιμικη ομάδα παρατηρήθηκε σημαντική συσχέτιση μεταξύ ψοΐτη και 
υποκνημιδίου αναφορικά με τα επίπεδα των PC (r=0.913, p=0.002), της GSSG 
(r=0.766, p=0.027) και της CAT (r=0.743, p=0.035). 
Συζήτηση: Στην παρούσα διδακτορική διατριβή παρατηρήθηκε μία αύξηση στα 
επίπεδα της GSH στο αίμα της ουραιμικής ομάδας κονίκλων, που πιθανότατα 
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αποτελεί έναν προσαρμοστικό μηχανισμό απόκρισης στο οξειδωτικό στρες με σκοπό 
τη διατήρηση της οξειδοαναγωγικής ομοιόστασης. Πράγματι υπήρχε μία τάση για 
αύξηση του δείκτη λιπιδικής υπεροξείδωσης (TΒΑRS) γεγονός που αποτελεί ένα 
πρώιμο σημάδι αυξημένου οξειδωτικού στρες στο αίμα του ουραιμικού μοντέλου. 
Φαίνεται δηλαδή να υπάρχει ή έναρξη της εκδήλωσης ορισμένων αιτιών πρόκλησης 
καρδιαγγειακών προβλημάτων και αθηρογένεσης στους ασθενείς με ΧΝΝ (Μελέτη 
1). Επιπλέον διαπιστώθηκαν αυξημένα επίπεδα των πρωτεϊνικών καρβονυλίων και 
στους δύο τύπους μυϊκού ιστού στην ομάδα των ουραιμικών κουνελιών. Αυτό μπορεί 
να θεωρηθεί ως ένα πολύ ενδιαφέρον εύρημα για τη χρονική στιγμή που λαμβάνει 
χώρα η πρωτεϊνική οξείδωση αφού φανερώνει μία πρώιμη εκδήλωση βλάβης σε 
επίπεδο πρωτεϊνών. Όσον αφορά τους δύο διαφορετικούς τύπους σκελετικού μυός, 
στον υποκνημίδιο διαπιστώθηκαν υψηλότερα επίπεδα TBARS, ανεξαρτήτως της 
ομάδας. Το αποτέλεσμα αυτό οποίο είναι σύμφωνο με το διαφορετικό αριθμό των 
μιτοχονδρίων ανάμεσα στους δύο μύες, με τον υποκνημίδιο να παρουσιάζει 
υψηλότερο αριθμό και συνεπώς να είναι περισσότερο εκτεθειμένος σε ROS. Ωστόσο 
διαπιστώθηκε πως ο υποκνημίδιος μυς ανέπτυξε παράλληλα μία έντονη 
αντιοξειδωτική δραστηριότητα ώστε να αντιμετωπίσει τα αυξημένα επίπεδα του 
οξειδωτικού στρες. Παρόλο που τα επίπεδα TAC ήταν μειωμένα στον υποκνημίδιο μυ 
σε σύγκριση με τον ψοϊτη, τα αυξημένα επίπεδα GSH, CAT and GR-reductase 
υποδεικνύουν πως σε υγιείς συνθήκες ο υποκνημίδιος δύναται να αναπτύξει 
αυξημένη αντιοξειδωτική ικανότητα σε σύγκριση με τον ψοϊτη και σε συνθήκες 
ουραιμίας αυτή η ικανότητα αυξάνεται ακόμη περισσότερο (Μελέτη 2). Σχετικά με το 
λιπιδαιμικό προφίλ, πιθανόν να απαιτούνταν περισσότερος χρόνος για ουραιμικό 
μοντέλο ώστε να αναπτυχθούν διαταραχές αφού καμία διαφορά δεν βρέθηκε ανάμεσα 
στις ομάδες. Ωστόσο, η τάση που παρατηρήθηκε για αυξημένη λιπιδική 
υπεροξείδωση (TBARS) στο πλάσμα και η υψηλότερη τιμή του λόγου 
Τριγλυκερίδια/HDL στην ουραιμική ομάδα αποτελούν ένα σημάδι εμφάνισης 
προβλημάτων αθηρογένεσης εξαιτίας της ασθένειας. Αναφορικά με το αιματολογικό 
προφίλ της ουραιμικής ομάδας, παρατηρήθηκε μια σημαντική διαταραχή σε σχέση με 
την ομάδα ελέγχου γεγονός που αποτελεί πρώιμο σημάδι εμφάνισης της αναιμίας 
(Μελέτη 3). Στην παρούσα μελέτη παρατηρήθηκε επίσης ότι στο μοντέλο της ΧΝΝ 
δεν υπήρξε συσχέτιση μεταξύ των οξειδοαναγωγικών δεικτών που μετρήθηκαν στο 
αίμα με αυτούς που μετρήθηκαν στους δύο τύπους μυός, αποδεικνύοντας οι 
οξειδοαναγωγικές αλλαγές που συντελούνται στο μυ, δεν αντανακλώνται στις 
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αντίστοιχες μετρήσεις που διεξάγονται στο αίμα. Παράγοντες όπως, το ζωικό 
μοντέλο, οι διαφορές μεταξύ των τεχνικών μέτρησης των δεικτών και το στάδιο της 
ασθένειας είναι πιθανόν να κάλυψαν τη συμβολή του μυός στα επίπεδα οξειδωτικού 
στρες στο αίμα. Οι σημαντικές συσχετίσεις που παρατηρήθηκαν μόνο στην ουραιμική 
ομάδα σχετικά με τα επίπεδα των δεικτών οξειδοαναγωγικού στρες μεταξύ των δύο 
διαφορετικών τύπων μυός, υποδεικνύουν ότι η πειραματικά προκαλούμενη νεφρική 
ανεπάρκεια αποτελεί μία αξιόλογη πρόκληση για τη μελέτη του οξειδοαναγωγικού 
προφίλ του σκελετικού μυός, του οποίου τα δείγματα παρουσιάζουν μία 
συντονισμένη μεταβλητότητα στα επίπεδα οξειδοαναγωγικής κατάστασης. 
Συμπεράσματα: Τα ευρήματα της παρούσας μελέτης υποδηλώνουν ότι ακόμη και 
στα μη τελικά στάδια (αιμοδιάλυση) της ΧΝΝ το οξειδωτικό στρες εμφανίζεται στο 
αίμα και σαν απόκριση προσαρμογής η αντιοξειδωτική άμυνα αυξάνεται με σκοπό να 
διατηρήσει σταθερή την οξειδοαναγωγική ομοιόσταση. Επίσης, και στους δύο τύπους 
μυός (ψοϊτη, υποκνημίδιο) ο σχηματισμός πρωτεϊνικών καρβονυλίων υποδεικνύει ένα 
πρώιμο ερέθισμα αποσύνθεσης των μυϊκών πρωτεϊνών. Ωστόσο, τόσο η οξειδωτική 
βλάβη όσο και η αντιοξειδωτική απόκριση φαίνεται να εξαρτώνται από τον τύπο του 
μυός. Επίσης, στο λιπιδαιμικό του προφίλ του μοντέλου ΧΝΝ φάνηκε ότι δεν 
υπήρξαν σημαντικές διαταραχές σε αυτό το στάδιο της ασθένειας. Δεν μπορεί 
ωστόσο, να αποκλειστεί εντελώς η πρώιμη εμφάνιση αιτιών αθηρογένεσης η οποία 
και πρέπει να αντιμετωπιστεί από νωρίς. Ακόμη, βρέθηκε σημαντική διαταραχή στο 
αιματολογικό προφίλ του μοντέλου, υποδηλώνοντας ότι η έγκαιρη αναγνώριση της 
αναιμίας σε μη τελικό στάδιο, μπορεί να παίξει πολύ σημαντικό ρόλο στην θεραπεία 
της και στην πρόοδο της ασθένειας. Τέλος, όπως διαπιστώθηκε, τα επίπεδα των 
οξειδοαναγωγικών δεικτών στο αίμα δεν αντικατοπτρίζουν την εικόνα της 
οξειδοαναγωγικής κατάστασης μέσα στο μυ και για το λόγο αυτό χρειάζεται 
περισσότερη μελέτη στην κατεύθυνση της λιγότερο επεμβατικής παρακολούθησης 
των οξειδοαναγωγικών ανισορροπιών τους μυός.  
Συνολικά, τα αποτελέσματα υπογραμμίζουν την ανάγκη για έγκαιρες παρεμβάσεις, 
στα πρώιμα στάδια της νόσου με σκοπό την προστασία της ακεραιότητας των 
σκελετικών μυών, τη διατήρηση της οξειδοαναγωγικής ισορροπίας και την διόρθωση 
της αναιμίας, επιτρέποντας στους ασθενείς να φτάσουν στο τελικό στάδιο της νόσου 
σε όσο το δυνατόν καλύτερη κατάσταση. 
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Chronic kidney disease (CKD) is described as a complex state, where the 
kidney progressively loses its function and during this pathological condition a variety 
of metabolic abnormalities occurs, influencing several organs of the human body 
(Kovesdy & Kalantar-Zadeh, 2009a), including skeletal muscle. When kidney loses a 
significant part of its function, the terms “chronic renal failure” or “chronic kidney 
disease” are used to describe this condition. If less than 10% of kidney function 
remains, then the disease is usually referred to as “end stage renal disease” (ESRD) 
(McCance & Huether, 2002).  
Whether at a pre-dialysis stage or at the end-stage, as the disease progresses, 
CKD patients experience symptoms of muscle weakness, early fatigue, exercise 
intolerance, and present with signs such as muscle atrophy, metabolic dysregulation, 
insuline resistance, fat infiltration, all linked to the disturbance of skeletal muscle 
quantity and quality, collectively termed ‘uremic myopathy’ (Campistol, 
2002)Several interventions, including while helpful, can’t fully remedy the 
pathological phenotype. Muscle loss and weakness contribute to the high morbidity 
and mortality of these patients, especially at the end-stage of the disease. Complex 
mechanisms that stimulate muscle dysfunction in CDK have been proposed and 
oxidative stress could clearly be implicated given that skeletal muscle itself 
contributes notably in redox balance (Powers, Ji, Kavazis, & Jackson, 2011). Recent 
data have revealed that 2.6 million people receive dialysis treatment all over the world 
and by 2030 around 5.4 million people are expected to receive renal replacement 
therapy. Taking these numbers into consideration, it can be easily recognized that 
CKD has become a global public health problem (García-García & Jha, 2015). 
In recent years, only in the United States, the annual cost for patients suffering 
from end-stage renal disease (ESRD), has reached $40 billion. Regarding the patients 
receiving dialysis therapy, the annual cost is three time higher than the expenditures 
for the patients who have received kidney transplantation ("Kidney and Urologic 
Diseases Statistics for the United States," 2010). In the last 30 years a large increase 
in the number of deaths due to ESRD has been also noticed, from 10,478 in 1980 to 
90,118 in 2009. In parallel, not so precisely ascertained but present nevertheless is the 
cost that the disease impacts on life enjoyment and mental health. Such patients 
experience an extremely low Quality of Life linked to low physical activity levels and 
the severe comorbidities of CKD (such as cardiovascular disease, diabetes and other) 
(Ayus, Frommer, & Young, 1981; Sakkas, Ball, et al., 2003). 
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As far as patients’ life expectancy is concerned, the 5-year survival rate for 
transplant patients is 85.5%, while the same rate for dialysis patients is almost the 
half, 35.8% ("Kidney and Urologic Diseases Statistics for the United States," 2010). 
Many factors are implicated in the high mortality of these patients, with CVD being 
the leading cause of death (Gosmanova & Le, 2011). 
There is strong evidence suggesting that CKD is accompanied by an enhanced 
state of oxidative stress, which in turn is associated with higher risk of developing 
cardiovascular disease (CVD), morbidity and mortality (Bayes, Pastor, Bonal, 
Foraster, & Romero, 2006). The presence of oxidative stress in CKD patients is 
manifested by increases in the levels of several oxidative damage markers and by a 
parallel reduction in their antioxidant defense capacity (Stenvinkel & Barany, 2002; 
Terawaki et al., 2004). This state of redox imbalance is linked to additional 
pathological complications that CKD patients present with, such as malnutrition, 
anemia, and cardiovascular disease including atherosclerosis (Grune, Sommerburg, & 
Siems, 2000; Macdougall & Cooper, 2002; Stenvinkel & Barany, 2002). However 
most studies evaluating redox disturbances in CKD patients have been performed in 
blood and have focused on the end-stage (Kaltsatou et al., 2015) leaving unanswered 
questions as to the situation at the level of skeletal muscle, the influence of fiber type 
and the overall development of oxidative stress in pre-dialysis stages. 
Generally, a variety of mechanisms have been implicated in the generation of 
oxidative stress in CKD, such as antioxidant deficiency, chronic inflammation 
(Hensley, Robinson, Gabbita, Salsman, & Floyd, 2000; Zimmermann, Herrlinger, 
Pruy, Metzger, & Wanner, 1999) including advanced glycation mediated disturbances 
of glomerular homeostasis as disease progresses (Yamagishi et al., 2002). In addition, 
for the end-stage patients (ESRD), neutrophil activation during hemodialysis (HD) 
therapy (Grooteman et al., 1997) and dialysis treatment per se contribute to the 
increase of oxidative damage observed in patients with CKD (Miyazaki et al., 2000; 
Morena, Cristol, & Canaud, 2000; Nourooz-Zadeh, 1999). Four main factors have 
been proposed to be responsible for the harmful effects of oxidative stress in patients 
under HD : the uremic milieu, the HD treatment per se, the hemoincompatibility of 
dialysis system and the concomitant drug treatment (Canaud et al., 1999).  
 
In pre-dialysis patients the situation is less studied. One reason is that not only is 
CKD ‘silent’ in its early stages, but also that patients are led to CKD following 
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different paths (some from hypertension, some from glucose intolerance, others from 
nephrotic symptoms, (Yamagata et al., 2007) with oxidative stress not figuring as yet 
as high in the priority for treatment. Moreover, the relatively few animal studies so far 
(McLeland, Cianciolo, Duncan, & Quimby, 2015; Silva et al., 2013; Zhao, Niu, 
Zhang, Hou, & Du, 2009) have been either dealing with acute kidney damage or other 
mechanisms. A chronic animal model, allowing for the development of renal 
insufficiency and maintenance of the animal at a pre-dialysis stage (controlling for 
diet and gender) would be more appropriate to study oxidative stress in chronic renal 
insufficiency independently from confounding factors which plague patient studies. 
Until today most studies examining the redox status in CKD patients focused on 
the end stage of the disease when pathology is already too advanced or irreversible. 
Additionally, few studies have focused on the redox status evaluation of skeletal 
muscle with most focusing on blood. However, it remains unclear when during 
disease progression the redox imbalance manifests itself, and which one of its 
components, defense capacity or ROS overproduction, becomes critical first.  
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2. Aims – Significance 
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The primary aim of the current PhD research thesis was to investigate the effects 
of uremia on biochemical status and oxidative stress tolerance by using an animal 
model of CKD. More specifically the aims of this research were: 
1. To investigate the effects of uremia on blood redox status of uremic rabbits as 
compared with controls (sham-operated) counterparts. 
 
2. To investigate the effects of uremia on muscle redox status in two different 
types of skeletal muscle, (psoas and soleus) of uremic rabbits as compared 
with controls (sham-operated) counterparts. 
 
3. To assess the effects of uremia on biochemical status in both blood and muscle 
(psoas and soleus) of uremic rabbits as compared with controls (sham-
operated) counterparts. 
 
4. To investigate a possible relationship between the changes in blood and 
muscle redox status between the two groups as a result of uremia. 
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3.1 Renal failure and CKD 
 
According to KDIGO 2012 ("KDIGO 2012 clinical practice guideline for the 
evaluation and management of chronic kidney disease,") CKD is defined as the 
manifestation of abnormalities in kidney structure or function, being present for more 
than 3 months and accompanied by several implications in health. CKD is classified, 
according to the Glomerular Filtration Rate (GFR category) or albuminuria levels 
(albuminuria category CGA). The stages of CKD are mainly based on the measured 
or estimated GFR. Five stages of the disease exist, where kidney function is regarded 
as normal in stage 1 and is progressively reduced from stages 2 to 5. 
 
 Stage 1: GFR ≥ 90 ml/min – Normal or high kidney function 
 Stage 2: GFR 60-89 ml/min – Mildly decreased kidney function 
 Stage 3a: GFR 45-59 mol/min – moderately decrease kidney function  
 Stage 3b: GFR 30-44 ml/min – moderate decrease kidney function  
 Stage 4: GFR 15-29 ml/min – severely decrease kidney function  
 Stage 5: GFR < 15 ml/min – kidney failure (requiring kidney transplantation 
or dialysis to maintain life) 
 
CKD is accompanied by uremia, a clinical syndrome which is characterized by 
a multitude of changes in the metabolic, fluid and electrolyte balance of the organism. 
Piorry was the first to use the term uremia in order to describe this complex condition, 
which emerges when kidney function deteriorates (Piorry & l'Heritier, 1840). 
In uremic syndrome, urea and other metabolic waste products are retained in 
blood and tissues, due to kidney dysfunction and its incapability to normally excrete 
them through urine. Metabolic waste products are substances left over from metabolic 
processes (cellular respiration, protein metabolism, etc.) which cannot be used by the 
organism and therefore, they should be excreted. These includes nitrogen compounds, 
like ammonia, urea and uric acid, as well as water, CO2, phosphates, sulfates, etc.  
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Uremia is accompanied by various symptoms such as fatigue, nausea, loss of 
appetite, neurological dysfunction, vomiting, puritis and increased levels of blood 
urea and creatinine. As far as renal failure progress occurs and renal clearance is being 
continuously reduced, several compounds, molecules and solutes tend to accumulate 
in blood and other tissues of the uremic organism. Until today, no single uremic toxin 
has been identified to be responsible for all the clinical manifestations of uremia. A 
variety of toxins such as beta-2-microglobulin, parathyroid hormone (PTH), 
polyamines, advanced glycosylation end products, indoxyl sulfate and other middle 
molecules are thought to play a role in the uremic syndrome (Yavuz et al., 2005) 
More recently the progression of technology helped to the identification of many new 
uremic retention solutes such as adipate, malonate, methylmalonate, α-phenylacetyl-l-
glutamine, 5-hydroxyindole, indoxyl glucuronide, using proteomic and metabonomic 
methods (Aronov et al., 2011; Rhee et al., 2010). Furthermore, there is no specific 
mechanism which causes the uremic milieu, but a multifactorial process takes place 
including retained solutes, imbalance of significant hormones and  metabolic 
disorders (McCance & Huether, 2002). 
 
3.1.1 Blood manifestations of CKD  
 
Several biochemical manifestations take place due to the uremic syndrome and 
the eventual progression of renal failure. Hyperphosphatemia, 
hypokalemia/hyperkalemia (Lowrie & Lew, 1990) and hyperparathyroidism (Ganesh, 
Stack, Levin, Hulbert-Shearon, & Port, 2001) have been observed as adverse 
outcomes in CKD and have been associated with increased morbidity and mortality of 
patients. Anemia is a common characteristic in CKD including a combination of 
factors such as erythropoietin (EPO) deficiency (Besarab & Ayyoub, 2007a), 
deterioration or inhibition of erythropoiesis process, due to the uremic environment (J. 
W. Eschbach, 1989), disturbed iron homeostasis (Babitt & Lin, 2010) and short red 
blood cell life (Vos et al., 2011).  
Another common feature of patients with CKD is protein-energy wasting 
(PEW), which constitutes one of the greatest risk factors associated with negative 
consequences and mortality (Kovesdy & Kalantar-Zadeh, 2009b). This term has been 
established by the International Society of Renal Nutrition and Metabolism (ISRNM) 
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in order to describe the “state of decreased body stores of protein and energy fuels”. 
Protein-energy waste is associated with increased dysfunctionality that emerges from 
metabolic abnormalities (Fouque et al., 2008). An imbalance in a variety of 
biomarkers such as creatinine (Lowrie & Lew, 1990), transferrin (Kalantar-Zadeh et 
al., 1998), serum albumin (Beddhu et al., 2002), prealbumin (Sreedhara et al., 1996) 
cholesterol (Iseki, Yamazato, Tozawa, & Takishita, 2002), and hormones like thyroid 
hormones (Zoccali, Mallamaci, Tripepi, Cutrupi, & Pizzini, 2006), leptin (Scholze, 
Rattensperger, Zidek, & Tepel, 2007), visfatin (Axelsson et al., 2007) and adiponectin 
(Zoccali et al., 2002) has been demonstrated to be responsible for the protein energy 
wasting in CKD. Apart from the above imbalances, insulin resistance is also a 
common feature in patients with CKD, suggesting that disturbance in insulin signaling 
may also play an important role in protein waste (Sakkas, Karatzaferi, et al., 2008). 
It is considered that inflammation strongly affects patients with CKD and 
increased levels of inflammatory and proinflammatory cytokines have been observed 
in plasma, such as IL-1β, IL-6, IL-8 TNF-a, C-reactive protein and serum amyloid A 
(Zhang et al., 2009; Zhang et al., 2011). Two of these increased levels of cytokines, 
IL-1β and TNF-a are not confined only in hemodialyzed patients, but also in pre 
dialysis stage (Pereira et al., 1994). 
 
3.1.2 Skeletal muscle_ Structure and function 
 
Skeletal muscle is one of the most dynamic and plastic tissues in the human 
body, comprising approximately of 40% of total body weight and containing 50-75% 
of all body proteins. Muscle is mainly composed of water (75%), protein (20%) and 
other substances such as minerals, fat, inorganic salts and carbohydrates (5%) and 
contributes to multiple body functions (Frontera & Ochala, 2015).  
The main function of skeletal muscle is to convert chemical energy into 
mechanical energy generating force and power, to maintain posture and to produce 
movement. From a metabolic point of view, skeletal muscle contributes to basal 
energy metabolism, being storage for significant substrates such as carbohydrates and 
amino acids, the production of heat for the maintenance of core temperature, and the 
consumption of oxygen and energy used during physical activity (American College 
of Sports Medicine, 2012; Frontera & Ochala, 2015; Wolfe, 2006). 
Institutional Repository - Library & Information Centre - University of Thessaly
30/09/2018 04:54:58 EEST - 137.108.70.6
  
34 
 
The architecture of skeletal muscle is characterized by an arrangement of 
muscle fibers which are also referred to as myofibers or muscle cells, surrounded by 
connective tissue. The significant variability of biochemical, metabolic and 
mechanical phenotypes of individual skeletal muscle fiber enables muscle to respond 
with flexibility during activities with various metabolic and mechanical demands. 
During the last few decades, muscle fibers have been classified using different 
criteria. The most frequently used classification for adult human limb muscles 
includes the: (1) color of muscle fibers (red vs. white) depending on myoglobin 
content, (2) speed of shortening during a single twitch (fast vs. slow), (3) 
predominance of certain metabolic or enzymatic pathways (oxidative vs. glycolytic), 
(4) degree of fatigability during sustained activation (fatigable vs. fatigue-resistant), 
(5) protein isoform expression such as myosin heavy chain (MCH). Thus, three fiber 
types are commonly referred: type I (slow-twitch, red, oxidative, fatigue-resistant), 
IIA (fast-twitch, red, oxidative, intermediate metabolic properties, fatigue resistant) 
and IIx (fast-twitch, white, glycolytic, fatigable) (Wolfe, 2006). However, it has been 
demonstrated that more than one type of MCH can be expressed simultaneously, for 
example type I and IIA, or IIA and IIx together creating the so-called hybrid fibers 
which have been shown to increase with aging, exercise and under pathological 
conditions (American College of Sports Medicine, 2012; Andersen, 2003).  
 
3.1.3 Skeletal muscle related manifestations in CDK 
 
It has been reported that uremic myopathy is common with an overall 
prevalence of 50 % in dialysis patients (Clyne, 1996), usually appears when GFR is 
under 25ml/min and its progression parallels the decline of renal function (Campistol, 
2002) 
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Figure 3.1. The multifactorial nature of uremic myopathy. Many specific disease-related but also 
lifestyle factors contribute to the pathological muscle state (Figure appearing in  (Kaltsatou et al., 2015). 
 
Although the pathogenesis of uremic myopathy has not been yet clarified, 
uremic toxicity and hypokinesis seem to play a key role for these muscle 
abnormalities in patients with CKD and especially in ESRD patients undergoing 
hemodialysis (HD) therapy. A significant correlation between GFR and exercise 
tolerance has been observed, revealing the low activity and functionality of CKD 
patients (Clyne, Jogestrand, Lins, & Pehrsson, 1994; Clyne, Jogestrand, Lins, 
Pehrsson, & Ekelund, 1987). A variety of interventions, such as exercise has been 
introduced in order to treat or stop muscle deterioration in pre-dialysis (Clyne, 
Ekholm, Jogestrand, Lins, & Pehrsson, 1991) and dialysis patients (Johansen et al., 
2006; Sakkas, Sargeant, et al., 2003). Despite the evident improvement in exercise 
capacity and muscle morphology (Sakkas, Hadjigeorgiou, et al., 2008; Sakkas, 
Sargeant, et al., 2003), in increasing muscle mass with steroid supplements (Topp et 
al., 2003), in improving sleep and overall quality of life (Sakkas, Karatzaferi, et al., 
2008), none of the interventions can restore muscle functionality in ESRD patients to 
the level of age-matched healthy sedentary individuals (Sakkas, Hadjigeorgiou, et al., 
2008; Sakkas, Sargeant, et al., 2003). Furthermore morphological abnormalities have 
been noticed in locomotory as well as in non-locomotory muscles of CKD patients 
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(Sakkas, Ball, et al., 2003), leading to the conclusion that not all of the dysfunction 
can be attributed to hypokinesis. 
Apart from the compromised or accelerated muscle waste, the decreased ability 
to anabolize muscle could also be an issue in CKD. Interventions with nandrolone 
decanoate has positive effects on increasing muscle mass but no improvement in 
muscle strength was observed (Topp et al., 2003). In the study of Zhang et al (Zhang, 
Wang, Wang, Du, & Mitch, 2010) a delayed regeneration of damaged muscle and 
reductions in MyoD protein was observed in a mouse model of CKD, indicating a 
decreased satellite cell proliferation and differentiation. 
As it is mentioned above, CKD patients are characterized by muscle loss and 
weakness. It has been also demonstrated that this waste of muscle strength is a factor 
for easy fatigability in these patients and can be associated with loss of muscle fibers 
and atrophy of the remaining fibers (Sakkas, Ball, et al., 2003),(Porter, Vandervoort, 
& Lexell, 1995). Abnormal mitochondrial respiratory capacity and disturbed 
mitochondrial morphology can also be referred as additional factors for premature 
fatigue in CKD patients (Kouidi et al., 1998).  
 
3.1.4 Oxidative stress  
 
The majority of molecular species maintain the electrons in their outer orbital, 
arranged in pairs, which is fundamental for their stability and function. A free radical 
is defined as an atom or molecule that contains one or more single unpaired electron 
in the outer orbital. This structure of unpaired electron makes the radical unstable and 
highly reactive, thus it reacts with other molecules in order to pair this electron and 
become stable (Guetens, De Boeck, Highley, van Oosterom, & de Bruijn, 2002). In 
1954, Commoner et al first reported that biological material produces free radicals 
(Commoner, Townsend, & Pake, 1954). 
Free radicals can be generated in cells during several reactions, by losing or 
gaining a single electron. The general term reactive oxygen species (ROS) includes 
not only the oxygen-centered radicals but also the non-radicals derivatives of oxygen 
such as hydrogen peroxide. Apart from ROS, the term reactive nitrogen species 
(RNS) also exists, referring to nitrogen centered radicals (Halliwell & Gutteridge, 
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2007). ROS arise from numerous endogenous and exogenous sources (Ray et al., 
2001).  
Endogenous sources of ROS: In vivo, most ROS are generated during aerobic 
respiration as by-products of incomplete reduction of oxygen in mitochondria electron 
transport chain. ROS are also produced during the metabolism of xenobiotic 
compounds, the stimulation of phagocytosis by pathogens and during numerous 
enzymatic reactions (Nicholls & Budd, 2000). 
Exogenous sources of ROS: ROS are also produced from a variety of lifestyle 
factors such as toxin and pollution exposure, radiation and electromagnetic fields, 
cigarette smoke, medication, anxiety, excessive exercise, dietary restrictions and 
saturated fats and various diseases (Cadenas & Davies, 2000). The most common 
ROS and RNS are: 
 
 Superoxide anion (O2
•-
): is a main negatively charged free radical, which is 
generated as an intermediate during biochemical reactions (Halliwell, 1995), and is 
relatively impermeable to cell membranes. However, when superoxide is being 
protonated, it is converted to hydroperoxyl radical (HO2
•
) which can permeate cell 
membranes (Salvador, Sousa, & Pinto, 2001). Moreover superoxide can be 
produced by inflammatory cells in order to protect against invading pathological 
organisms (Fuchs, 1992). 
 Hydroxyl radical (OH
•
) is highly reactive and is regarded as the most harmful free 
radical in the biological material. It is short-lived and non cell membrane 
permeable (Halliwell, 1995). 
 Hydrogen peroxide (H2O2) is a stable and non-radical ROS that can generate free 
radicals such as hydroxyl radical (OH
•
) through specific reactions (Fenton 
reaction). Hydrogen peroxide is permeable to cell membranes, is not capable of 
oxidizing lipids and proteins directly but can inactivate several enzymes (Halliwell 
& Gutteridge, 2007).  
 Singlet oxygen (O2
•
) is not a radical, as it does not contain unpaired electron but is 
highly reactive, short-lived and permeable to cell membranes (Halliwell & 
Gutteridge, 2007).  
 Nitric oxide (NO) is a free radical and one of the numerous oxides of nitrogen. 
When exposed to oxygen, NO is converted into nitrogen dioxide with in turn reacts 
with superoxide to produce peroxynitrite (Halliwell, 1994). 
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 Peroxynitrite (ONOO
-
) is not a radical but is highly reactive. Despite its short half-
life, peroxynitrite can permeate cell membranes and thus constitute a strong 
damaging agent of molecules, including proteins, DNA and thiol groups (Marla, 
Lee, & Groves, 1997).  
 
ROS in relatively low levels play a key role in the regulation of several 
biological and physiological processes including the regulation of cell signaling 
pathways, the control of gene expression (Droge, 2002; Finkel, 2011) as well as the 
modulation of skeletal muscle force production (Reid, 2001b, 2008) and catalytic 
oxidation of some endogenous compounds and xenobiotics. In high levels, ROS can 
damage cellular components and molecules such as proteins, lipids and DNA by 
altering its structure and function (J. M. Roberts & Hubel, 2004), thus the 
maintenance of cellular redox balance is of high importance. For this reason cells 
contain a variety of antioxidant defense mechanisms to provide protection against the 
damaging role of the excessive ROS production and activity. 
 In 1985, Sies and Cadenas introduced the term “oxidative stress” as a 
“disturbance in the pro-oxidant and antioxidant balance in favor of the former (Sies & 
Cadenas, 1985). As it was referred above, cells contain antioxidant defense 
mechanisms which consist of enzymatic and non-enzymatic antioxidants working 
synergistically to scavenge ROS. The major enzymes that convert ROS to less 
reactive molecules are superoxide dismutase, catalase and glutathione peroxidase 
(Zhu, Zhang, Amin, & Li, 2008). 
Superoxide dismutase (SOD): SOD dismutates superoxide radicals to form hydrogen 
peroxide and oxygen. There are three isoforms of superoxide, one of them is located 
in the extracellular space and the other two are found in the intracellular space, 
cytosol and mitochondria (Suzuki et al., 2000). 
Catalase (CAT): Catalase is a homotetrameric heme-containing enzyme which 
catalyzes the breakdown of H2O2 to H2O and O2 (Kirkman & Gaetani, 2007). It is 
located in peroxisomes but in some cell types it can also be found in cytosol and 
nucleus (Legakis et al., 2002; Yamamoto, Volkl, & Fahimi, 1992).  
Glutathione peroxidase (GPx): Glutathione peroxidase catalyzes the reduction of 
H2O2 or hydroperoxide (ROOH) to H2O and alcohol (ROH), using reduced 
glutathione (GSH) (Bjornstedt, Kumar, Bjorkhem, Spyrou, & Holmgren, 1997). Three 
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isoforms of GPx exist and are localized in cytosol and mitochondria (Brigelius-Flohe, 
1999). 
Some of the main non-enzymatic antioxidants are glutathione (GSH), uric acid 
bilirubin, and coenzyme Q10. 
Reduced Glutathione (GSH):Glutathione is the most abundant non-protein thiol which 
is synthesized in liver and transported to tissues via the bloodstream (Meister & 
Anderson, 1983). GSH acts as an ROS scavenger donating its hydrogen atom (Yu, 
1994) and also act as a substrate, for GPx to reduce H2O2 or hydroperoxide, through 
its conversion to oxidized form GSSG. The enzyme glutathione reductase reduces 
GSSG back to GSH using NADPH as an electron donor. The ratio of reduced 
glutathione to oxidized glutathione (GSSH/GSSG) is used for the evaluation of 
cellular toxicity (Meister & Anderson, 1983; Pastore et al., 2001). Moreover, another 
role of GSH is to maintain exogenous antioxidants like Vitamin E and C in their 
reduced forms (Hughes & Kilpatrick, 1964).  
Uric acid: Uric acid is not only a by-product of purine metabolism but it can also 
maintain protection against oxidative damage acting as an electron donor and 
scavenging peroxyl radicals, hydroxyl radicals and singlet oxygen (Howell & 
Wyngaarden, 1960; Sevanian, Davies, & Hochstein, 1985). 
Bilirubin: Bilirubin is known as the end product of hemoprotein catabolism but also, 
is considered to protect cells against harmful peroxyl radicals and hydrogen peroxide 
(Baranano, Rao, Ferris, & Snyder, 2002; Stocker, Yamamoto, McDonagh, Glazer, & 
Ames, 1987).  
Coenzyme Q10: Coenzyme Q10 is primarily known as a component of mitochondria 
electron transport which participates in aerobic cellular respiration and ATP 
production (Halliwell & Gutteridge, 2007). It can inhibit lipid peroxidation by 
preventing the production of lipid peroxyl radicals (Crane, 2001). 
Apart from cell’s endogenous antioxidant mechanisms, the defense against ROS 
is incomplete without exogenous reducing compounds such as Vitamin E, Vitamin C, 
carotenoids and polyphenols with the diet to be their main source (Ratnam, Ankola, 
Bhardwaj, Sahana, & Kumar, 2006) (André, Larondelleb, & Evers, 2010; Biehler & 
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Bohn, 2010). Endogenous and exogenous antioxidants act synergistically to maintain 
or to re-establish cell’s redox homeostasis.  
Except for measuring oxidants and antioxidant molecules, evaluating oxidative 
stress involves also the quantification of oxidatively modified molecules. Protein 
carbonyls (PC) is a biomarker which is indicative of protein oxidation, evaluation of 
malondialdeyde (MDA) and isoprostanes biomarkers are characteristics of lipid 
peroxidation and 8-hydroxy-2′-deoxyguanosine (8-OH-dG) levels are indicative of 
DNA oxidation (M. J. Davies, Fu, Wang, & Dean, 1999; E. S. Hwang & Kim, 2007; 
Kasai, 1997; Lawson, Rokach, & FitzGerald, 1999). 
 
3.2 The role of Oxidative stress in CKD- Blood levels 
 
In the literature there is strong evidence suggesting that uremia, which develops 
in tandem with renal deterioration, is accompanied by an enhanced state of oxidative 
stress, which in turn is associated with higher risk of developing cardiovascular 
disease (CVD) and mortality (Bayes et al., 2006). The presence of oxidative stress in 
uremic patients is manifested by an increase in the levels of several oxidative damage 
markers and by a parallel reduction in their antioxidant defense capacity (Stenvinkel 
& Barany, 2002; Terawaki et al., 2004). In CKD patients this state of redox imbalance 
is linked to additional pathological complications, such as malnutrition, anemia, and 
cardiovascular disease including atherosclerosis (Grune et al., 2000; Macdougall & 
Cooper, 2002; Stenvinkel & Barany, 2002). 
CVD remains the leading cause of death in CKD patients, with oxidative stress 
being implicated in the onset and the development of atherosclerosis, via mechanisms 
such as oxidation of low-density protein (LDL) (Gosmanova & Le, 2011). It is 
reported that levels of lipid and protein peroxidation markers, such as 
malondialdehyde (MDA), advanced glycosylation end-product (AGE), and advanced 
oxidation protein products (AOPPs) are elevated in CKD patients, with some studies 
indicating a correlation between some lipid peroxidation markers and intima-media 
thickness (Drueke et al., 2002; Shoji et al., 2003; X. B. Yang et al., 2005). Lipid 
peroxidation could be described as a process where oxidants, such as free radicals, 
assault lipids especially in membranes (Ayala, Munoz, & Arguelles, 2014). 
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Additionally, regarding erythrocyte membrane integrity, modifications due to 
oxidation and the increased membrane rigidity could play a key role in shortening 
erythrocyte half-life compounding the development of anemia (Peuchant et al., 1997), 
which characterizes these patients. Furthermore, a disturbance of the Glutathione 
antioxidant system, including overall compromised blood levels of reduced 
glutathione (GSH), increased oxidized glutathione (GSSG), and increased erythrocyte 
glutathione peroxidase (GPx) and glutathione reductase (Gr-reductase) activities, has 
been reported in CKD (Ceballos-Picot et al., 1996; Ross, Koo, & Moberly, 1997). 
Likewise, a decrease in catalase (CAT), a key enzyme for the detoxification of 
hydrogen peroxide and organic hydroperoxide, accompanied by increased nitric oxide 
(NO) inactivation and protein nitration by reactive oxygen species (ROS) (Sindhu et 
al., 2005), have been linked to the pathogenesis of CKD related hypertension, via a 
dysregulation of NO function.  
A variety of mechanisms have been implicated in the generation of oxidative 
stress in uremic patients, such as antioxidant deficiency, chronic inflammation 
(Hensley et al., 2000; Zimmermann et al., 1999) and, for the end-stage patients 
(ESRD), neutrophil activation during hemodialysis (HD) therapy (Grooteman et al., 
1997), with dialysis treatment per se contributing in the increase of oxidative damage 
observed in patients with CKD (Miyazaki et al., 2000; Morena et al., 2000; Nourooz-
Zadeh, 1999). Four main factors have been proposed to be responsible for the harmful 
effects of oxidative stress in patients under HD : the uremic milieu, the HD treatment 
per se, the hemoincompatibility of dialysis system and the concomitant drug treatment 
(Canaud et al., 1999).  
Until today most studies examining the redox status in CKD patients focused on 
the end stage of the disease. However, it remains unclear when, during disease 
progression, the redox imbalance manifests itself, and which one of its components, 
defense capacity or ROS overproduction, becomes critical first. 
 
3.2.1 Pre-dialysis patients and redox status 
 
Regarding lipid peroxidation damage, MDA levels were assessed in plasma or 
red blood cells (RBC) of CKD patients. Specifically, Peuchant et al 1996 (Peuchant et 
al., 1997) found increased levels of RBC free MDA in 16 patients with stage - 5 CKD 
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compared to age-matched controls. Additionally, Sahni et al (Sahni, Gupta, Rana, 
Prasad, & Bhalla, 2012) found increased RBC MDA levels in 60 patients with severe 
(near stage 5) and in 85 patients with moderate CKD compared to age-matched 
controls, with RBC MDA levels being significantly higher in the severe compared to 
moderate disease group. MDA levels were also evaluated in plasma and Papavasiliou 
et al (Papavasiliou, Gouva, Siamopoulos, & Tselepis, 2005) found them increased in 
23 patients with stage 3 - 5 CKD, compared to age-matched controls. In the same 
study 13 patients on stages 1 - 2 CKD, exhibited a tendency for higher MDA levels 
compared to healthy controls but values’ differences did not reach statistical 
significance. In contrast, stages 1 - 2 patients, exhibited significantly lower MDA 
levels compared to the stages 3-5 CKD patients (Papavasiliou et al., 2005). Bober et 
al 2010 (Bober et al., 2010), measuring TBARS (which are expressed as equivalents 
of MDA levels) reported higher plasma levels in 21 pre-dialysis CKD patients 
patients on conservative treatment compared to age-matched healthy controls. 
However it was not clear if results were statistically significant, nor was there 
information on the pre-dialysis stage of those patients. Choi et al (Choi et al., 2011) 
reported that xanthine oxidase (XO) activity was increased in the plasma of 16 
patients with stage - 4 CKD (almost ~1.5 fold compared to values of healthy 
individuals), indicating an increase in free radicals generation. 
 
The results of these five studies concur to that CKD progression leads gradually 
to a state of increased ROS production, which is reflected by the elevated levels in 
markers of lipid damage and the decrease in the concentration of antioxidant 
molecules and activity of antioxidant enzymes. As mentioned already, lipid 
peroxidation affects erythrocyte half-life, as its excess could overcome cell repair 
capacity (Ayala et al., 2014). According to Peuchant et al (Peuchant et al., 1997) their 
results could be attributed to the fact that patients with CKD have decreased 
erythrocytes survival. Thus erythropoiesis is activated and could increase RBC 
precursors and enzymatic synthesis as well as consumption of antioxidant enzymes. 
Moreover, additional mechanisms are implicated in the enhanced lipid peroxidation in 
CKD such as the reduction in glucose-6-phosphate dehydrogenase activity, which 
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Table 3.1. Redox status in pre-dialysis CKD patients. 
Authors Groups MDA XO GSH SOD CAT GPx 
(Peuchant et 
al., 1997) 
a. 16 CKD patients, (age: 43.6±11.2 yr) 
GFR:12.6±5.4 ml/min  
b. 26 healthy subjects, (age: 43.6±11.2 yr) 
RBC free MDA:              
a. 3.88±2.67                             
b. 1.74±0.56  
Total MDA:       
a.10.0±9.31  
b.7.85±2.82  
(nmol/ml) 
   
a.800  
b.790                          
(U/g Hb) 
 
a.45  
b.43                 
(U/g Hb) 
 
a.34  
b.32                               
(U/g Hb) 
(Papavasiliou 
et al., 2005) 
a.12 CKD patients, (age: 66 yr) 
Creatinine clearance:23.9±6.6 ml/min 
b. 11 CKD patients (age: 61 yr) 
Creatinine clearance:20.2±6.5 ml/min   
c. 13 CKD patients (age: 63 yr) 
Creatinine clearance:87.2±7.1 ml/min  
d. 15 healthy subjects (age: 59 yr) 
Plasma:                        
a. 1.2  
b.1.25  
c.1.15 
††
 
d. 0.9              
(nmol/ml) 
     
a. 15.50±5  
b. 15.20±4.70  
c. 11.30±2.88  
d. 9.98±3.33                 
(IU/g Hb) 
 
(Bober et al., 
2010) 
a.21 CKD patients  
(age: 56.8±16.0 yr) 
b. 21 healthy subjects  
(age: 56±16.6 yr) 
Plasma:                
a.1.05±0.21  
b.0.79±0.12 
 (μmol/L) 
 a.8.26±1.16  
b. 7.26±1.50                
(nmol/g Hb) 
   
(Choi et al., 
2011) 
a.16 CKD patients 
GFR:23.56±10.64 ml/min/1.73 m2 
b. 18 healthy subjects  
(age: 48.9±15.4 yr) 
 a.6.3±1.5  
b. 4.5±0.9 
(RLU) 
    
(Sahni et al., 
2012) 
a. 60 CKD patients, (age: 43.05±11.9 yr) 
GFR:12.75±5.52 ml/min          
b. 85 CKD patients, (age: 42.88±11.4 yr) 
GFR:28.61±12.93 ml/min         
c. 40 Healthy subjects (age: 42.42±2.2 yr) 
RBC :                
a.4.89±1.33
†
   
b.2.77±1.015  
c. 1.13±0.219  
(μmol/g Hb) 
  
a.0.61±0.40
†
 
b.1.05±0.334          
c.1.87±0.608                        
(μmol/g Hb) 
 
 
 
a.994.57±87.14 
†
 
b.1136.99±101.56  
c.1382.55±93.93      
(IU) 
 
a.125.86±17.36
†
  
b.139.19±24.35  
c. 184.66±17.29             
μL/min/ml Hb) 
 
 
 
 
MDA: malondialdehyde; XO: xanthine oxidase; GSH: reduced glutathione; SOD: superoxide dismutase; CAT: catalase; GPX: glutathione peroxidase; yr: years;  versus healthy controls, 
†
 difference between a 
and b groups, 
††
difference between a and b groups with c group. 
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leads to a decrease in NADPH and GSH concentrations and vitamin E deficiency 
(Schiavon, Guidi, Biasioli, De Fanti, & Targa, 1994; Yalcin et al., 1989; Yawata & 
Jacob, 1975).  
Undeniably, a compromised antioxidant intake may contribute to the above 
observations, as pre-dialysis patients need to adhere to specific diet guidelines and 
restrictions (Sahni et al., 2012). Indeed, intake of exogenous antioxidant vitamins, 
such as vitamins A and C, and glutathione precursors, were found to be at lower 
levels in pre-dailysis patients compared to healthy subjects, with nutritional intakes 
worsening as CKD became more severe, and evident negative correlations between 
antioxidant intakes with oxidative stress levels (Sahni et al., 2012), (Table 3.1). 
 
3.2.2 Interventions in pre-dialysis patients and redox status 
 
At the pre-dialysis stage, several interventions to correct for anemia, counteract 
inflammation and supplement nutrition have become part of clinical and peri-clinical 
care in addition to appropriate pharmacological therapy, and could affect redox 
balance. 
Ganguli et al (Ganguli et al., 2009), reported that various forms of intravenous 
iron [low molecular weight iron dextran (ID), sodium ferrigluconate complex, in 
sucrose (SFGC), and iron sucrose (IS)] at clinically used doses, resulted in elevated 
MDA levels, measured immediately after the iron transfusion period (Ganguli et al., 
2009). Marsillach et al (Marsillach et al., 2007) evaluated the 6-months effects of 
EPO treatment, together with iron treatment (SFGC or IS), measuring antibodies 
against ox-LDL, and paraoxonase (PON1) activity and concentration which is 
assumed to play an important role in oxidized lipid degradation. Results revealed 
decreased levels of ox-LDL antibodies and increased serum PON1 activity despite the 
iron treatment (Marsillach et al., 2007). However, in addition to an effect of EPO, 
large differences in baseline LDL and ferritin levels between the two studied cohorts 
can explain the conflicting reports. 
Ramos et al (L. F. Ramos et al., 2011) investigated whether the administration 
of mixed tocopherols and lipoic acid for 2 months could modify oxidative stress 
indices in CKD patients. However, no significant changes in F2- isoprostanes and 
protein thiols concentrations were observed in these patients compared to matching 
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controls. As the authors discussed, the sample size, the intervention’s duration, the 
dose or the composition of antioxidants all could probably have been biologically 
ineffective in altering the redox status of this particular patient population (L. F. 
Ramos et al., 2011). Moreillon et al (Moreillon et al., 2013) assessed the antioxidant 
effects of two types of herbal supplements curcumin and boswellia serrata, on GPx 
levels, after 8 weeks supplementation. Despite the increase in plasma GPx levels in 
the treatment group, results were not statistically significant. Perhaps the duration of 
supplementation was not sufficient enough for the small sample size used (Moreillon 
et al., 2013) to detect an effect. 
Data in non-CKD patients suggest that higher doses of vitamin E 
supplementation may be necessary to observe measurable changes in redox status. For 
example, in hypercholesterolemia patients, after 4 months of Vitamin E 
supplementation, there was a decrease in F2-isoprostane concentration, only with the 
high doses of 1600 and 3200 IU/day (L. J. Roberts, 2nd et al., 2007). Herbal 
supplements such as curcumin (Hatcher, Planalp, Cho, Torti, & Torti, 2008) and 
Boswellia serrata, (Gupta et al., 2001) (Madisch et al., 2007), are known for their anti-
inflammatory and antioxidant characteristics, for example in patients with colitis 
(Gupta et al., 2001) (Madisch et al., 2007). While one study (Moreillon et al., 2013) 
did not report an effect, future studies could explore further their possible contribution 
to ameliorate oxidative stress in pre-dialysis patients via nutritional strategies. 
Apart from the impaired nutritional status, CKD patients are also characterized 
by iron deficiency and depletion of iron storage. Although the administration of 
intravenous iron is fully recommended in these patients for anemia correction, the 
short and long-term safety of this administration remains unclear. According to Bishu 
and Agarwal (Bishu & Agarwal, 2006) intravenous iron administration contributes to 
elevated oxidative stress and endothelial dysfunction in CKD patients. Moreover, 
according to Himmelfarb et al (Himmelfarb, Stenvinkel, Ikizler, & Hakim, 2002) 
endothelial dysfunction plays a key role in the pathogenesis of atherosclerosis in CKD 
patients and oxidative stress is implicated in this pathway. It can be surmised that a 
treatment meant to correct anemia, iron supplementation, could exacerbate 
atherosclerosis by promoting oxidative stress. The two studies supplementing iron to 
pre-dialysis patients reviewed above,  Ganguli et al (Ganguli et al., 2009), and 
Marsillach et al (Marsillach et al., 2007) reported conflicting effects of iron on lipid 
peroxidation. However the interaction of iron to circulating LDL cannot be 
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underestimated (i.e. a systemically atherogenic environment) while at the same time 
EPO appears to confer an antioxidant advantage (as shown earlier by Papavasileiou et 
al (Papavasiliou et al., 2005), that EPO treatment prevented the reduction in 
erythrocytes GPx activity observed in patients not receiving EPO). 
 
3.2.3 HD patients and redox status 
 
According to literature, increased levels of MDA (Bober et al., 2010; 
Dimitrijevic et al., 2012; Guo, Chen, Hsu, & Wang, 2013; Haklar, Yegenaga, & 
Yalcin, 1995; Sakata et al., 2008; Sommerburg et al., 1998; Triolo et al., 2003) were 
observed in HD patients compared to healthy individuals, reflecting extensive lipid 
damage. Sommerburg et al (Sommerburg et al., 1998), reported that HD patients who 
received long-term EPO treatment showed decreased levels of lipid peroxidation 
compared to patients who did not receive EPO treatment. Furthermore, Dolegowska 
et al (Dolegowska et al., 2007) reported a significant increase in plasma isoprostanes 
(8-iPF2a-III) concentrations, in HD patients. 
Regarding protein damage, levels of protein carbonyls were also found to be 
elevated in HD patients in four studies (Anraku et al., 2004; Haklar et al., 1995; Mera 
et al., 2005; Ward, Ouseph, & McLeish, 2003). In addition, advanced oxidation 
protein products (AOPPs) were found to be in high levels in HD patients in two 
studies (Sakata et al., 2008; Ward et al., 2003) however they were reported to be no 
different than controls in one study (Fragedaki et al., 2005). In the study of Fragedaki 
et al (Fragedaki et al., 2005) patients were on dialysis for a shorter period (an average 
of 3 years) than the other studies (Sakata et al., 2008; Ward et al., 2003) a fact that 
could affect AOPPs levels. Finally, Choi et al (Choi et al., 2011) reported increased 
XO activity in HD patients compared to healthy subjects (by almost 3 fold); with XO 
activity being also higher (by 2.1 fold) than pre-dialysis patients. Taking into 
consideration the above results, there is evidence of extensive oxidative damage to 
total protein content and lipids in HD patients. 
Regarding the antioxidant capacity in HD patients, the literature provides 
differing results. Sakata et al reported a significant increase in ‘global’ antioxidant 
capacity markers, such as ORAC and TEAC (Sakata et al., 2008). On the other hand, 
Dimitrijevic et al (Dimitrijevic et al., 2012) reported a significant decrease in total 
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antioxidant capacity (TAC) of HD patients compared to controls while decreased 
albumin levels were also observed. It should be noted that these global antioxidant 
capacity markers do not represent innate antioxidant capacity but rather represent 
global availability of free radical scavenging compounds, whose levels are greatly 
affected by nutrition.   
Moreover, the activity of the free radical scavenging enzymes plasma GPx 
(GSH-Px) and SOD was found to be significantly decreased in HD patients (Guo et 
al., 2013). GPx has been identified in two forms: cellular or cytosolic (GPx-1) which 
is presented in red blood cells and the cytosol of almost all tissues, and extracellular 
(GPx-3) in the plasma, with selenium (Se) being a basic structural component in both 
forms, (Guo et al., 2013), an element also affected by nutrition. Additionally, Gr 
Reductase activity was found to be significantly higher in HD patients compared to 
healthy subjects (Stepniewska et al., 2006), probably reflecting the organism’s efforts 
to activate the antioxidant defense. Likewise, that study also reported increased GSH 
total blood concentrations in the HD patients studied (Stepniewska et al., 2006). On 
the other hand, two studies (Dimitrijevic et al., 2012),(Ward et al., 2003) reported a 
large reduction of free sulfhydryl groups levels in HD patients, measured in plasma. 
All the results (Table 3.2) concur to that HD treatment seems to contribute to 
augmented oxidative stress. Most of the studies observed increased levels of protein 
and lipid damage in HD patients, which were measured with established biomarkers. 
As it appears, HD treatment causes an enhanced rate of LDL oxidation, which leads to 
the development of atherosclerosis, as reflected in elevated blood MDA levels. One 
mechanism is that the uremic milieu and the HD process per se stimulate neutrophils, 
a procedure known as “neutrophil burst”, which directly or indirectly results to 
hydrogen peroxide production. This is then converted to hypochlorous acid, which in 
turn contributes to the oxidation of plasma proteins and LDL, assaulting their 
membranes (Morena, Delbosc, Dupuy, Canaud, & Cristol, 2005; Sakata et al., 2008).  
Furthermore, as it was referred above, lipid peroxidation negatively affects 
erythrocyte half-life leading to decreased survival and manifestation of anemia. EPO 
appears to help as Sommerburg et al (Sommerburg et al., 1998) reported that HD 
patients who received long-term EPO treatment presented decreased levels of lipid 
peroxidation. These results in HD concur with findings in pre-dialysis patients, where 
also EPO appears to confer an antioxidant advantage (Papavasiliou et al., 2005), by 
preventing the reduction in erythrocytes GPx activity observed in patients not 
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Table 3.2. Redox status in HD patients 
Authors Groups HD modality & 
period 
TBARS /MDA Free sulfhydryl 
groups 
Isoprostanes8-
iPF2a-III 
AOPP Protein 
Carbonyls 
XO GSH ORAC/ TEAC/ 
TAC 
SOD/ GPx/ GR 
Reductase 
(Haklar et al., 
1995) 
a. 14 HD patients 
(age: 52 yr) 
b. 14 healthy subjects 
(age: 40 yr) 
Cuprophan, 
dialyzers,22 months, 
3x/week/ 4 h 
MDA(nmol/ml) 
a.5.50±0.6 
b.2.82±0.36  
   a.41.2±10.4 
b.22.6±5.5 
(nmol/mg 
protein) 
    
(Sommerbur
g et al., 
1998) 
a. 8 HD patients Hb<10 g/dl, 
(age: 58 yr) 
b. 8 HD patients Hb>10 g/dl, 
(age: 62 yr) 
c. 27 HD patients receiving 
rHuEpo (age: 66 yr) 
d. 20 healthy subjects 
(age: 59 yr) 
Bicarbonate HD, 6-
10 years,3x/week/4-
5 h 
 MDA (μM) 
a.3.81±0.86  
b.  2.77±0.58  
c.  2.50±0.12  
d. 0.37±0.03  
 
        
(Ward et al., 
2003) 
a. 11 HD patients 
(age: 51± 5 yr) 
b. 12-17 healthy subjects 
(age 23-54 yr) 
49±11 months  a. 268±22 
b.438±16 (μmol/ L) 
 a.191±27 
b. 74±8   
(μmol/ L) 
a.0.144± 0.037  
b. 0.041± 0.008 
(nmol/mg) 
    
(Choi et al., 
2011) 
a.18 patients,  
age 52.0±17 yr,  
b.16 healthy subjects  
(age: 48.9±15.4 yr) 
94.3±43.5 months, 
3x/wk/4h 
      
a. 
13±9.4  
b. 4.5±0.9 
(RLU) 
   
(Triolo et al., 
2003) 
a. 10 HD patients 
(age: 64.6±13.7 yr) 
b. 30 healthy subjects  
(age: 59.8±9.4 yr) 
Bicarbonate HD,  
86.6±47.2 months, 
3 x/week/3.5-4 h 
MDA ( nmol/mL) 
a.1.87±0.36  
b. 1.13±0.18  
        
(Anraku et 
al., 2004) 
a. 11 HD patients 
(age 25 to 87 yr) 
b.11 age-matched healthy 
subjects 
Bicarbonate,1- 9 
years, 
3 x/week/4-5 h 
    a. 1.0±0.1 
b.0.4±0.03 
(nmol/mg 
protein)     
    
(Fragedaki et 
al., 2005) 
a. 12 SHD patients 
(age: 57.5±12.8 yr) 
b. MHD 13 patients 
(age: 48±11.5 yr) 
c. 12 healthy subjects 
(age: 52.9±10.7 yr) 
a.Polyethersulfone, 
3.6±1.82 years, 
3 x/week/4-4.5 h 
b.Polyethersulfone, 
3.3±1.37 years, 
6 x/week/2-2.5 h 
   a.0.44±0.23  
b.0.57±0.36  
c. 0.60±0.46 
(nmol/mg protein) 
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Authors Groups HD modality & 
period 
TBARS /MDA Free sulfhydryl 
groups 
Isoprostanes8-
iPF2a-III 
AOPP Protein 
Carbonyls 
XO GSH ORAC/ TEAC/ 
TAC 
SOD/ GPx/ GR 
Reductase 
 
 
Mera et al., 
2005) 
a. 20 HD patients 
(age 62.8±12.7 yr) 
b. 10 healthy subjects 
(age 67.8±1.8 yr) 
 
Bicarbonate HD,1-9 
years, 
3 x/week/4-5 h 
    a.3.12±1.1 
b.2.10±0.34 
(nmol/mg protein) 
    
(Stepniewska 
et al., 2006) 
a. 25 HD patients 
(age 50.3±13.79 yr) 
b. 26 HD patients 
(age 60.54±13.54 yr) 
c.29 healthy subjects 
(age 49.7±11.4 yr) 
 
a. Polysulfone HD, 
glucose-free fluid, 
27.44±15.87 
months,3 x/week,4h 
b. Polysulfone HD, 
glucose fluid, 
24.43±12.68 months 
3 x/week/4h 
      a.19.6±8.8  
b.20.5±8.0  
c. 14.2±2.1 
(μmol/g Hb) 
 Gr Reductase 
a.2.82±0.98  
b.2.57±0.76  
c. 1.95±0.40 
(U/g Hb) 
(Dolegowska 
et al., 2007) 
a.22 HD patients 
(age: 53.06±11.43 yr) 
b.22 HD patients 
(age: 57.70±14.78 yr) 
c. 22 healthy subjects 
(age: 51.93±9.94 yr) 
a. Polysulfone HD. 
glucose-free fluid, 3 
x/week/4h 
b. Polysulfone HD, 
glucose fluid,3 
x/week/4h 
 
 
a.Plasma: 0.05±0.02           
RBC:  7.19±10.45  
b.Plasma:0.19±0.15 
RBC:8.75±7.58 
c.Plasma:0.10±0.05 
RBC:5.29±7.54 
(ng/ml), (ng/g Hb) 
     
(Sakata et 
al., 2008) 
a.36 HD patients 
(age: 63.6±12.1 yr) 
b.15 healthy subjects 
(age: 32.5±8.6 yr) 
 
Bicarbonate HD,    
12.1±7.0 years 
 MDA (μΜ) 
a.0.25±0.11    
b.0.05±0.02  
  a.88.8±39.7  
b.43.8±20.3 
(μΜ) 
   a.ORAC: 
2,672±554    
TEAC: 
0.77±0.2 
b.ORAC: 
1,363±174  
TEAC: 
0.43±0.12  
(U/ml), mM Trol 
eq/l 
 
(Bober et al., 
2010) 
a.22 HD patients 
(age: 55.9±14.8 yr) 
b.23 HD patients 
(age: 64.3±12.1 yr) 
c. 21 healthy subjects 
(age: 56±16.6 yr) 
a. Polysulfone HD, 
glucose-free fluid, 
8.78±6.42 months, 3 
x/week 
b. Polysulfone HD 
glucose fluid, 
9.45±6.62 months 
3x/week 
MDA a.1.56±0.27  
b.1.36±0.30  
c.0.79±0.12 
(μmol/L) 
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TBARS: Thiobarbituric acid reactive substances; MDA: malondialdehyde; AOPP: Advanced Oxidation Protein Products; GSH: reduced glutathione; ORAC: Oxygen Radical Absorbance 
Capacity; TEAC: Trolox Equivalent Antioxidant Capacity; TAC: Total Antioxidant Capacity; SOD: superoxide dismutase; GPX: glutathione peroxidase; yr: years;  versus healthy controls 
 
 
 
 
 
 
 
 
Authors Groups HD modality & 
period 
TBARS /MDA Free sulfhydryl 
groups 
Isoprostanes8-
iPF2a-III 
AOPP Protein 
Carbonyls 
XO GSH ORAC/ TEAC/ 
TAC 
SOD/ GPx/ GR 
Reductase 
(Dimitrijevic 
et al., 2012) 
a.15 HD patients 
(age: 55.6±18.2 yr) 
b.29 healthy subjects 
(age: 55±15.8 yr) 
Bicarbonate HD    
52.5±61.6 months 
MDA 
a.Plasma:11.3±11
.2  
RBC: 14.7±2.2 
b.Plasma:6.0±1.1  
RBC: 8.7±1.3 
(mmol/l),(nmol/ml) 
a.284.4±44.5  
b.449.2±66.6 
(μmol/ L) 
     a.TAC: 
2.5±0.3  
b. TAC: 
3.6±0.5 (μmol/ 
L) 
 
(Guo et al., 
2013) 
a.20 HD patients     
(age:55±7 yr) 
b.25 healthy subjects 
(age: 53±7 yr) 
 HD 6±1 years,   
3 x/week/4 h 
 MDA        
a.6 (median) 
b. 2.9 (nmol/L) 
       a. GPx: 
50.5±8.4  
SOD:: 
3.4  
b. GPx: 
85.2±6.1 SOD:: 
8.3 (U/ml) 
(median) 
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receiving EPO. Moreover, while erythropoiesis is, in a healthy individual, stimulated 
by ROS, as discussed by Migliaccio, erythropoiesis also counteracts circulating ROS 
levels via increases in available catalase and possibly other antioxidant enzymes 
(Migliaccio, 2013). Further on the atherosclerosis mechanism, the presence of F2 –
isoprostanes has been determined in human atherosclerotic lesions (Pratico et al., 
1997). F2–isoprostanes are created during the non-enzymatic peroxidation of 
arachidonic acid bound up with phospholipids of cells membranes and lipoproteins 
(Cracowski et al., 2001; Morrow et al., 1990; L. J. Roberts, 2nd & Morrow, 2002), 
and they are considered sensitive and specific indicators of oxidative stress intensity 
in vivo (Dillon, Lowe, Billington, & Rahman, 2002; Pratico et al., 1997). Given 
reports, such as (Dolegowska et al., 2007), of a significant increase in plasma 
isoprostanes in HD patients, the link between oxidative stress and CVD in HD 
patients is further highlighted.  
The results on the antioxidant capacity of HD patients are not as straightforward 
to explain. Caloric restriction (without essential nutrient deficiency) in rats has been 
shown to result in decreased antioxidant capacity (ORAC) (Cao, Prior, Cutler, & Yu, 
1997). CKD patients however, are subject to both caloric restriction and deficient 
antioxidant intakes [23]. Differences between studies reporting on HD antioxidant 
capacity could be thus attributed not only to adaptive mechanisms, due to years in 
dialysis and comorbidities, but also to dietary restrictions and inter-individual 
differences in antioxidant nutritional intakes, as already reported in pre-dialysis 
patients (Sahni et al., 2012). 
Additionally, the hemodialysis process per se may compromise key nutrient and 
trace mineral levels as highlighted with regards to levels of Se, a basic component of 
GPx. Guo et al (Guo et al., 2013) reported that HD patients presented with lower 
plasma Se concentrations than healthy subjects and this could be attributed to either 
impaired diet/absorption or increased loss of Se during dialysis treatment (Pakfetrat, 
Malekmakan, & Hasheminasab, 2010). Additionally, taking into account that the 
kidney is the main site of plasma GPx synthesis and is also capable of Se 
accumulation (Avissar et al., 1994), that the levels of both Se and GPx are reduced in 
ESRD patients is not unexpected. A similar explanation could be also given for the 
significant reduction in plasma SOD activity observed in HD patients, linked to Zn 
availability, which is a structural element of SOD and whose levels tend also to be 
reduced in renal insufficiency (Zumkley, Bertram, Lison, Knoll, & Losse, 1979). 
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Regarding GSH depletion in HD patients, many mechanisms have been 
proposed. According to Yawata et al. (Yawata & Jacob, 1975), an obstruction to the 
pentose phosphate pathway leading to impaired production of NADPH occurs in 
patients with ESRD. As a result, Gr Reductase cannot recycle GSSG back to GSH 
using NADPH as electron source (Yawata & Jacob, 1975). Notwithstanding, in many 
studies, GR activity has been found to be increased or in normal levels (Ceballos-
Picot et al., 1996; Romeu et al., 2010; Schettler, Wieland, Methe, Schuff-Werner, & 
Muller, 1998; Stepniewska et al., 2006). Thus, GSH depletion could be alternatively 
attributed either to a diminished GSH synthesis and/or to an increased GSH 
degradation, since its precursors cystine, glutamate and glycine could be normal or 
elevated in patients’ blood (Ceballos et al., 1990).  
 
3.2.4 Redox status before and after the HD treatment  
 
The hemodialysis treatment can affect patients’ redox status, and several studies 
examined the possible contribution of HD treatment on redox imbalance (Table 3.3). 
Three studies indicated that HD treatment per se augments lipid peroxidation, 
assessed by MDA (Bober et al., 2010; Ogunro, Olujombo, Ajala, & Oshodi, 2014) 
and F2 – isoprostanes levels (Dolegowska et al., 2007) and induces protein damage, 
assessed by protein carbonylation (Ward et al., 2003). However, there were studies, 
which did not observe any significant changes in lipid peroxidation (unchanged MDA 
levels) (R. Ramos & Martinez-Castelao, 2008; Trimarchi et al., 2003), F2-
isoprostanes levels (Smith et al., 2003) and ox-LDL levels (Malindretos et al., 2007) 
following the HD process (Malindretos et al., 2007; R. Ramos & Martinez-Castelao, 
2008; Smith et al., 2003; Trimarchi et al., 2003). Moreover, in the Malindretos et al 
study, oxidized LDL levels didn’t significantly change after HD treatment, neither 
intravenous iron administration during HD changed its concentration following HD 
(Malindretos et al., 2007).  
Regarding antioxidant capacity after completion of HD therapy, there are 
conflicting findings. Two studies reported that the levels of GSH and the activities of 
GPx and Gr-reductase increased after HD therapy (Stepniewska et al., 2006; 
Westhuyzen, Saltissi, & Stanbury, 2003). However, there were three studies in 
younger patients, which observed reduced levels of GSH (Bober et al., 2010; Ogunro 
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et al., 2014), reduced GPx activity (Ogunro et al., 2014) and reduced TAS levels (K. 
C. Huang et al., 2006; Ogunro et al., 2014) following HD. 
Ogunro et al (Ogunro et al., 2014), evaluated the effects of cellulose and 
polysulfone membranes, which are the most commonly used types, on redox status in 
chronic HD patients. SOD activity was significantly reduced in both cellulose and 
polysulfone membrane dialysis. Regarding other antioxidant biomarkers evaluated in 
this study, both types of membranes caused changes to same direction but not 
significant in all cases. Specifically, CAT activity was significantly increased only in 
polysulfone membrane while GPx activity was reduced in both types but not 
significantly. Additionally, TAS and GSH levels were significantly reduced after 
cellulose membrane HD while the reductions were not significant in polysulfone 
membrane users. Lastly, following HD treatment, MDA levels were increased in both 
types but the change was significant only in cellulose membrane.  
On the other hand, Ward et al (Ward et al., 2003), did not find differing 
responses to the use of polysulfone or cellulose membranes on protein oxidation. 
These HD patients demonstrated already high plasma protein carbonyls and AOPP 
concentrations compared to normal values, before HD treatment. With HD, using 
either membrane, protein carbonyls increased significantly over the course of HD and 
remained significantly elevated for the post-dialysis period, indicating a worsening in 
protein oxidative damage. Dialysis had no effect on AOPP levels and their values 
remained significantly higher than normal after dialysis. Perhaps counterintuitively, in 
that study, following HD a significant increase in plasma free sulfhydryl groups 
concentrations was found (levels essentially corrected to the levels of normal values), 
for both membranes used (Ward et al., 2003). 
Bober et al (Bober et al., 2010), assessed the effects of glucose content in the 
dialyzing fluid on RBC antioxidant capacity. They found that glucose concentrations 
of about 5.6 mmol/l resulted in an augmentation of the hexose monophosphate cycle 
(HMP) in erythrocytes and accordingly benefited the antioxidant system. 
Furthermore, the group received the glucose-free HD treatment presented with 
increased TBARS concentration after the treatment (Bober et al., 2010). According to 
the authors, this probably occurred, because the free radicals produced during the 
glucose-free HD session could not be neutralized through the non-enzymatic pathway 
at a satisfactory rate (Bober et al., 2010). In the cross-sectional study of Dolegowska 
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et al (Dolegowska et al., 2007), there were no significant differences, either pre or 
after HD treatment, in 8-iPF2a-III levels in RBC membranes of HD patients treated. 
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Table 3.3 Redox status before and after the HD treatment 
Authors Groups HD modality & 
period 
AOPP Ox-LDL Free 
sulfhydryl 
Protein 
Carbonyls 
TBARS 
/MDA 
F2-Isoprostanes GSH SOD GPx GR-
Reductase 
CAT TAS 
(Ward et al., 
2003) 
11 HD patients, 
(age 51±5 yr)  
a.  polysulfone 
membrane 
 b. cellulose 
membrane      
49±11 months 
a.190±3
7  
b.163±
26 
(μmol/
L) 
 a. 425±15  
b. 408±23 
(μmol/L)  
a.0.175±0.03  
b.0.178±0.04 
(nmol/mg)  
        
(Westhuyzen 
et al., 2003) 
13 HD patients, 
(age 69.2±15.6 yr)  
Vitamin E 
membrane, 3x/wk                 
a. Baseline                
b. at 6 wk                   
c. at 13 wk 
      a.0.99±0.17  
b.1.08±0.16  
c.1.04±0.20 
(mmol/L) 
a.725±102 
b.746±130 
c.771±151 
(U/g Hb) 
a.46.8±14.8  
b. 55.7±14.8  
c. 56.7±17.2 
(U/g Hb) 
   
(Trimarchi et 
al., 2003) 
12 HD patients, 
(age 65.5±13.1 yr)  
Cellulose 
membrane, for 
20.83 months, 
3x/wk   
     
4.62±0.9 
(μmol/L) 
       
(Smith et al., 
2003) 
11 HD patients,  
(age 64±4 yr)  
Polysulfone 
membrane,3x/wk 
     602±105 (pg/ml)       
(Stepniewska 
et al., 2006) 
a. 25 HD patients, 
(age 50.3±13.7 yr) 
b. 26 HD patients 
(age 60.5±13.5 yr) 
 
 
a. Polysulfone 
membrane, 
glucose-free fluid, 
for 27.44±15.87 
months,3x/week/4h 
b. Polysulfone 
glucose fluid,for 
24.43±12.68 
months 3 x/week/ 
4h 
 
      a.18.3±7.2 
b.19.8±8.2 
(mmol/gHb) 
  a.2.69±0.95  
b.  2.05±0.59 
(U/g H) 
  
(K. C. Huang 
et al., 2006) 
25 HD patients, 
(age 58±3yr) 
 
HD for 12 months             0.5 
(mmol/l ) 
(Malindretos 
et al., 2007) 
20 HD patients, 
(age 64.7±17.3 yr): 
Polysulfone 
membrane, 3x/wk/ 
4h 
  
14.52±8.3 
(mU/L) 
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Authors Groups HD modality & 
period 
AOPP Ox-LDL Free 
sulfhydryl 
Protein 
Carbonyls 
TBARS 
/MDA 
F2-Isoprostanes GSH SOD GPx GR-
Reductase 
CAT TAS 
(Dolegowska 
et al., 2007) 
a.22 HD patients, 
(age 53.1±11.4 yr) 
b.22 HD patients, 
(age 57.7±14.7 yr) 
 
a. Polysulfone 
membrane, 
glucose-free fluid, 
3x/week/4h 
b. Polysulfone 
glucose fluid, 
3x/week/ 4h 
     a.Plasma: 0.18±0.17 
RBC:7.40±11.22 
b.Plasma:0.16±0.10 
RBC:7.62±7.03 
(ng/ml),  (ng/g Hb) 
      
(R. Ramos & 
Martinez-
Castelao, 
2008) 
34 HD patients, 
(age 57±1 yr) 
 
Cellulose 
membrane 
    0.28±0.19 
(ng/g 
HDL) 
       
(Bober et al., 
2010) 
a.22 HD patients, 
(age 55.9±14.8 yr) 
b.23 HD patients, 
(age 64.3±12.1 yr) 
 
a. Polysulfone 
membrane glucose-
free fluid, 3x/week 
b. Polysulfone HD 
glucose 
fluid,3x/week 
    a.2.01±0.5
5 
b.1.17±0
.31 
(μmol/L) 
 a.  8.82±2.22  
b.11.07±3.28 
(nmol/g Hb) 
     
(Ogunro et al., 
2014) 
a.35 HD patients, 
(age 51.9±12.4 yr)  
b. 38 HD patients, 
(age 49.8±10.6 yr) 
a. Cellulose 
membrane 
b. Polysulfonate 
membrane,  
3x/wk/ 4-5 h 
    a.6.05±0.9  
b. 
4.71±0.7 
(nmol/mL
) 
 a. 2.09±0.3  
b.3.68±0.2 
(μmol/g Hb) 
a. 
378±13.2  
b. 
418±19.7 
(U/g Hb) 
a.22.5±3.1  
b. 27.5±4.2 
(U/g Hb) 
 a.1231±41
.6  
b.1370±
39.4 (U/g 
Hb) 
a.1.0.±0.7  
b.1.16±0.
2 
(mmol/L 
trolox) 
 
AOPP: Advanced Oxidation Protein Products; Ox-LDL: oxidized Low Density Lipoprotein; MDA: malondialdehyde; GSH: reduced glutathione; SOD: superoxide dismutase; GPX: glutathione 
peroxidase; CAT: Catalase; TAS: Total Antioxidant Status; yr: years; :versus before the HD treatment; : versus before the HD treatment;  
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with glucose or glucose-free dialyzing fluids. Still, they reported a significant increase 
of plasma 8-iPF2 -III concentration following HD in the glucose-free group (which 
however started at a much lower level than the glucose treated group).  
Various mechanisms have been proposed to account for the increased oxidative 
damage following HD treatment. Firstly, the issue of hemoincompatibility induced by 
the contact between human blood and the non-biological materials of the 
hemodialyzer and the resulting effects on leukocyte and platelet activation and 
inflammation (Fumeron et al., 2005; Morena et al., 2000; Washio et al., 2008). 
Moreover, systemic inflammation effects mediated via neutrophil activity burst 
resulting in the release of ROS into the bloodstream (Morena et al., 2005; Sakata et 
al., 2008). Furthermore, the role the HD process per se in reducing plasma antioxidant 
defense because several antioxidant dialyzable solutes are removed during HD.  
The role of the type of dialysis membrane used is not straightforward 
(Trimarchi et al., 2003; Ward et al., 2003). This is probably due to the different 
reactions that take place in sulfhydryl groups and protein carbonyl formation. 
Possibly, protein sulfhydryl groups are oxidized reversibly through small molecules 
oxidants, which can be removed by dialysis process, while AOPP and protein 
carbonyls may represent a chronic state of irreversible oxidative damage (Ward et al., 
2003). 
With regard to dialyzing fluid composition, it could be generally concluded that 
glucose has a beneficial effect on the antioxidant properties of RBC and protects them 
by decreasing the risk for hemolysis (Bober et al., 2010; Dolegowska et al., 2007), 
(Table 3). 
 
3.2.5 Intervention in HD 
 
Three studies examined the effects of Vitamin C administration on redox status 
of HD patients. Fumeron et al (Fumeron et al., 2005) reported that oral administration 
of 250 mg Vitamin C three times per week for two months, could not either increase 
GSH or reduce protein carbonyls levels. Washio et al (Washio et al., 2008), found that 
oral administration of Vitamin C for 3 months, ranging from low (200 mg) to high 
dose (1000 mg) could not suppress the enhancement of Cu/Zn-SOD expression, an 
oxidative stress marker. On the other hand, Tarng et al (Tarng, Liu, & Huang, 2004) 
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found that intravenously administration of 300 mg Vitamin C for 8 weeks decreased 
significantly 8-OHdG contents in cellular DNA of lymphocytes. Moreover in the 
same study vitamin C significantly reduced intracellular ROS production of 
lymphocytes of patients on HD (Tarng et al., 2004). 
Regarding Vitamin E, another important antioxidant substance, Smith et al 
(Smith et al., 2003) examined the effects of 400IU administration for 2 months, on 
redox status of 11 HD patients. The elevated free F2-isoprostane plasma 
concentrations were not decreased by vitamin E supplementation. Likewise, treatment 
with a combination of mixed tocopherols plus αlipoic acid (oral) for 6 months didn’t 
change plasma F2- isoprostane and F2- isofurane of HD patients compared to placebo 
group as reported by Himmelfarb et al  (Himmelfarb et al., 2014).  
A pilot study by Trimarchi et al (Trimarchi et al., 2003) showed that the daily 
administration of 1,200 mg NAC for one month could significantly reduce plasma 
lipid peroxidation of HD patients compared to the control group. Finally, Fatouros et 
al (Fatouros et al., 2010) reported that daily administration of 20 mg/kg L-carnitine in 
12 HD patients for 8 weeks resulted in 2,7 fold increased GSH/GSSG ratio, a 4.5%  
increase in glutathione peroxidase activity, a 19% decrease in MDA levels and 27% 
decrease in protein carbonyls concentration. 
Vitamin C is one of the most important water-soluble antioxidants. There is 
evidence that HD patients exhibit a 30-50% decrease in Vitamin C levels after 
dialysis treatment, as reviewed elsewhere (Deicher & Horl, 2003). Moreover, reduced 
Vitamin C levels in HD patients have been associated with an increased risk for CVD 
morbidity and mortality (Deicher, Ziai, Bieglmayer, Schillinger, & Horl, 2005). 
However, elsewhere, only intravenous administration was found to have a measurable 
beneficial effect (Tarng et al., 2004). Thus, oral administration of Vitamin C may not 
be sufficient to correct its deficiency in HD.  
Oral administration of Vitamin E did not decrease plasma isoprostanes in HD 
patients (Deicher et al., 2005; Malindretos et al., 2007). In contrast,  it has been 
reported that long-term administration of 200 mg of Vitamin E decreased F2-
isoprostanes plasma levels in mildly hypercholesterolemic men (Kaikkonen et al., 
2001). Moreover in healthy subjects Vitamin E administration resulted in lower F2-
isoprostane concentrations in urinary samples (H. Y. Huang et al., 2002). Perhaps 
differences in outcomes relate to dosage and duration of administration could explain 
these results, notwithstanding the augmented oxidant production characterizing HD 
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patients which perhaps oral administration of Vitamin E, at safe levels for these 
patients, could not combat. 
N-acetylcysteine (NAC) is a ROS scavenger and its administration seems to 
increase glutathione concentration given that it raises intracellular levels of one of its 
precursors, cysteine (Afaq, Abidi, & Rahman, 2000; Aruoma, Halliwell, Hoey, & 
Butler, 1989; Vendemiale et al., 2001). Along with L-Carnitine, these products 
showed promising results and should be further examined in larger patient cohorts. 
 
3.2.6 Other type of Dialysis and redox status 
 
In the literature, there have been also studies that examined other types of 
dialysis in relation to oxidative stress and antioxidant status biomarkers (Table 3.4). A 
metabonomics study by Choi et al examined the effects of different dialysis 
modalities on serum profiles of patients (Choi et al., 2011). XO activity levels were 
similar for both HD and peritoneal dialysis (PD) patients. Still XO activity was 
significantly higher in PD compared to controls and to non-dialysed uremic patients 
(non HD or PD) (Choi et al., 2011), perhaps justifying the need to address it 
pharmaceutically (see below Interventions in PD).  
In the study of Canestrari et al (Canestrari et al., 1995) erythrocyte GSH levels 
were unchanged or slightly increased in the patients compared to the control group 
while a nearly 3-fold increase in GSSG was observed in the PD group (Canestrari et 
al., 1995). In the same study, plasma GSH levels were significantly decreased in the 
PD group compared to control group and GSSG levels were slightly increased in PD 
patients (Canestrari et al., 1995). Moreover, increased RBC and plasma TBARS 
levels were found in PD patients compared to control group. Finally, significantly 
higher erythrocyte GSH-Px activity was observed in the PD group while plasma 
GSH-Px activity was similar in PD and controls (Canestrari et al., 1995). 
Moreover, a study by Gonzales-Diez et al (Gonzalez-Diez et al., 2012), 
examined and compared the effects of haemodiafiltration (HFR) to HD with 
polysulfone membranes (HD-PS). The HFR group demonstrated moderate changes in 
oxidative stress biomarkers and antioxidant capacity markers, indicating that this 
method may in the long term preserve a more stable and balanced redox status 
compared to HD-PS (Gonzalez-Diez et al., 2012), (Table 4). 
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Table 3.4. Other modalities of HD and redox status 
Authors Groups HD modality TBARS/MDA Protein 
Carbonyls 
GSSG GSH SOD GPx XO CAT TAC 
(Canestrari 
et al., 1995) 
a. 18 patients              
(age 62.9±13.9 yr) 
b. 15 healthy subjects 
(age: 59.2±8.3 yr) 
 
Peritoneal dialysis 
for 26.56±23.27 
months 
a.  RBC: 10.8±3.8  
Plasma: 74.5±20.5  
b. RBC: 4.8±2.6  
Plasma: 46.6±16.1        
(nmol/g Hb or prot) 
 
 a.RBC:0.039±0.014  
Plasma: 0.011±0.006  
b.RBC 0.012±0.011 
Plasma: 0.009±0.005 
(μmol/g Hb or prot) 
a.RBC:6.40±1.36 
Plasma:  1.53±0.69 
b.RBC: 4.97±0.78 
Plasma:2.07±0.20 
(μmol/g Hb or prot) 
 a.RBC: 
48.7±11.5  
Plasma: 
5.02±1.36  
b.RBC 36.1±8.5  
Plasma: 
5.50±0.79 (U/g 
Hb or prot) 
 
   
(Choi et al., 
2011) 
 
a. 18 patients                               
(age 48.1±16.4 yr) 
b. 18 patients                         
(age 52.0±17 yr) 
c.16 healthy subjects              
(age 48.9±15.4 yr) 
a. Peritoneal 
dialysis (PD) for 
99.8±39.4 months, 
1.7x/wk 
b. Typical HD for 
94.3±43.5 months, 
3x/wk  
      a.12.2±3.5  
b. 13.0±9.4  
c.4.5±0.9 
(RLU) 
 
  
(Gonzalez-
Diez et al., 
2012) 
a. 25 patients 
b. 15 patients 
(age: -) 
a. 
Haemodialfiltration 
(HFR) for 1 year 
b. HD with 
polysulfone 
membrane for 1 
year 
a.~19 
b. ~17 (μΜ) 
 
a. ~2.2 b.~ 
2.2 
(nmol/mg 
prot) 
 a.~1  
b.~ 0.9                          
(μmoles/g) 
 
a.~2100  
b. ~1400    
(U/g prot) 
a.~42  
b.~34 (U/g prot) 
 
 a. ~18  
b. ~25 
(U/g 
prot) 
 
a. ~4  
b. ~4 
(mM 
Trolox) 
 
TBARS: Thiobarbituric acid reactive substances ; Ox-LDL: oxidized Low Density Lipoprotein ;GSSG: oxidized glutathione; GSH: reduced glutathione ; SOD: superoxide dismutase ; GPx: glutathione peroxidase ; 
XO:Xanthine Oxidase ; CAT:Catalase ; TAC:Total Antioxidant Capacity; yr: years; : versus healthy, : versus healthy, ~: values were estimated according to figures. 
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3.2.7 Interventions in PD 
 
Imani et al (Imani et al., 2009), evaluated the effects of soy consumption (28 
g/day) for 8 weeks on oxidative stress in PD patients. Results indicated no changes in 
serum ox-LDL between soy and control group of PD patients, however an 
improvement in thrombosis risk was reported. The fact that the 78% of the specific 
peritoneal dialysis patients received Vitamin C and/or E, could explain the lack of a 
measurable effect. We do consider however that such dietary interventions as well as 
antioxidant interventions of adjunct pharmaceuticals need further examination (see 
below). 
Overall, based on the limited data reviewed so far, PD also appears to be 
associated with increased oxidative stress, with the Choi et al study (Choi et al., 2011) 
showing PD patients to have as high XO activity as HD patients and the Canestrari et 
al study (Canestrari et al., 1995) showing not only increased oxidative stress but also 
evidence of reductions in antioxidant capacity, compared to controls. As XO is a 
superoxide producing enzyme its inhibition has been viewed as a way to reduce CVD 
risk (e.g. via allopurinol, (Dawson & Walters, 2006). To circumvent possible 
allopurinol’s toxicity in renal insufficiency patients careful screening and tolerance 
protocols are needed (Jung et al., 2015). A new non-purine alternative, febuxostat, has 
been shown to reduce serum levels of uric acid and levels of a marker of DNA 
oxidation (8-oxo-dG) following 6 month administration in HD patients (Akimoto et 
al., 2014). 
In non-CKD patients, soy consumption has been reported to improve redox 
status (for example in gestational diabetes (Jamilian & Asemi, 2015)). Notably, the 
combination of soy milk with Lactobacillus plantarum was recently shown not only to 
improve redox status, vs consumption of plain soy milk, but also to exert a promising 
epigenetic effect on the DNA repair capability of type II diabetic patients (Hariri et 
al., 2015). Dietary antioxidants may play a role even before disease diagnosis, 
whether independently or as a component of a generally ‘healthy lifestyle’, as an 
increased albuminuria (a prognostic marker for kidney disease), has been found to be 
associated with reduced levels of diet-derived carotenoids in an indigenous Australia 
population (Rowley, O'Dea, Su, Jenkins, & Best, 2003). Such and other findings 
highlight the complexity and overarching effect on redox status introduced by diet. 
We suspect that whether early in the disease, or towards advanced stages (especially 
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when CKD patients face severe nutritional restrictions, but were at the same time, not 
only noxious but potentially beneficial antioxidant intermediates as well may 
accumulate (Himmelfarb et al., 2003)), the role of targeted nutritional aids to reduce 
systemic oxidative stress could prove crucial for the reduction of CVD and 
malignancies risk. 
In conclusion it could be indicated that oxidative stress is implicated in the CKD 
pathophysiology and as the kidney function is getting worse, the redox status 
imbalance becomes more profound. Even at an early disease state, lipid peroxidation 
markers are elevated. This premature development sets perhaps the pace for 
accelerated atherogenesis, which appears to explain the profoundly negative CVD risk 
of end-stage patients. Thus early interventions to combat lipid peroxidation in pre-
dialysis patients need to be considered. 
At the end-stage, patients present both with overabundance of ROS and mostly 
compromised antioxidant capacity. HD therapy per se seems to contribute to the 
oxidant and antioxidant imbalance. Iron supplementation has a pro-oxidant role but 
appears largely balanced out by appropriate EPO supplementation. The choice of 
dialysis membrane and dialyzing fluid glucose content may modulate the pro-oxidant 
effect of HD treatment. Moreover, antioxidant supplements may ameliorate the 
oxidative stress biomarkers by enhancing antioxidants defense, however mode of 
administration (i.e. intravenous for Vitamin C) should be carefully considered for 
efficacy. Vitamin E supplementation has been so far shown to be ineffective in HD 
patients, however small studies testing NAC and L-carnitine reported promising 
results. 
Peritoneal dialysis did not appear to have a clear advantage over HD treatment, 
despite the biocompatibility advantage, while HFR may better preserve some 
antioxidant molecules. However the small number of studies in PD and HFR do not 
allow for safe conclusions and further work is needed to clarify the role of dialysis 
modality on redox status of ESRD patients. 
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3.3 The role of Oxidative stress in CKD-Skeletal Muscle levels 
 
 It is widely known that skeletal muscle activity generates ROS. Although high 
levels of ROS can damage cellular components, physiological levels of ROS play an 
important role in cells function including the regulation of cell signaling pathways, 
control of gene expression and modulation of muscle force production (Droge, 2002; 
Powers, Duarte, Kavazis, & Talbert, 2010; Reid, 2001a, 2001b).  Several sources of 
endogenous and exogenous sources of ROS generation in skeletal muscle have been 
introduced.  
Regarding endogenous sources, mitochondria are thought to produce ROS by a 
leak of single electron in the respiratory chain in the mitochondrial inner membrane of 
the contracting muscle cells. NADPH oxidases (NOX), which are transmembrane 
proteins in the transverse tubules and the sarcoplasmatic reticulum transport electrons 
across biological membranes to reduce oxygen to superoxide or H2O2 (Bedard & 
Krause, 2007; Brandes, Weissmann, & Schroder, 2014) and contribute to the 
cytosolic ROS production in skeletal muscle. Mitochondria and NADPH oxidase 
produce ROS in skeletal muscle both at rest and during contractile activity with 
NAPDH oxidase to produce ROS to a larger extent than mitochondria (Shkryl et al., 
2009; Xia, Webb, Gnall, Cutler, & Abramson, 2003). Moreover, xanthine oxidase is 
present in the cytosol of skeletal muscle and catalyzes the hydroxylation of 
hupoxanthine to xanthine and of xanthine to uric acid (Harrison, 2002) During 
contraction xanthine oxidase contributes to lipid peroxidation, protein oxidation and 
muscle cell damage via the production of ROS.  Finally, phospholipase A2 enzymes 
(PLA2) and myostatin is capable of signaling ROS production (Sriram et al., 2014; 
Zuo, Christofi, Wright, Bao, & Clanton, 2004). 
Additionally, it has been shown that ROS are also produced from non-muscle 
sources disturbing muscle redox status and leading to tissue damage. Muscle injury, 
often observed during strenuous exercise, activates neutrophils and macrophages and 
although this process is necessary for fiber regeneration, it also results in ROS 
releasing (oxidative burst) (Moylan & Reid, 2007; Peake & Suzuki, 2004).   
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It is suggested that oxidative stress enhances the catabolic state and accelerates 
muscle atrophy (Moylan & Reid, 2007). The contractility of the remaining muscle and 
the sarcomeric protein expression are also affected by the imbalance of redox status. 
Several studies have observed that oxidative stress causes acute and log-term 
effects on contractility. As an acute effect it is regarded the decrease in Ca
2+ 
sensitivity which contributes to muscle fatigue, with reversible characteristics though. 
On the opposite, irreversible alterations in gene and protein expression or damages in 
proteins and lipids are considered as long-term effects (Lamb & Westerblad, 2011).  
 Regarding acute effect of ROS on muscle contractility, the reduced 
myofibrillar Ca
2+ 
sensitivity and/or sarcoplasmic reticulum Ca
2+
 release has been 
proposed to play an important role in muscle fatigue (Allen, Lamb, & Westerblad, 
2008). Furthermore, the increase of NO donors during fatigue has a negative impact 
on myofibrillar Ca
2+ 
sensitivity in fast-twich muscle fibers (Lamb & Westerblad, 
2011). However, such a decrease in myofibrillar Ca
2+ 
sensitivity observation was not 
noticed in slow-twitch fibers (Spencer & Posterino, 2009). Reardon & Allen (Reardon 
& Allen, 2009) have also observed that iron is capable of enhancing ROS production 
in skeletal muscle at high temperature.  
 It is widely accepted that actomyosin complex is essential for force generation 
in skeletal muscle. ROS can acutely affect its structure and functionality with negative 
results to the contractility. Prochniewicz et al (Prochniewicz et al., 2008) found that 
exposure to low or high concentrations of hydrogen peroxide (5 or 50 mM) reduces 
maximum force and velocity of contractions. More specifically, the exposure to high 
concentrations of peroxide can cause oxidative damage of methionines which are 
contained in the heavy and essentially light chain of myosin. As a result, due to the 
irreversible loss of calcium regulation of force, a reduction of maximum force and 
velocity of contraction was observed (Prochniewicz et al., 2008). Moreover, changes 
in the expression of myosin heavy chain in uremic animals have been reported (Taes 
et al., 2004).  
 Besides the effects on contractile kinetics, oxidative stress also contributes to 
modulation of several signaling pathways such as calcium, phospholipases, 
phosphatases, serine/threonine kinases and protein tyrosine kinases (Jackson et al., 
2002) These modulation leads to changes in gene expression, cell function, 
metabolism and damage. Oxidative stress is accompanied by an increase in protein 
loss and muscle atrophy. Specifically, protein complexes such as NF-kΒ and FOxO 
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are activated via excessive ROS and in turn activate two muscle- specific E3 ubiquitin 
ligases, Muscle RING Finger 1 (MuRF-1) and Muscle Atrophy F-box (MAFbx, also 
known as Atrogin-1) (Gumucio & Mendias, 2013). Particularly, MurF-1 and MAFbx 
have been shown to over-express in muscle atrophy (Bodine et al., 2001; Brooks & 
Myburgh, 2014; Gomes, Lecker, Jagoe, Navon, & Goldberg, 2001) and degrade 
several protein such as myosin light chains 1 and 2, myosin heavy chain, titin, 
nebulin, troponin and myosin-binding protein C (Cohen et al., 2009; Witt, Granzier, 
Witt, & Labeit, 2005). 
 Nonetheless, in many chronic inflammatory diseases, such as CDK, muscle 
weakness runs parallel with, and in part independently of muscle atrophy. In 
populations studied so far, although absolute strength is reduced, force normalized for 
loss of muscle mass remains unchanged. For example, ageing human populations 
experience the reduction in muscle strength that exceeds the loss of muscle mass 
(Goodpaster et al., 2006; Hairi et al., 2010). Studies with skinned fibers of patients 
with chronic obstructive pulmonary disease (Levine et al., 2003; Ottenheijm et al., 
2005) or chronic heart failure (Szentesi et al., 2005) revealed reduced muscle force 
production that is independent of muscle mass loss.  
 Circulating pro-inflammatory mediators such as interleukin-6, C-reactive 
protein, sphingomyelase and tumor necrosis factor-α (TNF) found elevated in patients 
with chronic diseases and associated with muscle weakness (Cicoira et al., 2001; 
Doehner et al., 2007; Toth, Ades, Tischler, Tracy, & LeWinter, 2006; Yende et al., 
2006), with TNF to be the most strongly implicated. Studies have shown that chronic 
exposure to TNF promotes decreased specific force and muscle weakness (X. Li et al., 
2000; Tisdale, 2008) which is not entirely attributed to loss of muscle mass. It has 
been suggested that TNF has a direct effect on muscle by altering myofibrillar 
function with troponin, myosin heavy chain, or tropomyosin to constitute potential 
molecular targets of TNF/TNFR1 signalling. Experimental evidence suggested that 
muscle derived-oxidants are essential mediators of TNF/TNFR1-induced dysfunction. 
However the exact mechanism by which TNF depresses contractile function via 
oxidant activity has not been elucidated. Existing data supports that a cascade of 
potential signaling events takes place. There have been suggested several mechanism 
for TNF-stimulated oxidants without though the predominant to have been identified. 
Additionally, the mechanism by which oxidant activity depresses myofibrillar 
function remains also unknown. Perhaps the mechanisms involve direct reaction of 
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TNF-stimulated oxidants with myofilament proteins (Burke, Reisler, & Harrington, 
1976; Putkey, Dotson, & Mouawad, 1993; Williams & Swenson, 1982) or activation 
of redox-sensitive kinases or phosphatases that modify the phosphorylation state of 
myofibrillar protein and thereby influence force (Andrade, Reid, & Westerblad, 
2001). Other post-translational mechanisms may include carbonylation (Coirault et 
al., 2007), ubiquitination (Dalla Libera et al., 2005) and myosin degradation 
(Tikunov, Mancini, & Levine, 1996). 
 In the literature, several studies evaluated the role of oxidative stress in 
skeletal muscle using in vivo or in vitro methods (Powers et al., 2011). However, only 
three studies (Table 5) have examined the oxidative damage in human skeletal muscle 
of uremic patients and the outcomes derive only from those being in the end stage of 
the disease. 
 Lim et al (Lim, Cheng, & Wei, 2002), found statistically significant elevation 
in the levels of protein carbonyls and malondialdehyde (MDA) in skeletal muscle of 
uremic patients, compared to healthy subjects, reflecting increased protein and lipid 
oxidation. It is suggested by the authors that oxidative damage in uremic patients is 
generated due to the increase of inflammatory cytokines, which is supported by the 
hemodialysis and the uremia per se. Oxidative damage of proteins may result in 
alterations in amino acid sequence, accumulation of modified proteins, carbonylation 
and rapid degradation. Taking into consideration that skeletal muscle contains high 
levels of fibrillar proteins, their oxidative modifications play a key role in the 
impaired structure and functionality and the emergence of uremic myopathy. 
Oxidative damage of membrane phospholipids results in the loss of the selective 
permeability and functionally integrity of membranes, exposing them to damage. 
 According to another study of Lim et al (Lim, Ma, et al., 2002), it was 
observed that the average content of lipid peroxides and protein carbonyls in 
mitochondrial membranes of skeletal muscle of uremic patients were significantly 
higher than that of aged-matched healthy subjects. Additionally, oxidative damage to 
total cellular DNA was observed, suggesting not only a deterioration of mitochondrial 
function but also, an overall damage to the regenerative and bioenergetics capacity of 
skeletal muscle of uremic patients. Last but not least, increased mitochondrial DNA 
deletions was found in the skeletal muscle of ESRD patients compared with healthy 
subjects, attributed by the authors to the uremic toxins and the impaired antioxidant 
system of ESRD patients. These alterations in the genetic code of skeletal muscle may 
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contribute to the dysfunction of mitochondrial energy metabolism with negative 
effects for uremic patients (Lim, Cheng, & Wei, 2000).  
On the other hand, Crowe et al (Crowe et al., 2007), found decreased levels of 
MDA and increased concentration of total glutathione in the skeletal muscle of 
patients with ESRD on HD compared to healthy subjects. Also, no differences in 
protein thiols content, oxidized glutathione (GSSG) concentrations, superoxide 
dismutase (SOD) and catalase activities between two groups were observed, 
concluding that muscle atrophy observed in these patients is not related with oxidative 
stress.  
As it is noticed, there are conflicting results between the studies (Table 3.5) 
dealing with the evaluation of redox status indices in skeletal muscle of patients with 
CKD. If one takes into consideration the age difference in the patients of the studies, 
can conclude that younger patients have a better redox and mitochondrial status since 
they had spent less time on dialysis therapy. This could be an explanation why 
patients in Crowe et al study did not exhibit deteriorated muscle redox status indices. 
Furthermore, adaptation of several antioxidant mechanisms could be an additional 
factor for the conflicting results between the studies.  
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Table 3.5. Markers of oxidative stress in skeletal muscle tissue of uremic patients 
GSH, glutathione; GSSG, oxidized glutathione ;SOD, superoxide dismutase; MDA, malondialdehyde; CAT, catalase; PC, protein carbonyl; Thiols, protein thiol content Arrows indicate 
statistically significant differences reported by authors 
Reference Markers of oxidative stress in muscle tissue of uremic patients 
  
Total glutathione 
nmol/mg protein 
GSSG 
nmol/mg protein 
SOD 
U/mg protein 
MDA 
nmol/mg protein 
CAT 
U/mg protein 
PC 
nmol /mg of protein 
Thiols 
nmol/mg protein 
(Lim, Cheng, et al., 2002) - - - 
 
0.065±0.009 ↑ 
- 
 
3.78±-0.14 ↑ 
- 
(Lim, Ma, et al., 2002) - - - 
 
23.76±6.06 ↑ 
- 
 
24.9±4.00 ↑ 
- 
(Crowe et al., 2007) 
 
≈24 ↑ 
 
≈2.6 
 
≈20 
 
≈0.28 ↓ 
 
≈11 ↓ 
- 
 
≈79 
Reference Markers of oxidative stress in muscle tissue of healthy controls 
(Lim, Cheng, et al., 2002) - - - 
 
0.043±0.005 
- 
 
2.97±-0.28 
- 
(Lim, Ma, et al., 2002) - - - 
 
7.67±0.95 
- 
 
3.78±0.14 
- 
(Crowe et al., 2007) ≈5 ≈3.3 ≈27 ≈0.52 ≈34 - ≈60 
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3.4 The practicality of animal models 
 
The progressive and irreversible loss of renal function over a period of months 
or years is of diverse etiologies including metabolic syndrome, family history, 
environmental factors, and in many cases unidentified causes (Kurella, Lo, & 
Chertow, 2005). The disease is characterized by a variety of complex alterations in 
many organs and tissues making CKD a difficult task for medical and scientific 
approach. 
Several animal models of CKD have been introduced in order to overcome the 
confounding factors of human disease by studying solely mechanisms in a limited 
timespan (Becker & Hewitson, 2013). Using such experimental models, researchers 
have the opportunity to understand the physiology and pathophysiology of the 
disease, to examine potential novel therapies, or to improve the existing ones (Becker 
& Hewitson, 2013). Depending on the mechanism, or the system of interest, CKD can 
be induced by in vitro or in vivo models and the choice of the model is of crucial role 
for the outcomes of each study. In vitro models are of small utility while results may 
vary depending on the cell type examined and therefore studies examined this kind of 
models are limited (H. C. Yang, Zuo, & Fogo, 2010). On the other hand, in vivo 
models are of larger interest while outcomes have a better reflection in in vivo 
physiology. As a result, a lot of animal models of CKD have been introduced such as 
vascular injury models, genetically engineered models, spontaneous models or 
immune and non-immune models (H. C. Yang et al., 2010). Non-immune models can 
be induced in many ways including surgical intervention called nephrectomy and it 
represents an animal model of CKD of known etiology. Surgical manipulations are 
widely performed to mimic chronic kidney human disease by reducing renal mass and 
to test therapeutic approaches.   
Another critical factor for animal models is the choice of the right animal. There 
has been introduced a variety of species (mice, rats, rabbits, dogs) as animal models 
of CKD, but the right selection depends on what particular aspect of the disease is 
going to be reproduced each time. Murine models of kidney disease are increasingly 
preferred because of their small size, their low cost housing and the genetically 
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defined strains (Anders & Schlondorff, 2000). Furthermore, rodent models, remain 
the closest to human disease species (Becker & Hewitson, 2013).  
 New Zealand rabbits have been widely used for surgically induced CKD. One 
of these approaches was developed in 1982 by a two – step partial nephrectomy 
(Gotloib et al., 1982). First partial nephrectomy of left kidney was induced by 
electrocauterization keeping 1/3 of the kidney functional and after an interval of two 
weeks, a total removal of the right kidney was performed through a flank incision and 
by extraperitoneal approach. In this way the authors established a reliable animal 
model for investigating the metabolic complications of continuous ambulatory 
peritoneal dialysis (CAPD). This surgical approach that aims reproducing CKD by 
reduction of renal mass has been achieved by using different protocols and in various 
animal models (Dobbie, 1993; Gotloib et al., 1982; L. J. Ma & Fogo, 2003; L. J. Ma 
et al., 2005; Oreopoulos, Balaskas, Rodela, Anderson, & Oreopoulos, 1993).  
Our research interests focus on uremic myopathy. Therefore, we chose the 
animal model of White New Zealand rabbit (WNZ) that can provide us the necessary 
experimental material – blood and muscle- for a variety of experiments, including 
biochemical, molecular analysis and mechanics respecting the “Three R’s” (Guide for 
the Care and Use of Laboratory Animals).  
 
3.5 Conclusions and Unanswered Questions 
 
From the current literature review it can be concluded that the redox status of 
uremic patients have been widely studied. Although a variety of possible factors has 
been implicated, the results are usually controversial and there is not yet a clear 
explanation about the exact mechanism underlying redox status disturbance in CKD 
in blood as well as in skeletal muscle of patients.  
As far as redox status evaluation in blood is concerned, studies revealed that 
oxidative stress is implicated in CKD pathophysiology and as the kidney function is 
getting worse, the redox status imbalance becomes more profound. Even at an early 
disease state lipid peroxidation markers are elevated. This premature development 
sets perhaps the pace for accelerated atherogenesis which appears to explain the 
profoundly negative CVD risk of end-stage patients. At the end-stage, patients present 
both with overabundance of ROS and mostly compromised antioxidant capacity and 
HD pes se seems to contribute to the oxidant and antioxidant imbalance. Iron 
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supplementation has a pro-oxidant role but appears largely balanced out by 
appropriate EPO supplementation. The choice of dialysis membrane and dialyzing 
fluid glucose content may modulate the pro-oxidant effect of HD treatment. 
Moreover, antioxidant supplements may ameliorate oxidative stress levels by 
enhancing antioxidants defense, however mode of administration (i.e. intravenous for 
Vitamin C) should be carefully considered for efficacy. Vitamin E supplementation 
has been so far shown to be ineffective in HD patients, however small studies testing 
NAC and L-carnitine reported promising results. 
Peritoneal dialysis did not appear to have a clear advantage over HD treatment, 
despite the biocompatibility advantage, while HFR may better preserve some 
antioxidant molecules. However the small number of studies in PD and HFR do not 
allow for safe conclusions and further work is needed to clarify the role of dialysis 
modality on redox status of ESRD patients. 
CKD patients are affected by multiple concomitant conditions like diabetes, 
dyslipidemia, and hypertension which are all associated with oxidative stress. The 
presence of CKD appears to further enhance the oxidative stress independently from 
the underlying conditions. Increasing evidence suggests that oxidative stress is a 
plausible independent cardiovascular risk factor in CKD. A more comprehensive 
study combining the simultaneous evaluation of a variety of oxidative stress and 
biochemical status indices should be done in order to identify these biomarkers that 
could be used in clinical practice to monitor the disturbed redox and lipid profile in 
CKD patients. More early- stage research is necessary in order to identify all these 
mechanisms from the early beginning where several intervention and therapies may 
delay, or possibly halt, the progression of the disease 
Regarding skeletal muscle, the few studies that examined the effects of CKD on 
skeletal muscle redox status, do point to a possibly important role for oxidative stress 
in uremic myopathy. It is not known if hypothesized oxidative stress mediated effects 
on muscle function are more of an acute or a chronic nature. In vitro studies however 
show clearly that oxidative stress does have a role either via chronic, protein and other 
modifications or acute contractility effects. If anything these few studies and the 
peripheral literature highlight the need for a systematic study of the disease 
mechanisms affecting skeletal muscle performance in CKD.  
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 As long as great unknowns remain on the mechanisms and modulation of 
uremic myopathy, which leads to debilitation and premature death, progress in this 
new epidemic is the least slowed down. It is suggested that more muscle research 
should be done on pre-dialysis stages including work on the role of oxidative stress. 
This would allow researchers to decipher early changes, and perhaps identify 
susceptible individuals for accelerated muscle loss, before moving into the end-stage 
situation which on its own has detrimental effects on muscle status. 
Last but not least, judging from the above results, it is further confirmed the 
difficulties faced by the researchers in the field of CKD. A variety of confounding 
factors such as years in dialysis, comorbidities, pharmaceuticals, gender, nutritional 
status, physical activity levels can affect muscle and blood redox and biochemical 
status and accelerate or retard the disease manifestation. To answer such questions it 
was important to use methodology that avoids all those confounding factors which are 
unavoidable when studying patients. This issue can be satisfactorily addressed by 
employing an animal model mimicking chronic renal insufficiency.  
Thus the current PhD thesis will try to cover the lack of knowledge answering 
to all these unanswered questions related to oxidative stress and CKD. Is there any 
oxidative stress damage or reduction in the antioxidant capacity in the early stages of 
the disease and which of the two becomes critical first? Do all these possible redox 
status disturbances influence biochemical profile in the early stages of CDK? What 
about the redox status of skeletal muscle? Is there any difference in redox status 
between two different types of skeletal muscle? Is this possible disturbance muscle 
type specific? What about biochemical status of skeletal muscle in the early stages of 
the disease? Is there any possible relationship between the changes in blood and 
muscle redox status between the two groups as a result of uremia? 
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Research paper 1: Effects of CKD on blood redox status 
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Abstract 
 
Introduction: It has been suggested that oxidative stress constitutes the basis of 
several pathologies encountered in CKD. Although the progression of CKD is 
associated with the harmful effects of oxidative stress, its role has not yet been fully 
clarified during the different stages of the disease 
Aims: The aim of this study was to evaluate the systemic effects of CKD in redox 
status indices using an animal model of CKD and to identify which one of its 
components, defense capacity or ROS overproduction, becomes critical first. 
Methods: We used an animal model (partial nephrectomy) of renal disease in New 
Zealand white female rabbits. Surgery and euthanasia (after 3 months) protocols were 
approved by the ethic committee of the University of Thessaly. Renal insufficiency 
was induced by removal of the right kidney and partial nephrectomy of the left kidney 
(Uremic group, N=9). Control animals underwent sham operation (Control group, 
N=6). Blood samples were collected and analysed for Uric acid, Glutathione Reduced 
(GSH), Glutathione Oxidized (GSSG), GSH/GSSG ratio, Total Antioxidant Capacity 
(TAC), Catalase Activity (CAT), Protein Carbonyls (PC) and Thiobarbituric Acid 
Reactive (TBARS). Urea, creatinine, total protein and hemoglobin levels were also 
evaluated. 
Results: GSH concentration was significantly higher in the Uremic group (17.50 ± 
1.73 μmol/g protein) compared to Control (12.43 ± 1.01 μmol/g protein), p=0.033. 
TBARS concentration tended to be higher in the Uremic group (7.03 ± 0.81 nmol/ml), 
compared to Control (5.12 ± 0.42 nmol/ml), p=0.060. No significant differences were 
found in the rest of redox status indices evaluated in blood of Control and Uremic 
groups (p>0.05). 
Conclusion: Evidence of early oxidative stress appears in the blood of our model of a 
pre-dialysis stage of CKD. As an adaptive response the levels of GSH, an antioxidant 
molecule, increased in order to keep redox homeostasis stable. However the tendency 
for increased lipid peroxidation (TBARS) is probably indicative of premature 
development of cardiovascular problems and atherogenesis in pro dialysis patients. 
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Thus early interventions to combat lipid peroxidation in these early stages may need 
to be considered.  
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Introduction 
 
The term redox status described the dynamic balance between oxidants (or pro-
oxidants) and antioxidants and is considered a major factor for cellular homeostasis. 
Under physiological conditions the equilibrium between generation and elimination of 
ROS is maintained by several complex mechanisms. Redox homeostasis can be 
disrupted due to a dysfunction of any of these mechanisms, resulting in an increased 
ROS production and a decreased scavenging capacity, a condition which is described 
as oxidative stress. ROS are highly reactive to proteins, membrane lipids, 
carbohydrates and nucleic acids, causing irreversible damages which affect cell 
survival and lead to degenerative disorders and aging. (Trachootham, Lu, Ogasawara, 
Nilsa, & Huang, 2008). 
It has been suggested that oxidative stress constitutes the basis of several 
pathologies encountered in CKD, such as anemia, inflammation, fatigue, muscle 
waste, disuse atrophy, atherosclerosis and cardiovascular disease (Himmelfarb & 
Hakim, 2003). 
Although the progression of CKD is associated with the harmful effects of 
oxidative stress, its role has not yet been fully clarified during the different stages of 
the disease. The large majority of the existing data are referred to outcomes coming 
from the end-stage renal patients (ESRP) undergoing HD treatment. HD treatment is 
suggested to be responsible for increased oxidative stress mostly due to the 
hemoincompatibility induced by the direct contact of blood with the dialysis 
membrane (Horl, 2002; Morena et al., 2000). As a result, the neutrophils are activated 
releasing ROS into the blood stream (Hodkova et al., 2005). Four main factors have 
been proposed to be responsible for the harmful effects of oxidative stress in patients 
under HD: the uremic milieu, the HD treatment per se, the hemoincompatibility of 
dialysis system and the concomitant drug treatment (Canaud et al., 1999). 
Additionally, the precise evaluation of oxidative stress in ESRP is complex, since a 
variety of confounding factors, such as years in HD, comorbidities and 
pharmaceuticals are implicated. To avoid the above confounding factors, an animal 
model of CKD may be employed to better mimick CKD patients being in the pre-
dialysis stage of the disease. 
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The aim of this study was to evaluate the circulating redox status in animals 
with pre-dialysis stage of renal insufficiency and to identify which one of its 
components, defense capacity or ROS overproduction, becomes critical first.  
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Methods  
 
Animals and Experimental design 
New Zealand white female rabbits (young adult, N=15) with a body weight of 
approximately 3200 kg, were first acclimatized to the laboratory animal unit of 
Medical School (University of Thessaly, Greece) for 48 hours. The animals were 
housed in a controlled environment with stable conditions of room temperature (RT) 
(22–24°C) and lighting (12:12 h light-dark cycle). All rabbits were fed with a special 
rabbit chow containing low levels of protein, potassium, calcium, phosphorus and 
sodium (prepared by Research Diets, Inc. USA) and water ad libitum. All animal 
procedures, including surgery and euthanasia for this project were approved by the 
ethics committee of the University of Thessaly (decision 2-2/10-10-2012) and the 
scientific committee of the University Hospital of Larisa, Greece (decision 1/4-1-2012 
and animals were under veterinary care, in accordance to the national directives for 
the care and the use of laboratory animals.  
After acclimatization, surgical procedures were performed (sham operation for 
control animals - Control group and partial nephrectomy for experimental animals – 
Uremic group.  Animals were anaesthetized by intravenous administration of a 
solution mixture of ketamine hydrochloride 100 mg/ml (Imalgene® 1000; Merial, 
Duluth, Georgia, USA) and xylazine 20 mg/ml (Rompun®; Bayer, Leverkusen, 
Germany), 87 % and 13 % respectively (proportion 6,69:1 approximately). The initial 
dosage for the induction of anesthesia was 0.3 ml/Kg body weight of the above 
solution mixture, i.e. Imalgene® (87%) and Rompun® (13%), intravenously (i.v.). 
The maintenance of anesthesia was achieved by a dose of propofol (10mg/kg BW). 
Three hours before the intervention, each animal had only access to water and not to 
food and its weight was measured on a precision scale. Animal temperature was 
maintained via a heating pad.  
The induction of renal insufficiency was performed surgically (using a surgical 
protocol modified from Gotloib et al., 1982 (Gotloib et al., 1982). For the Uremic 
group nine animals (N=9), underwent removal of the left kidney after careful ligation 
of the left renal artery and vein; and partial nephrectomy (¾) of the right kidney. For 
the Control group six age-matched animals (N=6) underwent sham operation. Twelve 
weeks after surgery, the animals were weighed and then sacrificed by injection of 
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sodium pentobarbital solution (50 mg/ml) which was applied in a dosage of 100 
mg/Kg BW followed by bilateral thoracotomy. Immediately after cardiac arrest, 
sample collections were done in a blind fashion. 
 
Sample Preparation 
 
Blood sampling and treatment 
Blood samples (5ml) were collected from the rabbits’ heart and aorta by a 
heparinized syringe and were placed into ethylene diamine tetra-acetic acid 
(K2EDTA)-containing tubes (Vacutainer Plus Plastic K2EDTA; Becton Dickinson). 
For plasma collection, blood samples were centrifuged immediately at 1370 × g for 
10 min at 4
ο
 C and the supernatant was carefully collected, aliquoted in multiple 
eppendorf tubes, stored at -80
o
C and thawed only once before analysis. The remained 
packed erythrocytes were lysed with 1:1 (v:v), distilled water, inverted vigorously, 
and centrifuged at 4000 × g for 15 min at 4ο C. The supernatant, red blood cells 
(RBCs) lysate designated, collected, aliquoted, stored at -80
ο
 C and thawed only once 
before analysis. Finally, in order to obtain serum, another portion of blood sample (5 
ml) was collected and placed into separate tubes containing clot activator, left for 20 
min to clot at RT and centrifuged at 1,370 × g, at 4°C for 10 min. The supernatant was 
collected, aliquoted in eppendorf tubes, stored at -80°C and thawed only once before 
analysis. 
 
Biochemical Analyses 
 
Urea, Creatinine, Total protein and Hemoglobin determination 
Urea and creatinine concentrations in serum were determined with the 
colorimetric method using the commercially available kits (ab83362, Abcam) and 
(ab65340, Abcam) respectively, a 96-well microtiter plate and a programmable 
microplate reader (Biochrom, Asys Expert 96). Urea and creatinine concentrations in 
unknown samples were determined by comparison with the standard curves. 
Total protein concentration in plasma and skeletal muscle (psoas, soleus) 
homogenates were determined spectrophotometrically using the bicinchoninic acid 
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(BCA) protein assay kit (Pierce). In plasma, total protein concentration was 
determined in order to estimate the final concentration of Protein Carbonyls. 
Hemoglobin concentration in red blood cell lysate was determined using a 
commercially available kit (Dutch Diagnostics BV, Zutphen, The Netherlands), in 
order to estimate the final concentration of Glutathione (reduced and oxidized) and 
Catalase activity.   
 
Evaluation of oxidative stress 
 
Determination of Reduced Glutathione 
Reduced Glutathione (GSH) concentration was determined in RBCs lysate 
according to Rahman et al. (2006) (Rahman, Kode, & Biswas, 2006), using a 96-well 
microtiter plate and a programmable microplate reader (Biochrom, Asys Expert 96). 
Briefly, blood samples were deproteinized with 5% trichloroacetic acid (TCA) (1:1 
v/v) centrifuged at 16,000 × g for 10 min and the supernatant was collected. The 
following reagents were added in order (all reagents in 0.1 M potassium phosphate 
buffer, pH 7.5, with 5 mM EDTA) to 96-well flat-bottom plate (CytoOone) in 
duplicate. 20 μL of glutathione standard (0.103 to 26.4 μΜ) or blood sample, 120 μL 
of freshly prepared DTNB (2 mg/3 ml), Glutathione Reductase (10 Units) mix 
solution (1v:1v) and 60 μL of NADPH (2 mg/3 ml). The absorbance at 415 nm was 
measured every 30 s, for 3 min, at room temperature (RT). The rate of increase in 
absorbance per minute was calculated by linear regression. Glutathione concentration 
in unknown blood samples was determined by comparison with the standard curve. 
Determination of Oxidized Glutathione 
Oxidized Glutathione (GSSG) concentration was determined in RBCs lysate 
according to Giustarini et al. (2013) (Giustarini, Dalle-Donne, Milzani, Fanti, & 
Rossi, 2013), modified for using a 96-well microtiter plate and a programmable 
microplate reader. Blood samples were deproteinized with 5% trichloroacetic acid 
(TCA) (1:1 v/v) centrifuged at 16,000 × g for 10 min and the supernatant was 
collectedTo avoid the rapid oxidation of GSH to GSSG, through the deproteination 
procedure, and the consequent overestimation of GSSG, the alkylating reagent N- 
ethylmaleimide (NEM) 310 mM was added upon collection of blood sample or the 
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tissue homogenization. This was extracted before the actual measurement with three 
volumes of dichloromethane DCM, carefully collecting the upper volume of the 
ensuing bilayer (typically 750 μL of DCM for 250 μL of deproteinized supernatant, in 
a 1.5-ml Eppendorf tube, vortexed 5 min at 800 rpm RT and centrifuged at 14,000 × g 
for 30 sec at 4
ο
 C). To measure GSSG the following reagents were added in order (all 
reagents in 0.1 M potassium phosphate buffer, pH 7.5, with 5 mM EDTA) to 96-well 
flat-bottom plate (CytoOone) in duplicate: 20 μL of glutathione disulfide standard 
(0.103 to 26.4 μΜ) or the sample to be assayed, 120 μL of freshly prepared DTNB (2 
mg/3 ml) and Glutathione Reductase (10 Units) mix solution (1v:1v) and 60 μL of 
NADPH (2 mg/3 ml). The absorbance at 415 nm was measured every 30 s, for 3 min, 
at RT. The rate of increase in absorbance per minute was calculated by linear 
regression. Glutathione oxidized concentration in unknown samples was determined 
by comparison with the standard curve. 
Determination of Glutathione Reductase activity 
Glutathione reductase (GR) activity was determined in RBCs samples according 
to Cribb et al. (1989) (Cribb, Leeder, & Spielberg, 1989), using a 96-well microtiter 
plate and a programmable microplate reader. To measure glutathione reductase, the 
following reagents were added in order (all reagents in 0.1 M sodium phosphate 
buffer, pH 7.5, with 1 mM EDTA) to 96-well flat-bottom plate (CytoOone) in 
duplicate: 150 μL of 0.1 mM DTNB, 10 μL of NADPH (10 mg/ml; 12 mM), and 20 
μL of reductase standard (0.015 to 0.50 U/ml) or the blood  sample to be assayed. The 
reaction was initiated by the addition of 10 μL of GSSG (1 mg/ml; 3.25 mM). For 
blank wells, no GSSG was added. The absorbance at 415 nm was measured every 30 
s, for 3 min, at room temperature. The rate of increase in absorbance per minute was 
calculated by linear regression. Glutathione reductase in unknown blood  samples was 
determined by comparison with the standard curve 
Measurement of Total Antioxidant Capacity 
Total antioxidant capacity (TAC) was determined in plasma samples according 
to Janaszewska and Bartosz (2002) (Janaszewska & Bartosz, 2002), based on the 
scavenging of 2,2-diphenyl-1 picrylhydrazyl (DPPH) free radical. DPPH stock 
solution (10mM) was prepared by dissolving 0.02g DPPH in 5ml of methanol and 
mix in the stirrer. The working solution was obtained by diluting stock solution 100 
times with methanol. In 20 μL of plasma, 480 μL of 10 mM sodium potassium 
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phosphate (pH 7.4) and 500 μL of 0.1 mM DPPH were added and incubated in the 
dark for 30 min at RT. The samples were centrifuged for 3 min at 20,000 × g and 900 
μl of the supernatant was transferred into a clean plastic cuvette. The absorbance was 
read at 530 nm using a spectrophotometer. TAC values were presented as mM of 
DPPH reduced to 2,2-diphenyl-1picrylhydrazine (DPPH:H).  
Determination of Catalase activity 
Catalase (CAT) activity was determined in RBCs lysate according to Aebi 
(1984) method (Aebi, 1984). 20 μL of RBCs hemolysate was added to 2975 μL of 
sodium potassium phosphate buffer 67 mM, pH 7.4 and the samples were incubated at 
37
ο
 C for 10 min. 5 μL of hydrogen peroxide 30% was added and the change in 
absorbance was immediately read at 240nm for 2 min. One unit of catalase is equal to 
1 µmol of H2O2 decomposed/minute. Results were normalized to hemoglobin content 
in the sample (units/mg hemoglobin). 
Spectrophotometric DNPH assay for protein carbonyls content determination 
Protein carbonyls in oxidized proteins were determined in plasma samples 
according to Fields and Dixon (1971) (Fields & Dixon, 1971). In 50 μL of plasma, 50 
μL of 20 % TCA was added, incubated in the ice bath for 15 min and centrifuged at 
15,000 × g for 5 min at 4ο C and the supernatant was discarded. Afterwards, 500 μL 
of 14 mM 2,4-dinitrophenylhydrazine (DNPH), in 2.5 N HCl, for the sample or 500 
μL of 2.5 N HCl for the blank was added to the pellet. Both samples were incubated 
in the dark at RT for 1 h, with intermittent vortexing every 15 min. Samples were 
centrifuged at 15,000 × g for 5 min. at 4ο C. The supernatant was discarded and 1 mL 
of 10% TCA was added, vortexed, and centrifuged at 15,000 × g for 5 min at 4οC. 
The supernatant was discarded, and 1 mL of ethanol-ethyl acetate (1:1 v/v) was 
added, vortexed, and centrifuged at 15,000 × g for 5 min at 4ο C. The washing step 
was repeated two more times. The supernatant was discarded, and 1 mL of 5 M urea 
(pH 2.3) was added, vortexed, and incubated at 37
ο
 C for 15 min. The samples were 
centrifuged at 15,000 x g for 3 min at 4
ο
 C, and the absorbance was read at 375 nm. 
Protein carbonyls values were obtained by using the molar extinction coefficient of 
2,4- dinitrophenylhydrazine (22 mMcm-1). 
Institutional Repository - Library & Information Centre - University of Thessaly
30/09/2018 04:54:58 EEST - 137.108.70.6
  
84 
 
TBARS determination 
Thiobarbituric-acid reactive substances (TBARS) were determined in plasma 
samples according to Buege and Aust (1978) (Buege & Aust, 1978). (Buege & Aust, 
1978). In 100 μL of plasma, 500 μL of 35 % TCA and 500 μL of 200 mM Tris- HCl 
(pH 7.4) were added and incubated at RT for 10 min. Afterwards, 1 ml of 2 M 
Na2SO4 and 55 mM thiobarbituric acid (TBA) solution was added and incubated at 
95
ο
 C for 45 min. The samples were cooled on ice for 5 min and were vortexed. 1 ml 
of 70 % TCA was added, vortexed and centrifuged at 15,000 × g for 3 min at 25ο C. 
The absorbance of the supernatant was read at 530nm. A baseline absorbance was 
taken into account by running a blank along with all samples during the measurement. 
The calculation of TBARS concentration was obtained using the molar extinction 
coefficient of MDA (15600 mol/l). 
Uric acid determination 
Uric acid concentration was measured on a Clinical Chemistry Analyzer Z 1145 
(Zafiropoulos Diagnostica, Athens, Greece) using commercially available kits 
(Zafiropoulos Diagnostica). 6 μL of serum were added to 600 μL of working reagent, 
samples were incubated for 1 min at 37
o
 C and the absorbance was read at 340 nm.  
All materials for oxidative stress assays were purchased from Sigma (St. Louis, 
MO, USA 
Statistical Analysis 
Duplicate values were averaged. Data were analyzed using the commercially 
available statistical software package SPSS 22. The Shapiro-Wilk test was performed 
to initially test whether the data were normally distributed, as it was the case. Results 
are expressed as mean ± SEM and 95% confidence intervals.  
An independent t-test was conducted to examine whether there were any 
differences in blood redox status indices between Control and Uremic group. The 
significance level was set at p < 0.05.  
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Results 
 
 Body weight and biochemical indices 
Both surgery procedures (¾ partial nephrectomy (Uremic group) and sham 
operation (Control group) were well tolerated by animals who presented with a 
normal after-surgery recovery. At the end of the twelve-week period post surgery, 
body weight ranged between 3,045-4,965 gr (with mean ± SEM of 3,728 ± 336.47 gr) 
for Control group and 1,970-4,585 gr (with mean ± SEM of 2,935 ± 288.70 gr) for 
Uremic group (p>0.05). Renal insufficiency in experimental animals, compared to 
Control, was reflected in raised blood of urea and creatinine levels All results are 
represented in Table 4.1.1. 
 
Table 4.1.1. Biochemical indices (Mean ± SEM) in the Control and Uremic group. The exact statistical 
significance value P and the 95% Confidence Intervals are reported. 
 
Blood oxidative stress analysis 
GSH concentration was significantly higher in the Uremic group compared to 
Control t(9)=-2.071, p=0.033. TBARS concentration tended to be higher in the 
Uremic group compared to Control (p=0.080) (Figure 1). No significant differences 
were found in the rest of redox status indices evaluated in blood of Control and 
Uremic groups (p<0.05), as presented in Table 4.1.2. GSH and TBARS levels are 
presented also in Figure 4.1.1. 
 
 
 
 
 
 
CONTROL GROUP 
(n=6) 
95% Confidence 
Interval 
 
UREMIC 
GROUP (n=9) 
95% Confidence 
Interval 
P 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
Urea (mg/dl) 38 ± 4.3 33.43 43.24 60 ± 11.52 37.42 82.58 0.114 
Creatinine (mg/dl) 1.28 ± 0.15 1.11 1.45 2.45 ± 0.37 1.72 3.19 0.018* 
Total Protein (mg/ml) 68.59 ± 2.12 64.44 72.75 67.89 ± 2.28 63.41 72.37 0.825 
Hemoglobin (mg/dl) 11.08 ± 0.92 10.33 11.81 9.80 ± 0.30 78.22 11.77 0.368 
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Table 4.1.2. Blood redox status indices (Mean ± SEM) in the Control and Uremic group. The exact statistical 
significance value P and the 95% Confidence Intervals are reported.  
 
  
 
GSH: Reduced Glutathione GSSG: Oxidized Glutathione TAC: Total Antioxidant Capacity, CAT: Catalase, PC: Protein Carbonyls, 
TBARS: Thiobarbituric Acid Reactive Substances, * statistical significance between Control and Uremic group, p<0.05 
 
 
 
 
Figure 4.1.1. Indicative blood redox status indices (Mean ± SEM) in the Control and Uremic 
group. A: GSH and B: TBARS concentration in blood of Control and Uremic group, * P<0.05 
compared to Control 
 
 
No significant differences were found in the rest of redox status indices 
evaluated in blood of Control and Uremic group (p<0.05), as presented in Table 4.1.2. 
 
 
 
 
 
 
BLOOD 
 
CONTROL 
GROUP (n=6) 
95% Confidence 
Interval 
 
UREMIC GROUP 
(n=9) 
95% Confidence 
Interval 
P 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
Uric Acid (mg/dl) 1.39 ± 0.25 0.907 1.886 1.93 ± 0.38 1.18 2.67 0.263 
GSH (μmol/g protein) 12.43 ± 1.01 10.45 14.41 17.50 ± 1.73 14.12 20.88   0.033* 
GSSG (μmol/g protein) 0.027 ± 0.006 0.016 0.039 0.048 ± 0.010 0.028 0.067 0.110 
Ratio (GSH/GSSG) 481 ± 53 376 586 425.28 ± 61.19 305.36 545.21 0.511 
GR Reductase (U/g protein) 176.40 ± 25 127.39 225.42 153.1 ± 15.84 122.04 184.15 0.425 
TAC (μmol DPPH/ml) 0.786 ± 0.033 0.719 0.852 0.759 ± 0.041 0.679 0.838 0.611 
CAT (U/mg protein) 342.02 ± 17.69 307.35 376.68 303.63 ± 15.63 273.01 334.26 0.131 
PC (nmol/mg protein) 0.603 ± 0.09 0.427 0.780 0.620± 0.066 0.491 0.748 0.888 
TBARS (mmol/ml) 5.12 ± 0.42 4.29 5.94 7.03 ± 0.81 5.44 8.62 0.060 
Α Β 
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Discussion 
 
This study was performed to analyze a range of redox status indices in blood 
using a rabbit model of CKD. Our major findings were that GSH concentration was 
significantly higher in the erythrocytes of the Uremic group compared to the Control 
and that there was a tendency for an increase in TBARS concentration in the plasma 
of Uremic group compared to Control. 
GSH is a primary antioxidant molecule which belongs to the endogenous 
defense against ROS and its role is critical for the cellular redox environment (Small, 
Coombes, Bennett, Johnson, & Gobe, 2012), since it is the most abundant non-protein 
thiol that defends against oxidative stress (Lu, 2013). Specifically, GSH is synthesized 
in the cytosol in virtually all cells (highest concentrations are in the liver) from its 
constituent amino acids, glutamate, cysteine and glycine via the sequential action of 
two ATP-dependent cytosolic enzymes, namely gamma-glutamylcysteine synthetase 
(γ-GCS) and glutathione synthetase (GSH-S) (Anderson & Meister, 1983). With 
regard to red blood cells (RBCs), they can also synthesize GSH through the above 
procedure since they contain all the enzymes for its biosynthesis and a significant 
percentage of their GSH is produced de novo daily (Dass, Bermes, & Holmes, 1992). 
It exists in the thiol-reduced and disulfide-oxidized (GSSG) forms (Kaplowitz, Aw, & 
Ookhtens, 1985) but GSH is the predominant form and accounts for >98% of total 
GSH (Forman, Zhang, & Rinna, 2009). There are three GSH reservoirs in the 
eukaryotic cells. Most (80-85%) of the cellular GSH is in the cytosol, 10-15% is in 
the mitochondria and a small percentage is in the endoplasmic reticulum (C. Hwang, 
Sinskey, & Lodish, 1992; Meredith & Reed, 1982).  
Measured GSH blood levels are thus, the result of the dynamic balance between 
GSH synthesis, its recycling from GSSG (by Gr-Reductase) and its utilization (by 
peroxidases, transferases, transhydrogenases and transpeptidases). 
According to the literature (human studies), there are conflicting results 
regarding GSH concentration in CKD patients, which appear sometimes to depend on 
the severity of the disease (as reflected by urea and creatinine levels) and sometimes 
not. Thus, in moderately uremic pre-dialysis patients, in agreement to our 
observations, Bober et al showed higher levels of GSH in whole blood of CKD 
patients compared to age-matched healthy (Bober et al., 2010) (which increased 
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further in HD patients).  However, in other studies a reduction in GSH levels in the 
whole blood of CKD patients has been observed compared to controls (Annuk, 
Zilmer, Lind, Linde, & Fellstrom, 2001; Ceballos-Picot et al., 1996; Sahni et al., 
2012) reflecting a depletion in the antioxidant reserve. Alhamdani et al (Alhamdani, 
2005) evaluated the glutathione biosynthetic pathway in advanced uremia and 
hemodialysis measuring GSH levels, γ-GCS and GSH-S activities in non-dialysis, 
haemodialysis and continuous ambulatory peritoneal dialysis patients. Significant 
decreases in GSH levels and γ-GCS activity but not GSH-S were observed in all 
groups of patients compared to healthy individuals. Thus, low activity of γ-GCS, the 
rate limiting enzyme of GSH biosynthesis may have negatively affected de novo 
synthesis of GSH in those patients.  
GSH outcomes remain also contradictory in patients undergoing HD therapy, 
where either lower (Drai et al., 2001; Lim, Cheng, et al., 2002; Schettler et al., 1998) 
or higher (Biasioli, Schiavon, De Fanti, Cavalcanti, & Giavarina, 1996; Bober et al., 
2010; Stepniewska et al., 2006) GSH concentrations have been observed in the blood 
of HD patients compared to healthy individuals.  
The increased levels of GSH concentration in some CKD patients could be 
attributed to the upregulation of its synthesis in response to a greater demand. The 
antioxidant function of GSH is accomplished by GSH peroxidase (GPx)–catalyzed 
reactions, which reduce hydrogen peroxide and lipid peroxide to water and alcohols 
respectively, as GSH is oxidized to GSSG. GSSG in turn is reduced back to GSH by 
Gr-Reductase at the expense of NADPH, forming a redox cycle (Lu, 2009). Overall, 
the increased GSH levels in our study could be the result of the cell’s protective 
adaptive response to the uremic environment.  
The latter appears more likely in our case given the almost doubling of blood 
GSSG in UREM (UREM levels being 1.77 fold of those of CON) which, without 
reaching statistical significance, indicated increased levels of hydrogen peroxide or 
lipid peroxides, similarly to human studies (Annuk et al., 2001). Nonetheless, catalase 
also reduces hydrogen peroxide to water but there was no statistical difference in the 
activity of the specific antioxidant enzyme between the Control and the Uremic group 
(rather activity tended to be lower in erythrocytes of the Uremic group). As it is 
known catalase is located in peroxisomes and, in contrast, GSH and GPx is found 
mainly in the cytosol (Baud et al., 2004). This subcellular compartmentalization is 
undoubtedly important for hydrogen peroxide detoxification. Based on the above, it 
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appeared that hydrogen peroxide scavenging was undertaken in a greater degree by 
the glutathione redox cycling mechanism than catalase in our CKD model. The 
significant increase of GSH in uremic blood samples can also explain the undisturbed 
TAC and carbonylation levels of blood proteins. 
In our study animals followed the same diet, carefully designed not to tax the 
remaining kidney function, similarly to diet guidelines followed by patients, while 
providing balanced nutrients and minerals. However, dietary intakes can greatly 
influence GSH levels, and could explain the literature’s conflicting reports with 
regards to human patients’ GSH levels. As cysteine is the limiting amino acid for 
GSH synthesis, GSH concentration has been shown to be decreased by fasting, low-
protein diets, or diets limiting in sulfur amino acids (Paterson & Juurlink, 1999). 
Several studies revealed that α-Lipoic acid, a naturally occurring thiol compound, 
administration increases GSH levels in several cell types and tissues (Biewenga, 
Haenen, & Bast, 1997; Han et al., 1997; Paterson & Juurlink, 1999) and also restores 
intracellular GSH in several pathological conditions (Paterson & Juurlink, 1999). 
Moreover, selenium (Se) as an integral part of the enzyme GPx, plays a key role in 
GSH levels (Sunde & Hoekstra, 1980). In patient studies, while general clinical 
guidelines are the same, large differences in selenium or α-Lipoic acid intake cannot 
be excluded which could account for the literature’s conflicting results in GSH levels.   
An issue sometimes overlooked is the sensitivity of GSH and GSSG levels to 
sample handling errors and possible methodological oversights. Major artifacts can 
occur during GSH and GSSG titration, with the most important one being a 5-15% 
oxidation of GSH during sample deproteination with acids. This artifact can lead to 
remarkable overestimation of GSSG (Rossi et al., 2002) and underestimation of total 
GSH. To support the purposes of this research we applied the thiol alkylating agent 
NEM at the preparatory stages to prevent the oxidation of GSH. In perusing the 
conflicting patient studies (Annuk et al., 2001; Bober et al., 2010; Ceballos-Picot et 
al., 1996; Sahni et al., 2012) it is not clear if such measures were taken except for the 
study of Ceballos- Picot et al.,1996 where GSSG concentration was determined after 
sample derivatization by adding 2-vinylpyridine to prevent GSH oxidation (Ceballos-
Picot et al., 1996). Notwithstanding the above, it should be also noted that blood 
levels of GSH, as a ‘systemic’ marker, cannot reveal its origins. However, its 
increased levels in circulation confer an antioxidant advantage preventing or 
ameliorating vascular and other damage.  
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The increased (but not statistically significant) plasma TBARS levels by 
approximately 1.4 fold, in Uremic compared to Control samples, point to increased 
levels of lipid peroxidation, a process where oxidants, such as free radicals, assault 
lipids and especially their membranes (Ayala et al., 2014), leading to alterations of 
cell’s quality and survival. For example, oxidatively modified low-density lipoprotein 
(ox-LDL) is regarded as a pathogenetic factor in atherosclerosis (Steinberg, 1997). 
Furthermore, lipid peroxidation negatively affects erythrocytes membrane integrity, 
playing a major role to their half-life shortening and thus, to the development of 
anemia (Peuchant et al., 1997). Papavasiliou et al (Papavasiliou et al., 2005) found 
statistically significant increased TBARS levels in plasma of pre-dialysis patients with 
stage 3-5 CKD, compared to healthy individuals. In the same study, patients on stages 
1-2 CKD, exhibited a tendency for higher TBARS levels compared to healthy 
individuals. In contrast, stages 1-2 CKD patients, exhibited significantly lower MDA 
levels compared to the stages 3-5 CKD patients (Papavasiliou et al., 2005). Regarding 
HD patients, the large majority of studies reported increased TBARS levels in plasma 
compared to healthy individuals (Bober et al., 2010; Dimitrijevic et al., 2012; Guo et 
al., 2013; Haklar et al., 1995; Sakata et al., 2008; Sommerburg et al., 1998), reflecting 
extensive lipid peroxidation. Taking all the above into consideration together with our 
findings, it could be concluded that lipid peroxidation in CKD emerges even from the 
early stages and is getting worse during the progression of the disease.  
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Conclusion 
 
Evidence of early oxidative stress appears in the blood of our model of a pre-
dialysis stage of CKD. As an adaptive response the levels of GSH, an antioxidant 
molecule, increased in order to keep redox homeostasis stable. On the other hand, 
there was a tendency for increased lipid peroxidation in plasma of Uremic rabbits as 
compared to sham-operated. This premature development sets perhaps the pace for 
accelerated atherogenesis, which appears to explain the markedly increased incidence 
of cardiovascular disease (CVD) in ESRD patients. Thus early interventions to 
combat lipid peroxidation in pre-dialysis patients may need to be considered. 
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Research paper 2: Effects of Chronic Kidney Disease on skeletal 
muscle redox status: the role of muscle type  
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Abstract 
 
Introduction: Uremia affects skeletal muscle structure and function leading to 
muscle atrophy, muscle weakness, metabolic disorders, diminished exercise capacity 
and fatigue. Complex mechanisms that stimulate muscle dysfunction have been 
proposed, and oxidative stress may be implicated. 
Aims: The aim of this study was to evaluate the effects of uremia on muscle redox 
status in a rabbit model of renal insufficiency and more specific in two different types 
of skeletal muscle, in the fast and glycolytic psoas and in the slow and oxidative 
soleus. 
Methods: We used an animal model (partial nephrectomy) of renal disease in New 
Zealand white female rabbits. Surgery and euthanasia (after 3 months) protocols are 
approved by the ethic committee of the University of Thessaly. Renal insufficiency 
was induced by removal of the right kidney and partial nephrectomy of the left kidney 
(Uremic group, N=8). Control animals underwent sham operation (Control group, 
N=5). Psoas and soleus muscle samples were harvested, homogenized and analyzed 
for Protein Carbonyls (PC), Thiobarbituric Acid Reactive (TBARS), Glutathione 
Reduced (GSH), Glutathione Oxidized (GSSG), GSH/GSSG ratio, GR–Reductase 
activity, Total Antioxidant Capacity (TAC) and Catalase Activity (CAT). Total 
protein was also evaluated. 
Results: No interactions were found between the two examined muscle types (psoas, 
soleus) and two groups (Control, Uremic) for all the redox status indices (p>0.05). 
Significant group main effects were found for PC in both muscle types with its 
concentration to be higher in the Uremic group (psoas: 1.086 ± 0.294, soleus: 2.52 ± 
0.29 nmol/mg protein) compared to the Control (psoas: 0.596 ± 0.372, soleus: 0.929 ± 
0.41nmol/mg protein). 
 Significant muscle main effects were found for Total protein, PC, TBARS, GSH, 
TAC, CAT and GR-Reductase activity in both the Control and the Uremic group. 
Total protein and TAC concentrations were significantly lower in soleus compared to 
psoas muscle in both the Control and the Uremic group. Additionally, soleus 
demonstrated higher levels of TBARS and PC levels as well as higher GSH levels, 
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Catalase and GR-Reductase activities compared to psoas muscle in both the Control 
and Uremic group. 
Conclusion: The increased PC levels in soleus in Uremic compared to Control 
samples, point to increased levels of sarcomeric protein carbonylation and this early 
countermeasure for protein oxidation could be of great importance for patients before 
they move into the end-stage where the negative effects on muscle status may become 
irreversible. Since carbonyl formation is associated with protein degradation and 
proteolysis, the increased levels seem to constitute an early stimulus to muscle 
atrophy observed in these patients during the progression of the disease. 
Both oxidative damage and antioxidant reponse seems to be tissue-specific. Soleus 
muscle, which has greater number of mitochondria, by increasing ROS production it 
may be more exposed to ROS and their negative effects, but also that it develops an 
appropriate antioxidant capacity to withstand the oxidative load. In response to a 
further oxidative load due to renal insufficiency, uremic soleus appears to have further 
upregulated its defenses in comparison with uremic psoas. 
Our results highlight the need for interventions early during disease 
progression in order to protect skeletal muscle quality and reach at the end-stage at the 
best possible functionality. How the mechanisms of oxidative stress in the pre-dialysis 
stage of CKD accelerates protein carbonylation and degradation remains to be 
determined. 
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Introduction 
 
Oxidative stress is characterized by an imbalance between pro-oxidants and 
antioxidants. Over the last few years it is increasingly accepted that patients with 
CKD experience increased oxidative stress. Moreover it has also been shown that 
these patients frequently suffer from easy fatigability and muscle weakness. All of 
these pathological parameters are collectively termed uremic myopathy (Campistol, 
2002) which contributes to poor quality of life and high mortality.  
Skeletal muscle per se is a source of ROS. It has been shown that muscle 
activity leads to a strong increase in ROS production (Powers & Jackson, 2008), 
especially in exercise (Alessio, Goldfarb, & Cutler, 1988; K. J. Davies, Quintanilha, 
Brooks, & Packer, 1982; Reid, Haack, et al., 1992; Reid, Shoji, Moody, & Entman, 
1992). Oxidative stress mechanisms have been suggested to play a significant role in 
the conceivably related situations of disuse atrophy, age-related muscle atrophy and 
cancer cahexia (Jackman & Kandarian, 2004). However it remains unclear if 
oxidative stress plays a key role in the uremic myopathy commonly observed in CKD 
patients (Lim, Cheng, et al., 2002). 
Several studies have indicated that CKD is characterized by modifications of 
cell energy metabolism leading to a reduction in muscle performance (Brautbar, 1983; 
Del Canale et al., 1986; Metcoff et al., 1983). It has been suggested that hemodialysis 
treatment and/or uremia per se contribute to an increase in molecular oxidative 
damage which in turn play a key role for loss of skeletal muscle functionality. 
Additionally, animal studies have shown that experimentally induced oxidative stress 
cause myofibrillar protein modification and degradation (Nagasawa et al., 1997) 
through alterations of its amino acid sequences. A variety of amino acid modifications 
exists with carbonyl formation to be considered as an early marker of protein 
oxidation. Arginine, proline and threonine are the most likely amino acids to form 
carbonyl derivatives (Reznick & Packer, 1994). Given that skeletal muscle contains 
high levels of fibrillar proteins and it becomes extremely susceptible to free radical 
oxidation with adverse outcomes. 
Our hypothesis is that alterations of skeletal muscle function in CKD patients 
could be a consequence of the accumulation of oxidative damage to lipids and 
proteins that are exposed to the uremic milieu. The advance in methodologies for 
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evaluating oxidative stress will elucidate mechanisms and pathways which are 
responsible for redox status disturbances in skeletal muscle of CKD patients. 
However, most of the evidence of oxidative stress in skeletal muscle derives from 
studies in non-uremic populations (Haycock, Jones, Harris, & Mantle, 1996; Mecocci 
et al., 1999).  
In CKD, as reviewed by us (Kaltsatou et al., 2015), so far onlythree studies have 
evaluated the role of oxidative stress in skeletal muscle of patients (Crowe et al., 
2007; Lim, Cheng, et al., 2002; Lim, Ma, et al., 2002) undergoing hemodialysis. Two 
of three studies conducted by the same group indicated a possibly important role for 
oxidative stress in uremic myopathy via increased lipid peroxidation and protein 
carbonylation leading muscle cells into a catabolic state (Lim, Cheng, et al., 2002; 
Lim, Ma, et al., 2002).The authors also reported mitochondrial DNA mutations and 
overall oxidative damage to total cellular DNA. On the contrary, Crowe et al., 2007 
found decreased MDA levels, increased t-GSH and no change in protein thiols, SOD 
and GSSG levels and CAT activity in skeletal muscle of uremic patients compared to 
healthy individuals, concluding that there is no relationship between muscle atrophy 
and uremia (Crowe et al., 2007). 
The above discrepancies confirm that the precise evaluation of oxidative stress 
in ESRP is complex, since a variety of confounding factors, such as years in HD, 
comorbidities and pharmaceuticals are implicated. Thus there is a lack of data linking 
oxidative stress in skeletal muscle and its possible role in early stages of CKD. 
The aim of the present study was to evaluate the effects of uremia on muscle 
redox status in a rabbit model of renal insufficiency and more specific in two different 
types of skeletal muscle, in the fast and glycolytic psoas and in the slow and oxidative 
soleus. 
 
 
 
 
 
 
 
 
Institutional Repository - Library & Information Centre - University of Thessaly
30/09/2018 04:54:58 EEST - 137.108.70.6
  
97 
 
Methods  
 
Animals and Experimental design 
New Zealand white female rabbits (young adult, N=15) with body weight of 
approximately 3200 kg, were first acclimatized to the laboratory animal unit of 
Medical School (University of Thessaly, Greece) for 48 hours. The animals were 
housed in a controlled environment with stable conditions of room temperature (RT) 
(22–24°C) and lighting (12:12 h light-dark cycle). All rabbits were fed with a special 
rabbit chow containing low levels of protein, potassium, calcium, phosphorus and 
sodium (prepared by Research Diets, Inc. USA) and water ad libitum. All animal 
procedures, including surgery and euthanasia for this project were approved by the 
ethics committee of the University of Thessaly (decision 2-2/10-10-2012) and the 
scientific committee of the University Hospital of Larisa, Greece (decision 1/4-1-2012 
and animals were under veterinary care, in accordance to the national directives for 
the care and the use of laboratory animals.  
After acclimatization, surgical procedures were performed (sham operation for 
control animals - Control group and partial nephrectomy for experimental animals – 
Uremic group.  Animals were anaesthetized by intravenous administration of a 
solution mixture of ketamine hydrochloride 100 mg/ml (Imalgene® 1000; Merial, 
Duluth, Georgia, USA) and xylazine 20 mg/ml (Rompun®; Bayer, Leverkusen, 
Germany), 87 % and 13 % respectively (proportion 6,69:1 approximately). The initial 
dosage for the induction of anesthesia was 0.3 ml/Kg body weight of the above 
solution mixture, i.e. Imalgene® (87%) and Rompun® (13%), intravenously (i.v.). 
The maintenance of anesthesia was achieved by a dose of propofol (10mg/kg BW). 
Three hours before the intervention, each animal had only access to water and not to 
food and its weight was measured on a precision scale. Animal temperature was 
maintained via a heating pad.  
The induction of renal insufficiency was performed surgically (using a surgical 
protocol modified from Gotloib et al., 1982 (Gotloib et al., 1982). For the Uremic 
group nine animals (N=9), underwent removal of the left kidney after careful ligation 
of the left renal artery and vein; and partial nephrectomy (¾) of the right kidney. For 
the Control group six age-matched animals (N=6) underwent sham operation. Twelve 
weeks after surgery, the animals were weighed and then sacrificed by injection of 
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sodium pentobarbital solution (50 mg/ml) which was applied in a dosage of 100 
mg/Kg BW followed by bilateral thoracotomy. Immediately after cardiac arrest, 
sample collections were done in a blind fashion. 
Sample Preparation 
 
Skeletal muscle sampling  
 Psoas and soleus muscle samples were harvested from Control (sham-
operated) and Uremic group, were frozen immediately in liquid nitrogen, stored at -
80
ο
 C and part-thawed once (for homogenization) before final analysis. 
Skeletal muscle homogenization 
Tissues samples were thawed excised and kept chilled throughout 
homogenization. A weight portion of each muscle was washed several times with ice-
cold normal saline and was placed into pre-chilled epppendorfs containing cold 
homogenization buffer (138 mM NaCl, 2,7 mM KCl, 1 mM EDTA, pH 7.4) and a mix 
of protease inhibitors (1μΜ aprotinin, 1μg/ml leupeptin and 1mM PMSF). Initial 
homogenization was achieved with an electrical homogenizer (MICCRA D-9) for 10 
minutes with intermediate pauses of 10sec/20 sec. Then an ultrasound 
homogenizer (UP50H) was used for 1-2 minutes, with intermediate pauses as 
before. Homogenates were filtered through four layers of medical gauze to remove 
connective tissue debris, incubated for 10 m in at 4
ο
 C, and centrifuged at 10,000 X g 
for 10min again at 4
ο
 C. The supernatant was aliquoted in multiple portions and stored 
at -80
ο
 C. 
Biochemical Analyses 
Total protein in muscle homogenates was determined spectrophotometrically 
using the bicinchoninic acid (BCA) protein assay kit (Pierce), in order to estimate the 
final concentration of Protein Carbonyls concentration. 
Measurements of oxidative stress 
Determination of Reduced Glutathione 
Reduced Glutathione (GSH) concentration was determined in psoas and soleus 
homogenates  samples according to Rahman et al. (2006) (Rahman et al., 2006), using 
a 96-well microtiter plate and a programmable microplate reader. Briefly, homogenate 
samples were deproteinized with 5% trichloroacetic acid (TCA) (1:1 v/v) centrifuged 
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at 16,000 X g for 10 min and the supernatant was collected. The following reagents 
were added in order (all reagents in 0.1 M potassium phosphate buffer, pH 7.5, with 5 
mM EDTA) to 96-well flat-bottom plate (CytoOone) in duplicate. 20 μL of 
glutathione standard (0.103 to 26.4 μΜ) or homogenate sample, 120 μL of freshly 
prepared DTNB (2 mg/3 ml), Glutathione Reductase (10 Units) mix solution (1v:1v) 
and 60 μL of NADPH (2 mg/3 ml). The absorbance at 415 nm was measured every 30 
s, for 3 min, at room temperature (RT). The rate of increase in absorbance per minute 
was calculated by linear regression. Glutathione concentration in unknown blood 
samples was determined by comparison with the standard curve. 
Determination of Oxidized Glutathione 
Oxidized Glutathione (GSSG) concentration was determined in psoas and 
soleus homogenates samples according to Giustarini et al. (2013) (Giustarini et al., 
2013), modified for using a 96-well microtiter plate and a programmable microplate 
reader. Homogenate samples were deproteinized with 5% trichloroacetic acid (TCA) 
(1:1 v/v) centrifuged at 16,000 X g for 10 min and the supernatant was collected .  To 
avoid the rapid oxidation of GSH to GSSG, through the deproteination procedure, and 
the consequent overestimation of GSSG, the alkylating reagent N- ethylmaleimide 
(NEM) 310 mM was added during tissue homogenization. This was extracted before 
the actual measurement with three volumes of dichloromethane DCM, carefully 
collecting the upper volume of the ensuing bilayer (typically 750 μL of DCM for 250 
μL of deproteinized supernatant, in a 1.5-ml microcentrifuge tube, vortexed 5 min at 
800 rpm RT and centrifuged at 14,000 X g for 30 sec at 4
ο
 C). To measure GSSG the 
following reagents were added in order (all reagents in 0.1 M potassium phosphate 
buffer, pH 7.5, with 5 mM EDTA) to 96-well flat-bottom plate (CytoOone) in 
duplicate: 20 μL of glutathione disulfide standard (0.103 to 26.4 μΜ) or the 
homogenate sample, 120 μL of freshly prepared DTNB (2 mg/3 ml): Glutathione 
Reductase (10 Units) mix solution (1v:1v) and 60 μL of NADPH (2 mg/3 ml). The 
absorbance at 415 nm was measured every 30 s, for 3 min, at RT. The rate of increase 
in absorbance per minute was calculated by linear regression. Glutathione disulfide 
concentration in unknown homogenate samples was determined by comparison with 
the standard curve. 
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Determination of Glutathione Reductase activity 
Glutathione reductase (GR) activity was determined in psoas and soleus 
homogenates samples according to Cribb et al. (1989) (Cribb et al., 1989), using a 96-
well microtiter plate and a programmable microplate reader. To measure glutathione 
reductase, the following reagents were added in order (all reagents in 0.1 M sodium 
phosphate buffer, pH 7.5, with 1 mM EDTA) to 96-well flat-bottom plate (CytoOone) 
in duplicate: 150 μL of 0.1 mM DTNB, 10 μL of NADPH (10 mg/ml; 12 mM), and 
20 μL of reductase standard (0.015 to 0.50 U/ml) or the homogenate sample to be 
assayed. The reaction was initiated by the addition of 10 μL of GSSG (1 mg/ml; 3.25 
mM). For blank wells, no GSSG was added. The absorbance at 415 nm was measured 
every 30 s, for 3 min, at room temperature. The rate of increase in absorbance per 
minute was calculated by linear regression. Glutathione reductase in unknown 
homogenate samples was determined by comparison with the standard curve 
Measurement of Total Antioxidant Capacity 
Total antioxidant capacity (TAC) was determined in psoas and soleus 
homogenates samples according to Janaszewska and Bartosz (2002) (Janaszewska & 
Bartosz, 2002). In 20 μL of homogenate, 480 μL of 10 mM sodium potassium 
phosphate (pH 7.4) and 500 μL of 0.1 mM 2,2-diphenyl-1 picrylhydrazyl (DPPH) 
were added and  incubated in the dark for 30 min at room temperature. The samples 
were centrifuged for 3 min at 20,000g, and the absorbance was read at 520 nm. TAC 
values were obtained by calculating the number of DPPH molecules scavenged per 
minute. 
Determination of Catalase activity 
Catalase (CAT) activity was determined in psoas and soleus homogenate 
samples according to Aebi (1984) method (Aebi, 1984). 20 μL of homogenate was 
added to 2975 μL of sodium potassium phosphate buffer 67 mM, pH 7.4 and the 
samples were incubated at 37
ο
 C for 10 min. 5 μL of hydrogen peroxide 30% was 
added and the change in absorbance was immediately read at 240nm for 2 min. One 
unit of catalase is equal to 1 µmol of H2O2 decomposed/minute. Results were 
normalized to total protein content in the homogenatesample (units/mg protein). 
Spectrophotometric DNPH assay for protein carbonyls content determination 
Protein carbonyls in oxidized proteins were determined in psoas and soleus 
homogenate samples according to Fields and Dixon (1971) (Fields & Dixon, 1971). In 
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50 μL of plasma, 50 μL of 20 % was added, incubated in the ice bath for 15 min and 
centrifuged at 15,000 X g for 5 min. at 4
ο
 C. the supernatant was discarded.  
Afterwards, 500 μL of 14 mM 2,4-dinitrophenylhydrazine (DNPH) for the sample or 
500 μL of 2.5 N HCl for the blank was added to the pellet. Both samples were 
incubated in the dark at room temperature for 1 h, with intermittent vortexing every 
15 min. Samples were centrifuged at 15,000 X g for 5 min. at 4
ο
 C. The supernatant 
was discarded and and 1 mL of 10% TCA was added, vortexed, and centrifuged at 
15,000g for 5 min at 4
ο
 C. The supernatant was discarded, and 1 mL of ethanol–ethyl 
acetate (1:1 v/v) was added, vortexed, and centrifuged at 15,000g for 5 min at 4
ο
 C. 
The washing step was repeated two more times. The supernatant was discarded, and 1 
mL of 5 M urea (pH 2.3) was added, vortexed, and incubated at 37
ο
 C for 15 min. The 
samples were centrifuged at 15,000 Χ g for 3 min at 4ο C, and the absorbance was 
read at 375 nm. Protein carbonyls values were obtained by using the molar extinction 
coefficient of 2,4-dinitrophenylhydrazine (22 mMcm-1). 
TBARS determination 
Thiobarbituric-acid reactive substances (TBARS) were determined in in psoas 
and soleus homogenate samples according to Buege and Aust (1978) (Buege & Aust, 
1978). In 100 μL of plasma, 500 μL of 35 % TCA and 500 μL of 200 mM Tris- HCl 
(pH 7.4) were added and incubated at room temperature for 10 min. Afterwards, 1 ml 
of 2 M Na2SO4 and 55 mM thiobarbituric acid (TBA) solution was added and 
incubated at 95
ο
 C for 45 min. The samples were cooled on ice for 5 min and were 
vortexed. 1 ml of 70 % TCA was added, vortexed and centrifuged at 15,000 for 3 min 
at 25
ο
 C. The absorbance of the supernatant was read at 530nm.TBARS values were 
obtained using the molar extinction coefficient of MDA (15600 mol/l). 
All materials for oxidative stress assays were purchased from Sigma (St. Louis, 
MO, USA 
Statistical Analysis 
Duplicate values were averaged. Data were analyzed using the commercially 
available statistical software package SPSS 22. The Shapiro-Wilk test was performed 
to initially test whether the data were normally distributed, as it was the case. Results 
are expressed as mean ± SEM and 95% confidence intervals.  
Institutional Repository - Library & Information Centre - University of Thessaly
30/09/2018 04:54:58 EEST - 137.108.70.6
  
102 
 
Two-way MANOVA (two groups × two muscles) was conducted to examine 
the effects of uremia and muscle type on muscle’s redox status indices. Significant 
interactions and main effects were further investigated using LSD post-hoc analysis 
for multiple group comparisons. The significance level was set at p < 0.05.  
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Results 
 
Psoas and soleus muscle analysis results are summarized in Tables 4.2.1 and 
4.2.2 respectively. [It should be noted that analysis there after refers to n=5 for 
Control group and n=8 for Uremic group as a batch of samples became inappropriate 
for analysis]. 
No interactions were found between the examined muscle types (psoas, soleus) 
and groups (Control, Uremic) for all the redox status indices (p>0.05). Analytically, 
Total Protein (F(1,21)=2.857, p=0.106), PC (F(1,21)=2.482, p=0.130), TBARS 
F(1,21)=0.270, p=0.872), GSH (F(1,21)=0.761, p=0.393), GSSG (F(1,21)=0.207, p=0.654), 
Ratio (GSH/GSSG) (F(1,21)=0.921, p=0.348), GR-Reductase (F(1,21)=0.957, p=0.339), 
TAC (F(1,21)=0.020, p= 0.889), CAT (F(1,21)=0.229, p=0.637). 
Significant group main effects were found for PC concentration (F(1,21)=8.902, 
p=0.007) in both muscle types. The LSD post post-hoc test revealed that PC 
concentration was significantly higher in the Uremic group (psoas: 1.086 ± 0.294, 
soleus: 2.52 ± 0.29 nmol/mg protein) compared to the Control (psoas: 0.596 ± 0.372, 
soleus: 0.929 ± 0.41nmol/mg protein). (Fig. 4.2.1). No significant group main effects 
were found in the rest of redox status indices (p>0.05).   
Significant muscle main effects were found for Total protein concentration 
(F(1,21)=23.166, p=0.000), PC concentration (F(1,21)=6.410, p=0.019), TBARS 
concentration (F(1,21)=14.703, p=0.001) (Fig.1), GSH concentration (F(1,21)=6.175, 
p=0.021), TAC concentration (F(1,21)=18.316, p=0.000), Catalase activity 
(F(1,21)=20.597, p=0.000) and GR-Reductase activity (F(1,21)=7.498, p=0.012) (Fig.2) 
in both Control and Uremic group, respectively. The LSD post post-hoc test revealed 
that Total protein and TAC concentrations were significantly lower in soleus 
compared to psoas muscle in both the Control and the Uremic group. Additionally, 
soleus demonstrated higher levels of TBARS and PC levels as well as higher GSH 
levels, Catalase and GR-Reductase activities compared to psoas muscle in both the 
Control and Uremic group. The results are presents in Figures 4.2.1 & 4.2.2. 
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Table 4.2.1. Psoas biochemical and redox status indices (in Mean ± SEM) in the Control and Uremic 
group. The 95% Confidence Intervals are reported. 
 
PC: Protein Carbonyls, TBARS: Thiobarbituric Acid Reactive Substances, GSH: Reduced Glutathione, GSSG: 
Glutathione Oxidized, TAC: Total Antioxidant Capacity, CAT: Catalase, * statistical significance between Control and 
Uremic group, p<0.05. 
 
PSOAS MUSCLE 
 
CONTROL 
GROUP (n=5) 
95% Confidence 
Interval 
 
UREMIC GROUP 
(n=8) 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
Total Protein (mg/ml) 5.753 ± 0.43 4.865 6.642 4.537 ± 0.34 3.836 5.240 
PC (nmol/mg protein)   0.596 ± 0.372 0.179 1.370  1.086 ± 0.294* 0.474 1.699 
TBARS (nmol/ml)   3.179 ± 1.06 0.983 5.376  2.297 ± 0.835 0.561 4.034 
GSH (μmol/g protein) 5.539 ± 1.69 2.014 9.065 6.087 ± 1.34 3.300 8.875 
GSSG (μmol/g protein) 0.265 ± 0.09 0.060 0.470 0.322 ± 0.07 0.160 0.484 
Ratio (GSH/GSSG)  18.66 ± 11.11 4.455 41.775   25.60 ± 8.787 7.326 43.874 
GR Reductase (U/g 
protein) 
  10,59 ± 2.25 5.912 15.273 12.72 ± 1.78 9.018 16.419 
TAC (μmol DPPH/ml) 0.595 ± 0.06 0.458 0.732 0.519 ± 0.05 0.411 0.627 
CAT (U/mg protein) 6.992 ± 4.71 2.799 16.785 5.721 ± 3.72 -2.020 13.463 
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Table 4.2.2. Soleus biochemical and redox status indices (Mean ± SEM) in the Control and Uremic 
group. The 95% Confidence Intervals are reported. 
 
 
PC: Protein Carbonyls, TBARS: Thiobarbituric Acid Reactive Substances, GSH: Reduced Glutathione, GSSG: Glutathione 
Oxidized, TAC: Total Antioxidant Capacity, CAT: Catalase, * statistical significance between Control and Uremic group, 
p<0.05. 
 
SOLEUS MUSCLE 
 
CONTROL 
GROUP (n=5) 
95% Confidence 
Interval 
 
UREMIC 
GROUP (n=8) 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
Total Protein (mg/ml) 3.155 ± 0.478 2.161 4.148 3.29 ± 0.33 2.588 3.992 
PC (nmol/mg protein) 0.929 ± 0.41 0.063 1.795 2.52 ± 0.29* 1.905 3.129 
TBARS (nmol/ml) 6.81± 1.18 4.350 9.262 6.25 ± 0.83 4.511 7.984 
GSH (μmol/g protein) 8.09 ± 1.89 4.155 12.039 11.41 ± 1.34 8.625 14.20 
GSSG (μmol/g protein) 0.331 ± 0.11 0.102 0.560 0.472 ± 0.78 0.310 0.634 
Ratio (GSH/GSSG) 46.62 ± 12.43  20.782 72.468 33.61 ± 8.79 15.34 51.89 
GR Reductase (U/g 
protein) 
18.41 ± 2.52 13.184 23.651 16.42 ± 1.78 12.724 20.125 
TAC (μmol DPPH/ml) 0.322 ± 0.07 0.169 0.476 0.264 ± 0.05 0.155 0.372 
CAT (U/mg protein) 29.09 ± 5.26 18.140 40.063 23.60 ± 3.72 15.863 31.346 
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Fig. 4.2.1. Protein Carbonyls (PC), (A) and TBARS, (B) concentration in psoas and soleus muscles in Control 
and Uremic groups. Concentrations are expressed as nmol/mg protein and nmol/ml respectively. * depicts 
significant differences between psoas and soleus muscle,   # depicts significant differences between Control and 
Uremic groups, p<0.05. 
 
 
 
Fig. 4.2.2. GSH and TAC concentrations (A, B), GR Reductase and Catalase activities (C, D) in psoas and soleus 
muscles in Control and Uremic groups. Concentrations and activities are expressed as μmol/g protein, μmol 
DPPH/ml, U/g protein, U/mg protein for GSH, TAC, GR reductase and Catalase respectively. * depicts significant 
difference between psoas and soleus muscle, p<0.05. 
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Discussion 
 
Apart from the more recognized systemic negative manifestations, CKD is also 
accompanied by muscular weakness and wasting, reduced endurance and premature 
fatigue, characteristics and symptoms which collectively described as uremic 
myopathy (Campistol, 2002). Several studies have indicated that CKD is 
characterized by modifications of cell energy metabolism leading to a reduction in 
muscle performance (Brautbar, 1983; Del Canale et al., 1986; Metcoff et al., 1983). It 
has been suggested that hemodialysis treatment and/or uremia per se contribute to an 
increase in molecular oxidative damage which in turn play a key role for loss of 
skeletal muscle functionality. Additionally, animal studies have shown that 
experimentally induced oxidative stress causes myofibrillar protein modification and 
degradation (Nagasawa et al., 1997) through alterations of its amino acid sequences. 
A variety of amino acid modifications exists with carbonyl formation to be considered 
as an early marker of protein oxidation. Arginine, proline and threonine are the most 
likely amino acids to form carbonyl derivatives (Reznick & Packer, 1994). Given that 
skeletal muscle contains high levels of fibrillar proteins, it becomes extremely 
susceptible to free radical oxidation with adverse functional outcomes. 
The increased PC levels by approximately 1.82 fold for psoas and 2.71 fold for 
soleus in Uremic compared to Control samples, point to increased levels of 
sarcomeric protein carbonylation. Our findings are in agreement with those reported 
by Lim et al (Lim, Cheng, et al., 2002) in skeletal muscle of uremic patients on HD, 
which triggers an increased protein degradation. The increased levels of PC in pre-
dialysis stage of CKD, as it was observed in our study, could be regarded as a very 
interesting finding for the time point of protein oxidation, revealing the early 
emergence of oxidative damage to protein content. Taking into account the role of 
carbonyl stress in vascular damage (Chen et al., 2013) and the general functionality of 
muscle, the early countermeasure for protein oxidation could be of great importance 
for patients before they move into the end-stage where the negative effects on muscle 
status may become irreversible.  
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No other redox index differed between the control and uremic groups. However 
we observed large differences between the two muscle types (psoas and soleus) 
studied. 
Skeletal muscle is a heterogeneous tissue which consists of a large diversity of 
fiber types. This heterogeneity in muscle type composition determines distinct 
biochemical and structural characteristics which in turn are responsible for the variety 
of physiological and metabolic functions (Essen-Gustavsson, Karlström, & 
Lundström, 1992; Pette & Staron, 1990). In our study we examined the redox status of 
two different types of skeletal muscle, the slow twitch soleus (Fiber type I) and the 
fast twitch psoas (Fiber type II) in order to observe their possible different response in 
the uremic environment.  
Total protein concentration was found increased in psoas muscle compared to 
soleus in both Control and Uremic group. It is known that skeletal muscle wasting is a 
characteristic of several chronic diseases (Espat, Copeland, & Moldawer, 1994) and is 
strongly related with loss of protein. One of the several suggested mechanisms is the 
tumor necrosis a (TNF-α) – induced catabolism (Ahmad, Karlstad, Choudhry, & 
Sayeed, 1994; Buck & Chojkier, 1996). TNF-α can indirectly affect muscle 
catabolism via the regulation of hormones and catabolic cytokines (Dayer, Beutler, & 
Cerami, 1985; Gelin et al., 1991; Tessitore, Costelli, & Baccino, 1993), but can also 
promote muscle waste stimulating the ubiquitin gene expression (Llovera, Garcia-
Martinez, Agell, Lopez-Soriano, & Argiles, 1997) and activating the nuclear factor 
NF-κB (Beg, Finco, Nantermet, & Baldwin, 1993). Li et al (Y. P. Li, Schwartz, 
Waddell, Holloway, & Reid, 1998), observed that TNF-α can directly trigger protein 
loss and decrease in myosin heavy chain (MHCf) levels in skeletal muscle. It is also 
known that TNF-α/NF-κB signaling is widely affected from endogenous ROS. TNF-α 
widely excites mitochondria ROS production, promoting TNF-α/NF-κB activation 
(Hennet, Richter, & Peterhans, 1993; Schulze-Osthoff et al., 1992), a process which 
seems to be tissue specific (Y. P. Li et al., 1998). Taking into consideration that soleus 
muscle (type I fibers) contains a higher amount of mitochondria, it would be rather 
logical that it would be more sensitive to NF-κB activation and therefore, to protein 
loss and muscle wasting. Our findings, where soleus muscle exhibited lower total 
protein levels, seem to confirm this observation.  
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Regarding the oxidative damage that was examined in two muscles, protein 
carbonylation and lipid peroxidation as were expressed via PC and TBARS levels 
respectively, it was significantly increased in soleus muscle compared to psoas in both 
Control group and Uremic group. Specifically, levels of TBARS were higher in the 
soleus than psoas muscles without a differentiation between the control and uremic 
groups, (2.14 fold for control and 2.72 fold for uremic). We have not seen analogous 
data in pre-dialysis patients. In HD patients however, Lim et al reported increased 
TBARS levels in skeletal muscle (sampled during fistula creation) (Lim, Cheng, et al., 
2002) compared to healthy controls. It is known that in these patients extensive 
oxidation damage is usually observed, with this type of therapy to constitute one more 
aggravating factor.  
Slow-twitch skeletal muscles such as soleus, have a greater number of 
mitochondria (Engel, 1970), which are regarded to play a key role in the ROS 
production in skeletal muscle, due to their increased oxygen consumption (McArdle, 
Pattwell, Vasilaki, Griffiths, & Jackson, 2001). Based on the increased amount of 
mitochondria in soleus muscle, it could be expected that this type of skeletal muscle 
by increasing ROS production it may be more exposed to ROS and their negative 
effects, but also that it develops an appropriate antioxidant capacity to withstand the 
oxidative load. Despite the reduced TAC levels in soleus muscle in comparison with 
psoas, the increased GSH, CAT and CR-reductase indicates that healthy soleus indeed 
demonstrates a higher antioxidant capacity than psoas.  
In response to a further oxidative load due to renal insufficiency, uremic soleus 
appears to have further upregulated its defenses. Thus, we observed a further 
increased GSH levels and GR-Reductase and CAT activities in uremic soleus muscle 
compared to uremic psoas. As it is known, GR- Reductase is an enzyme which 
catalyzes the reduction of glutathione disulfide (GSSG) to the sulfhydryl form GSH. 
These two antioxidant molecules together with CAT activity constitute the antioxidant 
defense which has been brought into action as an adaptive response against the 
increased oxidative damage in soleus muscle. 
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Conclusion 
 
The increased PC levels in soleus in Uremic compared to Control samples, point 
to increased levels of sarcomeric protein carbonylation. Since carbonyl formation is 
associated with protein degradation and proteolysis, the increased levels seem to 
constitute an early stimulus to muscle atrophy observed in the early stages of CKD 
development. Thus early countermeasures for protein oxidation could be of great 
importance for patients before they move into the end-stage where the negative effects 
on muscle status may become irreversible 
Both oxidative damage and antioxidant response seem to be tissue-specific. 
Soleus muscle, which has greater number of mitochondria, may be more exposed to 
ROS and their negative effects, but also may develop an appropriate antioxidant 
capacity to withstand the oxidative load. This was reflected in the measured GSH 
values in soleus muscles. In response to a further oxidative load due to renal 
insufficiency, uremic soleus appears to have further upregulated its defenses in 
comparison with uremic psoas. 
Our results highlight the need for interventions early during disease progression 
in order to protect skeletal muscle quality and reach the end-stage at the best possible 
functional and biochemical status. How exactly CKD accelerates protein 
carbonylation and degradation remains to be determined in future work. 
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Abstract   
 
Introduction: Chronic Kidney Disease (CKD) constitutes a major health problem 
worldwide and is accompanied by several comorbidities such as anemia, 
cardiovascular diseases, atherosclerosis, diabetes, which contribute to the reduced 
quality of life and to the mortality of the patients. 
Aims: This aim conducted to evaluate the biochemical and hematological parameters 
using an animal model of renal insufficiency where confounding factors such as 
comorbidities and pharmacological treatment are not implicated. 
Methods: We used an animal model (partial nephrectomy) of renal disease in New 
Zealand white female rabbits. Surgery and euthanasia (after 3 months) protocols were 
approved by the ethic committee of the University of Thessaly. Renal insufficiency 
was induced by removal of the right kidney and partial nephrectomy of the left kidney 
(Uremic group, N=9). Control animals underwent sham operation (Control group, 
N=6). Blood samples were collected and analysed for the biochemical (lipid profile) 
indices Total Cholesterol, High-Density Lipoprotein (HDL), Low-Density Liporptein 
(LDL), Triglycerides, Triglycerides/HDL Ratio Glucose and Bilirubin and for the 
hematological parameters leukocytes, red blood cells (RBC), hemoglobin (Hb), 
hematocrit (Hct), Mean Corpuscular Volume (MCV) and Mean Corpuscular 
Hemoglobin (MCH). 
Results: We found no significant changes in the blood lipid profile of the Uremic 
group as compared to the Control group (p.0.05). However, the Ratio 
Triglycerides/HDL was 5.67, much higher than 4. Moreover, RBC, Hematocrit and 
MCH were found significant decrease in the Uremic group (3.92 ± 0.29, 26.06 ± 1.85, 
19.76 ± 0.67) as compared to the Control (5.10 ± 0.17, 35.24 ± 0.79, 21.64 ± 0.44), 
p<0.05, and MCV had a tendency to decrease in the Uremic (65.40 ± 1.89) group 
compared to the Control group (69.78 ± 1.36) p=0.087. 
Conclusion: The lipid profile of our Uremic group did not seem to be disturbed in a 
great extent. A tendency however, for an increased risk for coronary disease emerged 
through the calculation of the Triglycerides/HDL atherogenic index. Moreover 
significant signs of anemia manifestation were found suggesting that early 
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development of anemia, in pre dialysis stage, could be linked to muscle mechanisms 
of fatigue by the reduction of oxygen carrying capacity.  
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Introduction 
 
Chronic Kidney Disease (CKD) constitutes a major health problem worldwide 
(Hsu, Bates, Kuperman, & Curhan, 2001) and is accompanied by several 
comorbidities which contribute to the increased mortality of the patients.  
Cardiovascular complications are a major cause of mortality in patients with 
end-stage renal failure (K. Ma, Greene, & Raij, 1992). In these patients, several 
common atherogenic risk factors, such as hypertension, diabetes, dyslipidemia 
(Attman & Alaupovic, 1991; K. Ma et al., 1992) are combined with factors related to 
the uremic state, such as increased serum levels of homocysteine (Bostom et al., 
1997), and lipoprotein (Sechi et al., 1998) with adverse outcomes. Some of these risk 
factors could be detected early in the course of CKD (Jensen, Stender, & Deckert, 
1988) and may contribute to the development of cardiovascular complications in 
CKD patients. It has been suggested that often CKD patients are more likely to die 
from cardiovascular complications before full kidney failure development (Shulman 
et al., 1989). The increased CVD events in CKD are partly attributed to accelerated 
atherogenesis caused by dyslipidemia (London & Drueke, 1997). The common lipid 
abnormalities in pre-dialysis patients include high–density lipoprotein (HDL) and 
high triglyceridemia while low-density lipoprotein (LDL) and total cholesterol (TC) 
may be high, low or normal (Agaba IE, Agbaji OO, Anteyi EA, Omudu PA, & RS., 
2003; Ojo OE, Soyinka FA, Sanusi AA, Arogundade FA, & A., 2007). 
Additionally, it has been reported that dyslipidemia plays a key role to 
glomerural and tubulo-interstitial injuries (Keane, Mulcahy, Kasiske, Kim, & 
O'Donnell, 1991; Moorhead, 1991; Moorhead, Chan, El-Nahas, & Varghese, 1982) 
and thus contributes to the progression of renal insufficiency per se. Moreover, organ 
fat infiltration has been reported in end-stage patients. This is not only confined to the 
liver but is present in major limb skeletal muscles (Giannaki et al., 2013), and is 
associated with sleep problems and the presence of metabolic syndrome (Sakkas, 
Gourgoulianis, et al., 2008). Not surprisingly, disorders of glucose homeostasis affect 
approximately 50% of patients suffering from CKD. Glucose homeostasis depend on 
sufficient production of insulin from pancreatic β-cells and adequate insulin action on 
peripheral tissues. Thus glucose handling is carefully monitored upon CKD diagnosis. 
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Anemia is also a common clinical manifestation in patients with CKD and it is 
associated with fatigue, reduced exercise capacity, cognitive impairment and 
increased risk of cardiovascular disease and hospitalization, resulting in reduced 
quality of life and mortality (Silverberg, Wexler, Blum, Wollman, & Iaina, 2003). 
Anemia has been defined by the World Health Organization (WHO) as a hemoglobin 
(Hb) concentration < 13.0 g/dl for adult males and postmenopausal women and an 
Hb<12.0 g/dl for premenopausal women ("World Health Organization.Nutritional 
Anaemias: Report of a WHO Scientific Group.," 1968). Based upon these criteria, 
nearly 90% of patients with GFR<25-30 ml/min (stages 4 and 5) have anemia, many 
with Hb<10g/dl (Kazmi et al., 2001).  Although the exact mechanisms have not been 
fully elucidated, several metabolic and mechanical factors have been proposed (J. W. 
Eschbach, Jr. et al., 1967). Shortened red blood cell life and increased red cell 
apoptosis, with the hemolytic syndrome playing an important role, and decreased red 
cell production in bone marrow constitute the most common etiologies for anemia in 
CKD (Erslev & Besarab, 1997). Erythropoietin (EPO) deficiency is one of the 
predominant causes of anemia in CKD. It has been also suggested that circulating 
uremic toxins behave as inhibitors for the erythropoiesis process and/or the 
responsiveness to the hormone and contribute to anemia but no study has so far 
managed to observe and identify specific inhibitors pathways (Besarab & Ayyoub, 
2007b; J. W. Eschbach, 1989).  
Although there has been an improvement in prognosis for CKD patients over 
the past decade there are yet a lot to be done. An early detection of discrepancies in 
hematological and biochemical parameters may prove significant since treating these 
abnormalities may prevent the progression of renal insufficiency and delay adverse 
outcomes of CKD, including anemia and atherosclerosis. However, as alluded above, 
various comorbidities can influence hematological and muscular levels. 
This study was conducted to evaluate the biochemical and the hematological 
parameters using an animal model that correspond to an advanced but in pre-dialysis 
stage of CKD where confounding factors such as comorbidities and pharmacological 
treatment are not implicated. Thus, possible early findings could suggest new 
directions on how to use diagnostic and therapeutic procedures, which upon 
verification on human patients could help to improve care, patient’s functional 
condition, quality of life and probably the risk of morbidity and mortality. 
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Methods  
Animals and experimental design 
New Zealand white female rabbits (young adult, N=15) with body weight of 
approximately 3200 kg, were first acclimatized to the laboratory animal unit of 
Medical School (University of Thessaly, Greece) for 48 hours. The animals were 
housed in a controlled environment with stable conditions of room temperature (RT) 
(22–24°C) and lighting (12:12 h light-dark cycle). All rabbits were fed with a special 
rabbit chow containing low levels of protein, potassium, calcium, phosphorus and 
sodium (prepared by Research Diets, Inc. USA) and water ad libitum. All animal 
procedures, including surgery and euthanasia for this project were approved by the 
ethics committee of the University of Thessaly (decision 2-2/10-10-2012) and the 
scientific committee of the University Hospital of Larisa, Greece (decision 1/4-1-2012 
and animals were under veterinary care, in accordance to the national directives for 
the care and the use of laboratory animals.  
After acclimatization, surgical procedures were performed (sham operation for 
control animals - Control group and partial nephrectomy for experimental animals – 
Uremic group.  Animals were anaesthetized by intravenous administration of a 
solution mixture of ketamine hydrochloride 100 mg/ml (Imalgene® 1000; Merial, 
Duluth, Georgia, USA) and xylazine 20 mg/ml (Rompun®; Bayer, Leverkusen, 
Germany), 87 % and 13 % respectively (proportion 6,69:1 approximately). The initial 
dosage for the induction of anesthesia was 0.3 ml/Kg body weight of the above 
solution mixture, i.e. Imalgene® (87%) and Rompun® (13%), intravenously (i.v.). 
The maintenance of anesthesia was achieved by a dose of propofol (10mg/kg BW). 
Three hours before the intervention, each animal had only access to water and not to 
food and its weight was measured on a precision scale. Animal temperature was 
maintained via a heating pad.  
The induction of renal insufficiency was performed surgically (using a surgical 
protocol modified from Gotloib et al., 1982 (Gotloib et al., 1982). For the Uremic 
group nine animals (N=9), underwent removal of the left kidney after careful ligation 
of the left renal artery and vein; and partial nephrectomy (¾) of the right kidney. For 
the Control group six age-matched animals (N=6) underwent sham operation. Twelve 
weeks after surgery, the animals were weighed and then sacrificed by injection of 
sodium pentobarbital solution (50 mg/ml) which was applied in a dosage of 100 
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mg/Kg BW followed by bilateral thoracotomy. Immediately after cardiac arrest, 
sample collections were done in a blind fashion. 
 
Sample preparation and Biochemical Analyses 
Blood sampling and treatment 
Whole blood was collected from the rabbits’ heart and aorta by a heparinized 
syringe and placed into evacuated test tubes. A portion (1-2 ml) of the blood collected 
was used to determine leukocytes, red blood cells (RBC), hemoglobin (Hb), 
hematocrit (Hct), Mean Corpuscular Volume (MCV) and Mean Corpuscular 
Hemoglobin (MCH) using a Mythic 18 (Orphḝe S.A., Geneva, Switzerland) 
autoanalyzer. 
 For serum collection, another portion of blood (5 ml) blood was placed into 
seperate tubes containing clot activator (Vacutainer, BD, Franklin Lakes, NJ, USA) 
and was allowed to clot for 20 min at room temperature. Afterwards, tubes were 
centrifuged at 1370 × g for 10 min at 4ο C and The supernatant was collected, 
aliquoted in eppendorf tubes, stored at -80°C and thawed only once before analysis. 
Glucose, Bilirubin , Total Cholesterol, High-Density Lipoprotein (HDL), Low-
Density Liporptein (LDL) and Triglycerides concentrations were measured on a 
Clinical Chemistry Analyzer Z 1145 (Zafiropoulos Diagnostica, Athens, Greece) 
using commercially available kits (Zafiropoulos Diagnostica). 
Statistical Analysis 
Duplicate values were averaged. Data were analyzed using the commercially 
available statistical software package SPSS 22. The Shapiro-Wilk test was performed 
to initially test whether the data were normally distributed, as it was the case. Results 
are expressed as mean ± SEM and 95% confidence intervals.  
An independent t-test was conducted to examine whether there were any 
differences in blood redox status indices between Control and Uremic group. The 
significance level was set at p < 0.05.  
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Results 
 
Blood biochemical analysis 
No significant differences were found in the concentrations of Total Cholesterol, HDL, 
LDL, Triglycerides and Glucose levels in blood of Control and Uremic groups (p>0.05), as 
presented in Table 4.3.1. Bilirubin concentration tended to be higher in the Uremic group 
compared to Control (p=0.074). 
 
Table 4.3.1. Blood biochemical indices (in Mean ± SEM) in the Control and Uremic group. The exact 
statistical significance value P and the 95% Confidence Intervals are reported 
 
Significant level at (P <0.05)* HDL: High-Density Lipoprotein, LDL: Low-Density Lipoprotein 
 
Hematological analysis 
The Hematocrit levels were found to be decreased in the Uremic group 
compared to Control, ( t(11)= 3.732, p=0.001). Red blood cell count was significantly 
decreased in Uremic group compared to Control, (t(11)= 3.014, p=0.012). Mean 
Corpuscular Hemoglobin was found decreased in Uremic group compared to Control, 
which was statistically significant t(11)= 2.333, p=0.040. 
The leukocyte count was not statistically different from control (p>0.05). 
Likewise Hemoglobin concentration tended to be lower in the Uremic group 
compared to Control, which is not statistically significant (p>0.05). Mean Corpuscular 
Volume was found decreased in uremic group, which was not statistically significant 
(p>0.05). All data were presented in table 4.3.2. 
 
BLOOD 
 
CONTROL 
GROUP (n=6) 
95% Confidence 
Interval 
 
UREMIC 
GROUP (n=9) 
95% Confidence 
Interval 
P Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
Total Cholesterol (mg/dl) 102.73 ± 13.59 91.86 113.61 95.16± 11.94 71.75 118.57 0.683 
HDL (mg/dl) 29.77 ± 6.12 24.87 34.66 27.36 ± 4.49 18.55 36.17 0.758 
LDL (mg/dl) 51.07 ± 13.71 40.10 62.05  50.31 ± 13.64 23.57 77.05 0.969 
Triglycerides (mg/dl)  109.46 ± 17.45 95.49 123.43 121.05 ± 14.92 91.80 150.30 0.623 
Triglycerides/HDL Ratio 4.63 ± 1.33 3.56 5.70 5.97 ± 1.25 3.66 8.27 0.545  
Glucose (mg/dl) 388.25 ± 37.16 358.352 417.98 311.89 ± 31.48 250.19 373.58 0.145 
Bilirubin (mg/dl) 0.247  ± 0.03 0.224 0.273 0.418 ± 0.08 0.263 0.575 0.074 
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Table 4.3.2. Hematological indices (in Mean ± SEM) in the Control and Uremic group. The  
exact statistical significance value P and the 95% Confidence Intervals are reported.  
 
Significant level at (P <0.05)* MCV: Mean Corpuscular Volume, MCH: Mean Corpuscular Hemoglobin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BLOOD 
 
CONTROL 
GROUP (n=6) 
95% Confidence 
Interval 
 
UREMIC 
GROUP (n=9) 
95% Confidence 
Interval 
P Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
Leukocyte count (× 103/μL) 11.12 ± 1.76 9.58 12.66 10.86 ± 1.02 8.86 12.87 0.903 
Red Blood Cells  (× 106/mm3)  5.10 ± 0.17 4.95 5.25 3.92 ± 0.29 3.56 4.48 0.012* 
Hemoglobin (mg/ml) 110.77 ± 9.20 103.36 118.17 97.99 ± 10.08 78.22 117.76 0.368 
Hematocrit (%) 35.24 ± 0.79 35.54 35.93 26.06 ± 1.85 22.43 29.69 0.003* 
MCV (mm3) 69.78 ± 1.36 68.59 70.97 65.40 ± 1.89 61.68 69.12 0.087 
MCH (pg/cell) 21.64  ± 0.44 21.26 22.02 19.76 ± 0.67 18.44 21.09 0.04* 
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Discussion 
 
Our study examined a range of biochemical and hematological indices in an 
animal model of chronic renal insufficiency. While there were no significant changes 
in the blood lipid and glucose profile of the Uremic group as compared to the Control 
group, we observed a consistent decline in hematological parameters related to 
anemia and overall fitness status. 
We examined whether dyslipidemia could be traced in an animal model of pre-
dialysis CKD and compared the findings with those of the Control group (sham-
operated). We found no significant differences in Total Cholesterol, HDL, LDL or 
Triglycerides levels between the two groups. However we observed that 
Triglycerides/HDL ratio was > 4 in both groups but in uremic group it was 1.3 fold 
higher. Perhaps, if the duration of our model was longer a more substantial change in 
the lipid profile could have occurred.  
There is strong epidemiological and clinical evidence that increase in plasma 
LDL and decrease in plasma HDL concentrations are associated with increased 
atherosclerotic complications (Jungers et al., 1997; London & Drueke, 1997) partly 
attributed to the synergistic action of both LDL and HDL. While increased LDL 
levels are associated with increased deposition in the vessel wall, low HDL levels 
decrease the reverse cholesterol transport from tissues to the liver leading to their 
accumulation in the tissues. Akpan et al.,2014 (Akpan, Ekrikpo, Effa, Udo, & Kadiri, 
2014) evaluated lipid abnormalities in pre-dialysis patients with CKD from stage 1-5. 
The study revealed that total cholesterol (TC) and LDL were elevated above normal 
levels compared to controls, (Akpan et al., 2014).  
We did not find statistically significant differences in Cholesterol fractions 
between the Uremic and Control groups. Species and analysis methods aside, perhaps 
more time was needed for our model of uremia to develop such changes in 
Cholesterol. Furthermore, diet composition is known to influence blood biochemical 
parameters. A change in lipid blood parameters in a short period of time could be due 
to a change of diet lipid composition. The rabbits of the present study however were 
fed the same diet (3.5% fat content), our results could not be attributed to a change of 
diet. 
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The ratio of Triglycerides/HDL, initially proposed by Gaziano et al  (Gaziano, 
Hennekens, O'Donnell, Breslow, & Buring, 1997) has been proposed as an 
atherogenic index that has proven to be a highly significant independent predictor of 
myocardial infarction, even stronger than Total Cholesterol/HDL and LDL/HDL. 
Jeppesen et al (Jeppesen, Hein, Suadicani, & Gyntelberg, 1998) also found that 
stratifying triglycerides levels by HDL levels led to more accurate detection of 
increased risk of coronary disease. The atherogenic link between high triglycerides 
and HDL-c is due to the higher plasma concentration of triglyceride-rich, very low-
density lipoprotein that generates small, dense LDL during lipid exchange and 
lipolysis. More specifically, the ratio of Triglycerides/HDL correlates inversely with 
the plasma level of small, dense LDL particles. These LDL particles accumulate in 
the circulation and form small, dense HDL particles, which undergo accelerated 
catabolism, thus closing the atherogenic circle (Brinton, Eisenberg, & Breslow, 1991; 
Edwards, Mahaney, Motulsky, & Austin, 1999). Regarding the ratio value, da Luz et 
al (da Luz, Cesena, Favarato, & Cerqueira, 2005) found that a Triglycerides/HDL 
ratio > 4 constitutes the most powerful independent predictor of coronary artery 
disease and another the study of the same group  (da Luz, Favarato, Faria-Neto, 
Lemos, & Chagas, 2008) indicated that a ratio of Triglycerides/HDL>4  is also related 
to the severity of vessel compromise being an easy, non-invasive method of 
predicting the presence and extent of coronary atherosclerosis.  
Additionally, in a previous study (Research Paper 1) we observed a tendency for 
increased lipid peroxidation (TBARS) in the plasma of the Uremic compared to the 
Control. Thus, the tendency for a higher Triglycerides/HDL and increased levels of 
lipid peroxidation in the Uremic group fits well with a progressive atherogenic 
development due to chronic renal insufficiency. 
 There were significant decreased in the levels of hematological parameters 
(RBC, Hematocrit, MCH) in the Uremic group as compared to the Control. RBC 
count was found to be decreased in the Uremic group. The mean corpuscular 
hemoglobin or mean cell hemoglobin (MCH) was significantly lower in the Uremic 
group. MCH reflects the average mass of hemoglobin per red blood cell, and lower 
values may be linked to hypochromic anemias and microcytic RBC. The latter is 
possible as we observed a tendency for lower mean corpuscular volume or mean cell 
volume (MCV), in the Uremic group. MCV reflects the average volume of a red 
Institutional Repository - Library & Information Centre - University of Thessaly
30/09/2018 04:54:58 EEST - 137.108.70.6
  
122 
 
blood cell and is also associated with several types of anemia. However, both MCH 
and MCV values in Uremic animals were at the lower ends of the physiological range. 
The above hematological disturbances could be explained by an impairment in 
the erythropoietin production and other factors which influence negatively the red cell 
production in bone marrow and the red cell lifespan. Indeed, the expression of 
phosphatidylserine, an important phospholipid membrane component which plays a 
key role in cell cycle signaling and apoptosis, is found to be increased in the plasma 
of uremic patients. As a result, the damaged red blood cells are better recognized and 
removed by phagocytes (Fadok, Bratton, Frasch, Warner, & Henson, 1998; Jeng & 
Glader, 2004). A higher apoptotic rate could be hypothesized in our model from the 
higher bilirubin levels observed in the experimental group. 
Overall, taking into consideration the fact that Hb, Hct and MCH levels and red 
blood cell count in the Uremic group were at the lower limits of rabbit physiological 
values it is concluded that these findings constitute early signs of anemia 
development. 
The degree of anemia in CKD has been explored by several researchers and 
different ways of treatment has been proposed. Human studies have evaluated the 
prevalence of anemia in patients in different stages of CKD. Kazmi et al., observed 
that the prevalence of anemia for Hb<12 g/dl (the level at which the evaluation of 
anemia in CKD should be initiated) was 45 %, 49%, 58%, 92%, 92% in CKD stages 
1-5 respectively and for Hb<11g/dl (the minimum hemoglobin levels at which therapy 
should be initiated with EPO) as 24%, 34%, 41%, 79%, 74% respectively for stages 
1-5 (Kazmi et al., 2001). Similarly Shaheen et al., found that the prevalence of anemia 
was elevated for Hb<12g/dl in the different stages of CKD (Shaheen et al., 2011). The 
recombinant human erythropoietin, epoetin alfa (rHuEpo) was the first 
Erythropoiesis-Stimulating Agent (ESA) for the treatment of anemia reducing the 
transfusions and their side-effects such as infections and iron overload (Popovsky & 
Ransil, 1996). Several concerns (Garcia, Anderson, Rennke, & Brenner, 1988) about 
possible impairment of kidney function due to EPO treatment, have been rejected by 
clinical evidence (Kuriyama et al., 1997; Roth et al., 1994; Teplan et al., 2003). 
However, the administration of EPO in pre-dialysis stage patients with CKD is not so 
much popular since anemia development is not so clear.  
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Although the United States guidelines recommend EPO treatment when 
hemoglobin drops below 10 g/dl and the European guidelines recommend it for 
hemoglobin levels below 11 g/dl ("KDIGO 2012 clinical practice guideline for the 
evaluation and management of chronic kidney disease,"), EPO administration is not 
common in clinical practice (Horl et al., 2003; Valderrabano et al., 2003) among 
patients and most of them start EPO treatment when anemia is well advanced. This 
occurs despite findings on benefits of early EPO administration. For example, Gouva 
et al (Gouva, Nikolopoulos, Ioannidis, & Siamopoulos, 2004) observed that early 
initiation of EPO treatment in pre-dialysis patients with non-severe anemia is 
extremely beneficial resulting in 60% reduction in the risk of initiation of kidney 
replacement or death. Also, several studies highlighted the benefits of correcting 
anemia such as improved exercise capacity, cognitive function and improvement of 
left ventricular performance (Clyne & Jogestrand, 1992; Hayashi et al., 2000; Portoles 
et al., 1997). 
Our findings of low hematocrit and overall disturbed hematological parameters 
in an animal model of pre-dialysis CKD further verify that our model represents an 
(untreated) human renal disease condition (when EPO is not supplemented). Taken 
together, our observations and the human data, these findings indicate that anemia 
could have a major role in disease development and symptoms severity and should be 
addressed as early as possible. 
Conclusions 
Our model of CKD shows that the Lipid profile in this stage of the disease 
development does not seem to be disturbed to a great extent. However, an atherogenic 
development cannot be excluded and should be addressed early on. 
More importantly, significant signs of hematological disturbances were found 
suggesting that early recognition of anemia development in the pre-dialysis stage 
could play a key role in CKD treatment. 
Institutional Repository - Library & Information Centre - University of Thessaly
30/09/2018 04:54:58 EEST - 137.108.70.6
  
124 
 
 
Research paper 4: Do blood redox status indices reflect changes in 
skeletal muscle’s redox status?  
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Abstract 
 
Introduction: The redox status of an individual under normal or pathological 
conditions is assessed by evaluating a group of indices in non-invasive samples. 
However there is no information about tissue localization of oxidative stress. The 
large majority of studies examinint CKD and discussing comorbidities, such as 
uremic myopathy, have reported increased levels of oxidative stress by only assessing 
indices in blood samples of CKD patients without clear information of what is 
happening in the redox status of skeletal muscle 
Aims: The aim of the study was to examine whether the oxidative stress markers 
measured in blood adequately reflects redox status in skeletal muscle. Moreover it 
was examined if blood urea and creatinine levels in blood had any possible reflection 
on blood and skeletal muscle redox status and if there is a correlation between urea 
and creatinine levels. Finally it was investigated whether redox status in psoas muscle 
adequately depicts the redox status in soleus. All correlation analyses were conducted 
in pool data, as well as in Control group and in the Uremic group separately. 
Methods: We used an animal model (partial nephrectomy) of renal disease in New 
Zealand white female rabbits. Surgery and euthanasia (after 3 months) protocols were 
approved by the ethic committee of the University of Thessaly. Renal insufficiency 
was induced by removal of the right kidney and partial nephrectomy of the left kidney 
(Uremic group, N=9). Control animals underwent sham operation (Control group, 
N=6). Blood and skeletal muscle (psoas, soleus) samples were collected and analysed 
for the GSH, GSSG, GSH/GSSG ratio, GR-Reductase, CAT, TAC, TBARS and PC 
levels.  
Results: For each one the redox status indices, statistical analysis didn’t show any 
significant correlation between blood and the two examined muscles’ levels neither in 
the pool of samples nor for each group separately (p>0.05). Regarding the correlation 
analysis between Urea, Creatinine and redox status in blood and skeletal muscle, 
while no relationship reached statistical significance it is noteworthy that in the pool 
data Creatinine levels tended to correlate with blood GSH (r=0.664, p=0.073). 
Likewise, Urea tended to correlate with blood GSH (r=0.655, p=0.078). However 
there were significant correlations analysis results between the two different types of 
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skeletal muscle. Although in the Control group there was no significant correlation in 
redox status indices between two different types of skeletal muscle (p>0.05), in the 
Uremic group there was significant correlation between psoas and soleus muscle in 
PC levels (r=0.913, p=0.002), in GSSG levels (r=0.766, p=0.027) levels and in CAT 
levels (r=0.743, p=0.035) respectively. 
Conclusion: In our study we found that blood levels of the redox status indices 
examined did not reflect psoas or soleus muscle concentrations. However, we 
observed that chronic renal insufficiency disturbed skeletal muscle’s redox status in 
such a way as to create associations between psoas and soleus, two muscles with 
distinct metabolic profiles, in indices such as PC, GSSG and CAT, which were not 
evident in control muscles. Certainly, generalised conclusions based only on a single 
study cannot be drawn, and further studies are needed to verify or not these findings. 
based on our observations, caution should be taken when interpreting the literature 
and designing further studies to examine the contribution of oxidative stress in the 
pathophysiology of chronic disease, especially chronic renal insufficiency.  
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Introduction 
 
Oxidative stress has been implicated in several pathological conditions and 
constitutes a major factor for the progression of many diseases. Thus already, at least 
in the private sector of health care, companies have developed various diagnostics to 
trace redox imbalances (e.g. RedoxSYS
®
System, Oxidative Stress Analysis 2.0). 
Oxidative (and nitrosative) stress also holds great interests for exercise biochemists 
and physiologists as exercise training adaptations in healthy individuals are reflected 
by improvements in antioxidant capacity (Nikolaidis et al., 2007; Powers, Sollanek, 
Wiggs, Demirel, & Smuder, 2014; Soares et al., 2015). Moreover, the likelihood to 
develop overtraining (Tanskanen, Atalay, & Uusitalo, 2010) appears to be mediated 
by redox fluctuations, something that holds great interest for coaches and companies 
providing scientific support to athletes. In recent years, a variety of laboratory tests 
has been developed for the assessment of redox status indices in biological systems 
(Jackson, 1999) (de Zwart, Meerman, Commandeur, & Vermeulen, 1999; Holley & 
Cheeseman, 1993) but also a wide range of ‘applied’ testing services has been 
developed. 
In CKD, muscular weakness, muscle wasting and fatigue,  collectively termed 
as uremic myopathy, constitute functional and physiological abnormalities which 
characterize renal patients (Campistol, 2002). Previously, we (Research paper 2) and 
others (reviewed in (Kaltsatou et al., 2015)), have highlighted a role for oxidative 
stress in uremic myopathy in few but conclusive examinations of muscle tissue of 
CKD patients or animals. However, as in exercise studies (Bloomer, Fry, Falvo, & 
Moore, 2007; Bloomer, Goldfarb, & McKenzie, 2006; Deminice et al., 2010; 
Paschalis et al., 2007) and clinical literature (Gallou et al., 1994; Rockenbach et al., 
2011; Santulli et al., 2013; Sveen et al., 2015) the large majority of studies examining 
the role of ROS in CKD and discussing comorbidities, such as uremic myopathy, 
have reported increased levels of oxidative stress by only assessing indices in blood 
samples of CKD patients (Bober et al., 2010; Dolegowska et al., 2007; Filiopoulos et 
al., 2009; Guo et al., 2013; Papavasiliou et al., 2005; Sahni et al., 2012; Samouilidou 
& Grapsa, 2003).  Clearly popular blood indices such as TBARS and Protein 
Carbonyls reflect oxidative damage however there is no information about the 
Institutional Repository - Library & Information Centre - University of Thessaly
30/09/2018 04:54:58 EEST - 137.108.70.6
  
128 
 
specific tissue from which oxidative stress originates from and if uremic myopathy is 
implicated.  
There can be of course variable origins for the elevated concentrations of 
oxidative stress indices in blood. As with levels of other metabolic products and 
byproducts (e.g. glucose, lactate, protein etc), blood levels of ROS, whether at health 
or disease, at a given time point of sampling, reflect the dynamic balance between 
ROS generation and ROS removal. Firstly, a chronic systemic condition could result 
in a generalized elevation of these indices in all tissues of an individual. Secondly, 
increased levels of oxidative stress indices may reflect ROS production linked to 
damage in a particular tissue and probably constitute an early sign of disease 
emergence (e.g one kidney overworking as the other fails (Shah, Baliga, Rajapurkar, 
& Fonseca, 2007). Thirdly, increased indices in blood could be due to oxidative 
damage of the circulatory system per se (Arguelles, Garcia, Maldonado, Machado, & 
Ayala, 2004a). Still, many studies draw conclusions and form hypothesis with regards 
to muscle or other organ ROS levels by measuring only blood levels. 
This is an issue of importance not only for diagnosis but also for assessing 
benefit of intervention. For example, antioxidant supplementation, especially in HD 
patients is aid promising to counteract atrophy (R. Ramos & Martinez-Castelao, 2008; 
Tarng et al., 2004; Trimarchi et al., 2003). Since that skeletal muscle tissue sampling 
is difficult to obtain, there is no direct clinical evidence that antioxidant 
supplementation, could reliably reflect improvements in skeletal muscle redox status 
rather than a systemic benefit.  
In order to clarify whether the evaluation of redox status in less-invasive 
samples, like blood, reflects the redox status of skeletal muscle, the aim of the present 
study was to correlate and contrast indices of the glutathione system, as well as 
markers of lipid peroxidation, protein carbonylation and total antioxidant capacity in 
the blood and skeletal muscle of rabbits used as an animal model of CKD. Given that 
muscle’s mitochondria generate ROS in large quantities, and that slow muscle contain 
more mitochondria, we contrasted levels in two muscle types, a fast (psoas) and a 
slow twitch (soleus), at the two ends of the endurance-power continuum. 
 
Institutional Repository - Library & Information Centre - University of Thessaly
30/09/2018 04:54:58 EEST - 137.108.70.6
  
129 
 
Methods  
 
Animals and Experimental design 
 
New Zealand white female rabbits (young adult, N=15) with body weight of 
approximately 3200 kg, were first acclimatized to the laboratory animal unit of 
Medical School (University of Thessaly, Greece) for 48 hours. The animals were 
housed in a controlled environment with stable conditions of room temperature (RT) 
(22–24°C) and lighting (12:12 h light-dark cycle). All rabbits were fed with a special 
rabbit chow containing low levels of protein, potassium, calcium, phosphorus and 
sodium (prepared by Research Diets, Inc. USA) and water ad libitum. All animal 
procedures, including surgery and euthanasia for this project were approved by the 
ethics committee of the University of Thessaly (decision 2-2/10-10-2012) and the 
scientific committee of the University Hospital of Larisa, Greece (decision 1/4-1-2012 
and animals were under veterinary care, in accordance to the national directives for 
the care and the use of laboratory animals.  
After acclimatization, surgical procedures were performed (sham operation for 
control animals - Control group and partial nephrectomy for experimental animals – 
Uremic group.  Animals were anaesthetized by intravenous administration of a 
solution mixture of ketamine hydrochloride 100 mg/ml (Imalgene® 1000; Merial, 
Duluth, Georgia, USA) and xylazine 20 mg/ml (Rompun®; Bayer, Leverkusen, 
Germany), 87 % and 13 % respectively (proportion 6,69:1 approximately). The initial 
dosage for the induction of anesthesia was 0.3 ml/Kg body weight of the above 
solution mixture, i.e. Imalgene® (87%) and Rompun® (13%), intravenously (i.v.). 
The maintenance of anesthesia was achieved by a dose of propofol (10mg/kg BW). 
Three hours before the intervention, each animal had only access to water and not to 
food and its weight was measured on a precision scale. Animal temperature was 
maintained via a heating pad.  
The induction of renal insufficiency was performed surgically (using a surgical 
protocol modified from Gotloib et al., 1982 (Gotloib et al., 1982). For the Uremic 
group nine animals (N=9), underwent removal of the left kidney after careful ligation 
of the left renal artery and vein; and partial nephrectomy (¾) of the right kidney. For 
the Control group six age-matched animals (N=6) underwent sham operation. Twelve 
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weeks after surgery, the animals were weighed and then sacrificed by injection of 
sodium pentobarbital solution (50 mg/ml) which was applied in a dosage of 100 
mg/Kg BW followed by bilateral thoracotomy. Immediately after cardiac arrest, 
sample collections were done in a blind fashion. 
Sample Preparation 
Blood sampling and treatment 
Blood samples (5ml) were collected from the rabbits’ heart and aorta by a 
heparinized syringe and were placed into ethylene diamine tetra-acetic acid 
(K2EDTA)-containing tubes (Vacutainer Plus Plastic K2EDTA; Becton Dickinson). 
For plasma collection, blood samples were centrifuged immediately at 1370 × g for 
10 min at 4
ο
 C and the supernatant was carefully collected, aliquoted in multiple 
eppendorf tubes, stored at -80
o
C and thawed only once before analysis. The remained 
packed erythrocytes were lysed with 1:1 (v:v), distilled water, inverted vigorously, 
and centrifuged at 4000 × g for 15 min at 4ο C. The supernatant, red blood cells 
(RBCs) lysate designated, collected, aliquoted, stored at -80
ο
 C and thawed only once 
before analysis. Finally, in order to obtain serum, another portion of blood sample (5 
ml) was collected and placed into separate tubes containing clot activator, left for 20 
min to clot at RT and centrifuged at 1,370 × g, at 4°C for 10 min. The supernatant was 
collected, aliquoted in eppendorf tubes, stored at -80°C and thawed only once before 
analysis. 
 
Skeletal muscle sampling  
Psoas and soleus muscle samples were harvested from Control (sham-operated) 
and Uremic group, were frozen immediately in liquid nitrogen, stored at -80
ο
 C and 
part-thawed once (for homogenization) before final analysis. 
Skeletal muscle homogenization 
Tissues samples were thawed excised and kept chilled throughout 
homogenization. A weight portion of each muscle was washed several times with ice-
cold normal saline and was placed into pre-chilled epppendorfs containing cold 
homogenization buffer (138 mM NaCl, 2,7 mM KCl, 1 mM EDTA, pH 7.4) and a 
mix of protease inhibitors (1μΜ aprotinin, 1μg/ml leupeptin and 1mM PMSF). Initial 
homogenization was achieved with an electrical homogenizer (MICCRA D-9) for 10 
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minutes with intermediate pauses of 10sec/20 sec. Then an ultrasound homogenizer 
(UP50H) was used for 1-2 minutes, with intermediate pauses as before. Homogenates 
were filtered through four layers of medical gauze to remove connective tissue debris, 
incubated for 10 m in at 4
ο
 C, and centrifuged at 10,000 X g for 10min again at 4
ο
 C. 
The supernatant was aliquoted in multiple portions and stored at -80
ο
 C. 
Biochemical & Redox Status Indices Analyses 
Biochemical analysis in blood (urea, creatinine) and redox status indices (GSH, 
GSSG, Ratiio GSH/GSSG, GR-Reductase, CAT, TAC, TBARS and PC) analyses in 
blood as well as in skeletal muscle of control and uremic groups, were analyzed 
according to the assays described in the previous studies (Research Papers 1&2). 
 
Statistical Analysis 
Possible relationships between indices were examined using the Pearson 
Correlation Coefficient analysis in pool and per group data. The minimum 
significance level was set at P < 0.05.  
 
Results 
 
For each marker, the correlation between blood and skeletal muscle was 
evaluated in order to examine, firstly whether changes in blood levels reflected 
changes in skeletal muscle levels (whether in the sham-operated control or the uremic 
condition). Secondly, it was tested if there was evidence of muscle type specificity on 
the blood levels of the examined redox balance indices. 
A very strong and significant correlation between blood urea and creatinine 
levels, the two critical blood biochemistry markers for the diagnosis of renal 
insufficiency, in the Uremic group and pool data, but not in the Control group, 
verified that our animal model successfully mimicked chronic renal insufficiency. 
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Table 4.4.1. Pearson correlation (r) between blood levels of creatinine and urea levels in the 
pool and group data. 
 
 
 
 
 
For each one of the antioxidant or oxidative stress indices, statistical analysis didn’t 
show any significant correlation between blood and the two examined muscles’ levels 
neither in the pool of samples nor for each group separately (p>0.05).  
Table  4.4.2. Pearson correlation (r) between blood and skeletal muscle levels of redox indices in 
pool data, and separately in the Control and Uremic groups, psoas and soleus. Exact significance 
levels (p) are reported. 
GSH: reduced glutathione; GSSG: oxidized glutathione; TAC: total antioxidant activity; TBARS: thiobarbituric acid-
reactive substances; PC: protein carbonyls,  
 
Moreover, we examined the correlation between the critical blood 
biochemistry markers for the diagnosis of renal insufficiency, creatinine and urea, 
pool and group levels, with blood levels of the redox indices examined. While no 
relationship reached statistical significance it is noteworthy that in the pool data 
Creatinine levels tended to correlate with blood GSH (r=0.664, p=0.073). Likewise, 
Urea tended to correlate with blood GSH (r=0.655, p=0.078). 
 
 Pool Data                                
Blood  
Creatinine 
Control
Group 
Blood  
Creatinine 
Uremic 
Group 
Blood  
Creatinine 
 Pool Data                                
Blood UREA 
r=0.920*
p=0.000 
  
Control Group 
Blood UREA 
 r=0.779 
p=0.431 
 
Uremic Group 
Blood UREA 
  r=0.926* 
p=0.001 
 GSH GSSG GSH/G
SSG 
GR-
Reductase 
CAT TAC TBARS PC 
 Pool Data                                
Blood & Psoas 
r=0.123
p=0.719 
r=0.194 
p=0.567 
r=0.077 
p=0.822 
r=0.100 
p=0.757 
r=0.435 
p=0.137 
r=0.066 
p=0.832 
r=0.332 
p=0.268 
r=0.034 
p=0.913 
Pool Data                                
Blood & Soleus 
r=0.059
p=0.862 
r=0.518 
p=0.103 
r=0.532 
p=0.092 
r=0.553 
p=0.077 
r=0.093 
p=0.761 
r=0.400 
p=0.176 
r=0.402 
p=0.174 
r=0.008 
p=0.978 
Control Group 
Blood & Psoas 
r=0.359 
p=0.641 
r=0.408 
p=0.592 
r=0.071 
p=0.929 
r=0.451 
p=0.446 
r=0.311 
p=0.611 
r=0.416 
p=0.486 
r=0.214 
p=0.730 
r=0.480 
p=0.413 
Control Group 
Blood & Soleus 
r=0.229 
p=0.771 
r=0.543 
p=0.457 
r=0.221 
p=0.779 
r=0.639 
p=0.361 
r=0.449 
p=0.448 
r=0.039 
p=0.951 
r=0.726 
p=0.165 
r=0.740 
p=0.153 
Uremic Group 
Blood & Psoas 
r=0.004 
p=0.993 
r=0.089 
p=0.850 
r=0.197 
p=0.671 
r=0.152 
p=0.745 
r=0.152 
p=0.745 
r=0.503 
p=0.204 
r=0.776 
p=0.203 
r=0.385 
p=0.347 
Uremic Group 
Blood & Soleus 
r=0.388 
p=0.389 
r=0.452 
p=0.309 
r=0.727 
p=0.164 
r=0.538 
p=0.213 
r=0.538 
p=0.213 
r=0.519 
p=0.187 
r=0.452 
p=0.261 
r=0.174 
p=0.680 
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Table  4.4.3. Pearson correlation (r) between blood urea and creatine and blood levels of the 
redox indices examined in pool data, Control and Uremic group. 
GSH: reduced glutathione; GSSG: oxidized glutathione; TAC: total antioxidant activity; TBARS: thiobarbituric acid-
reactive substances; PC: protein carbonyls,  
 
Furthermore, we examined the correlation between the blood biochemistry 
markers, creatinine and urea, pool and group levels, with muscle levels of the redox 
indices examined. Neither in the Control nor in the Uremic group were there any 
statistically significant correlations observed between these two markers and soleus or 
psoas muscle levels of the redox indices. 
 GSH GSSG GSH/G
SSG 
GR-
Reductase 
CAT TAC TBARS PC 
 Pool Data                                
Urea 
r=0.655
p=0.078 
r=0.019 
p=0.965 
r=0.438 
p=0.277 
r=0.132 
p=0.716 
r=0.101 
p=0.769 
r=0.038 
p=0.911 
r=0.181 
p=0.595 
r=0.125 
p=0.713 
Pool Data                                
Creatinine 
r=0.664
p=0.073 
r=0.073 
p=0.864 
r=0.339 
p=0.411 
r=0.197 
p=0.586 
r=0.031 
p=0.929 
r=0.143 
p=0.676 
r=0.067 
p=0.844 
r=0.005 
p=0.988 
Control Group 
Urea 
r=0.113 
p=0.928 
r=0.241 
p=0.845 
r=0.062 
p=0.961 
r=0.988 
p=0.099 
r=0.293 
p=0.811 
r=0.375 
p=0.755 
r=0.419 
p=0.724 
r=0.942 
p=0.218 
Control Group 
Creatinine 
r=0.534 
p=0.641 
r=0.420 
p=0.724 
r=0.673 
p=0.530 
r=0.673 
p=0.530 
r=0.371 
p=0.758 
r=0.754 
p=0.456 
r=0.896 
p=0.293 
r=0.523 
p=0.649 
Uremic Group 
Urea 
r=0.614 
p=0.195 
r=0.180 
p=0.733 
r=0.641 
p=0.170 
r=-0.204 
p=0.661 
r=0.062 
p=0.883 
r=0.204 
p=0.628 
r=0.312 
p=0.452 
r=0.160 
p=0.705 
Uremic Group 
Creatinine 
r=0.495 
p=0.319 
r=0.262 
p=0.616 
r=0.683 
p=0.135 
r=-0.210 
p=0.651 
r=0.346 
p=0.401 
r=0.417 
p=0.305 
r=0.252 
p=0.547 
r=0.034 
p=0.936 
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Table  4.4.4. Pearson correlation (r) between blood urea and creatinine and psoas skeletal muscle 
redox status undices in pool data, Control and Uremic group. 
 
 
GSH: reduced glutathione; GSSG: oxidized glutathione; TAC: total antioxidant activity; TBARS: thiobarbituric acid-
reactive substances; PC: protein carbonyls,  
 
 
Table  4.4.5. Pearson correlation between blood urea and creatinine and  soleus skeletal muscle 
redox status undices  in pool data, Control and Uremic group 
GSH: reduced glutathione; GSSG: oxidized glutathione; TAC: total antioxidant activity; TBARS: thiobarbituric acid-
reactive substances; PC: protein carbonyls,  
PSOAS GSH GSSG GSH/G
SSG 
GR-
Reductase 
CAT TAC TBARS PC 
 Pool Data                                
Urea 
r=0.381
p=0.277 
r=0.372 
p=0.291 
r=0.205 
p=0.569 
r=0.398 
p=0.254 
r=0.104 
p=0.775 
r=0.264 
p=0.462 
r=0.111 
p=0.759 
r=0.222 
p=0.537 
Pool Data                                
Creatinine 
r=0.353
p=0.317 
r=0.420 
p=0.227 
r=0.338 
p=0.340 
r=0.393 
p=0.262 
r=0.034 
p=0.926 
r=0.269 
p=0.452 
r=0.49 
p=0.892 
r=0.349 
p=0.322 
Control Group 
Urea 
r=0.113 
p=0.918 
r=0.241 
p=0.845 
r=0.162 
p=0.961 
r=0.566 
p=0.617 
r=0.890 
p=0.305 
r=0.385 
p=0.715 
r=0.951 
p=0.201 
r=0.935 
p=0.218 
Control Group 
Creatinine 
r=0.534 
p=0.641 
r=0.420 
p=0.724 
r=0.573 
p=0.130 
r=0.075 
p=0.952 
r=0.408 
p=0.733 
r=0.873 
p=0.324 
r=0.547 
p=0.632 
r=0.323 
p=0.609 
Uremic Group 
Urea 
r=0.592 
p=0.162 
r=0.516 
p=0.236 
r=0.108 
p=0.818 
r=-0.622 
p=0.136 
r=0.280 
p=0.544 
r=0.362 
p=0.424 
r=0.484 
p=0.271 
r=0.047 
p=0.920 
Uremic Group 
Creatinine 
r=0.579 
p=0.173 
r=0.607 
p=0.149 
r=0.230 
p=0.620 
r=-0.679 
p=0.194 
r=0.307 
p=0.503 
r=0.393 
p=0.383 
r=0.493 
p=0.261 
r=0.101 
p=0.829 
SOLEUS GSH GSSG GSH/G
SSG 
GR-
Reductase 
CAT TAC TBARS PC 
 Pool Data                                
Urea 
r=0.345
p=0.364 
r=0.145 
p=0.709 
r=0.083 
p=0.277 
r=0.216 
p=0.577 
r=0.437 
p=0.207 
r=0.019 
p=0.959 
r=0.215 
p=0.551 
r=0.033 
p=0.928 
Pool Data                                
Creatinine 
r=0.419
p=0.262 
r=0.172 
p=0.658 
r=0.150 
p=0.700 
r=0.148 
p=0.703 
r=0.367 
p=0.297 
r=0.232 
p=0.520 
r=0.250 
p=0.485 
r=0.072 
p=0.842 
Control Group 
Urea 
r=0.055 
p=0.945 
r=0.162 
p=0.838 
r=0.439 
p=0.561 
r=0.673 
p=0.530 
r=0.972 
p=0.152 
r=0.725 
p=0.483 
r=0.962 
p=0.177 
r=0.674 
p=0.529 
Control Group 
Creatinine 
r=0.900 
p=0.100 
r=0.213 
p=0.787 
r=0.233 
p=0.767 
r=0.173 
p=0.742 
r=0.906 
p=0.279 
r=0.134 
p=0.914 
r=0.921 
p=0.254 
r=0.988 
p=0198 
Uremic Group 
Urea 
r=0.380 
p=0.401 
r=0.246 
p=0.594 
r=0.181 
p=0.698 
r=-0.300 
p=0.514 
r=0.612 
p=0.144 
r=0.300 
p=0.513 
r=0.170 
p=0.716 
r=0.258 
p=0.577 
Uremic Group 
Creatinine 
r=0.457 
p=0.302 
r=0.341 
p=0.455 
r=0.323 
p=0.479 
r=-0.274 
p=0.552 
r=0.590 
p=0.163 
r=0.281 
p=0.541 
r=0.221 
p=0.633 
r=0.318 
p=0.487 
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However there were significant correlations analysis results between the two 
different types of skeletal muscle and in a way indicative of disease-induced 
modifications. Although in the Control group there was no significant correlation in 
redox status indices between two different types of skeletal muscle (p>0.05), in the 
Uremic group there was significant correlation between psoas and soleus muscle in 
PC levels (r=0.913, p=0.002), in GSSG levels (r=0.766, p=0.027) levels and in CAT 
levels (r=0.743, p=0.035) respectively (Fig. 4.4.1).  
 
Fig.4.4.1. Correlation of redox indices between the two different types of skeletal muscle studied for 
CON (left) and UREM (right) samples. PC concentration, A: no significant correlation B: r=0.913, 
p=0.002. GSSG concentration C: no significant correlaion, D: r=0.766, p=0.027.  CAT activity, E: no 
significant correlation, F: r=0.743, p=0.035 between psoas and soleus muscle in Control and Uremic 
group respectively. 
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Discussion 
 
In the present study we observed that there was no correlation between the  
redox indices evaluated in the blood and their levels in the two different types of 
skeletal muscle (psoas, soleus). However we observed significant correlations in 
critical redox indices between the two different types of skeletal muscle only in the 
Uremic group indicating a disease-induced modification, in agreement to previous 
results. Also, a tendency existed for key biochemical indices, such as urea and 
creatinine, to correlate with blood redox status markers in the Uremic samples but not 
in the Control. 
As it is the case with levels of other metabolic products and byproducts (e.g. 
glucose, lactate, protein etc), blood levels of ROS at a given time point of sampling, 
whether in health or disease, reflect the dynamic balance between ROS generation 
and ROS neutralization. The origin of the ROS (or RNS), and their levels at the point 
of origin cannot be easily surmised. If a disease state is implicated then not only the 
primarily suffering organic system could be contributing to a redox imbalance (as e.g. 
in kidney disease (Shah et al., 2007)but also secondarily affected systems (e.g. 
muscle), as well as systemic inflammation (Lim, Cheng, et al., 2002; Silverstein, 
2009)and vascular stress (Arguelles, Garcia, Maldonado, Machado, & Ayala, 2004b) 
could be implicated. 
In this study, by employing an animal model of CKD, we sought to examine 
whether the increased levels of oxidative stress observed in the blood (Research Paper 
1) reflect perhaps the muscle levels of redox indices (Research Paper 2).  
We found no correlations between blood and skeletal muscle levels of redox 
indices either in the pool data, or separately in the Control and Uremic groups, for 
psoas and soleus muscle samples. In a previous study (Research Paper 2) we observed 
that PC levels were significantly increased in both muscle types of the UREM 
samples and that soleus muscle (whether in Control or Uremic) presented with 
significantly higher GSH, CAT and Gr-reductase but also TBAR levels compared to 
psoas. Our blood analysis did not reflect the muscle PC levels nor any muscle type 
specific attributes. It is possible that the development of uremic myopathy (and thus 
skeletal muscle’s contribution to oxidative stress) was not so advanced as to be 
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reflected in blood levels. A study from our group (Mitrou, Galler, & Karatzaferi, 
2015) indicated a moderate atrophy of about 11% in psoas muscle and we have no 
data on soleus. Based on human studies however we expect that fast muscles are the 
ones mostly affected by atrophy (Sakkas, Ball, et al., 2003) and the increased protein 
carbonylation observed in our psoas muscle re-iterate the human observations.  
The lack of correlations between redox indices’ levels in blood and muscle 
samples in our study do not agree with a recent rat study. Veskoukis et al (2009) 
reported that four redox status indices (PC, GSH, GSSG, Catalase) in blood could 
adequately reflect the redox status at rest, after exercise and/or following xanthine 
oxidase inhibition in skeletal muscle (gastrocnemius, which has a different myosin 
composition than rabbit psoas) (Veskoukis, Nikolaidis, Kyparos, & Kouretas, 2009). 
Moreover, blood GSSG was found in that study to correlate strongly with muscle, 
liver and heart GSSG levels. Animal model, techniques differences and the renal 
dysfunction it is possible that may have an overarching systemic effect that could 
mask muscle’s contribution to blood levels of redox indices in our data. Likewise, it is 
possible that the sham-operation also played a similar role. Moreover we should also 
note that it is not clear if in the study by Veskoukis et al the analysis for GSSG 
included an alkylating agent to preserve its levels, as done in the present work 
(Research Paper 1&2) thus precluding comparison due to methodological differences. 
As already discussed (Research Paper 3) in the literature for the majority of 
patient studies redox status indices are evaluated in blood and results are extrapolated 
to tissues. Rodriguez et al (2012) found that protein carbonyls concentrations 
moderately correlated between blood and skeletal muscle (vastus lateralis, a mixed 
muscle) in patients with chronic obstructive pulmonary disease (Rodriguez et al., 
2012). We cannot exclude that in advanced CKD patients PC muscle levels may be 
also reflected in blood. The increased protein carbonylation observed in our psoas 
muscle re-iterate the human observations and perhaps indicate that increased muscle 
PC levels is one of the earliest redox modifications occurring in uremic muscle. 
The present study was the first to evaluate the relationships between redox 
status indices in the blood and skeletal muscle under renal insufficiency. Notably, we 
observed that none of the redox status indices examined in the two different types of 
skeletal muscle, was reliably reflected in the blood.  Based in the above findings, it 
seems that there is no correspondence between blood and skeletal muscle redox status 
indices in CKD, demonstrating that tissue specific redox status changes do not cause 
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corresponding changes that can be measured in blood, unfortunately inhibiting our 
ability to use blood testing to monitor muscle redox status in pre-dialysis patients.  
However, we also examined if disease severity, as reflected in blood levels of 
creatinine and urea are associated with either blood or muscle redox status. We 
observed a tendency for Creatinine and Urea blood levels in the pool data to correlate 
with blood GSH. We have previously discussed that blood GSH levels are 
upregulated as an adaptive response to disease (Research Paper 1), in agreement to 
human studies (Bober et al., 2010). Perhaps, if verified by further work, clinicians 
which use blood creatinine and urea levels to monitor CKD progression could also 
develop threshold values to flag up redox disturbances. 
Significant correlations of redox status indices among the two types of skeletal 
muscle (psoas, soleus), were found only for the Uremic group and not for the Control 
group, in PC, GSSG and CAT levels between psoas and soleus muscle levels. This 
discrepancy indicated that the experimentally induced chronic renal insufficiency 
posed an appreciable redox challenge for skeletal muscle in the Uremic groups, whose 
samples presented with a coordinated variability in redox levels (in contrast to 
Control). Specifically, increasing GSSG and PC levels (the latter significantly 
increased in both Uremic soleus and psoas vs Controls – Research Paper 2) indicated 
disease-induced oxidative damage in both muscle types, which in turn stimulated the 
activation of the antioxidant enzyme CAT  (found to be significantly higher in soleus 
muscles overall – Research Paper 2). 
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Conclusion 
 
In our study we found that blood levels of the redox status indices examined 
(PC, GSH, GSSG, CAT, Cr-Reductase, TBARS, TAC) did not reflect psoas or soleus 
muscle concentrations. However, we observed that chronic renal insufficiency 
disturbed skeletal muscle’s redox status in such a way as to create associat ions 
between psoas and soleus, two muscles with distinct metabolic profiles, in indices 
such as PC, GSSG and CAT, which were not evident in control muscles. Moreover, 
critical biochemistry indices such as creatinine and urea tender to associate with blood 
GSH. Certainly, generalised conclusions based only on a single study cannot be 
drawn, and further studies are needed to verify or not these findings. Moreover, it is 
possible that other muscle redox indices, not examined here (such as advanced 
oxidation protein products AOPSS, F2 isoprostnane, advanced glycosylation end-
product AGE (Drueke et al., 2002)), could have a better reflection in blood levels in 
pre-dialysis CKD. However, we examined redox markers which are popular and 
affordable. Thus, based on our observations, caution should be taken when 
interpreting the literature and designing further studies to examine the contribution of 
oxidative stress in the pathophysiology of chronic disease, especially chronic renal 
insufficiency.  
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5. General Discussion 
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This PhD Thesis is a modest contribution to the ongoing discussion about 
“Redox status in Chronic Kidney disease” and its effects on patients. We used an 
animal model of renal disease (surgically induced partial nephrectomy in New 
Zealand rabbits) where confounding factors, common in human studies, such as 
comorbidities and pharmacological treatment are not implicated. Renal insufficiency 
was induced by removal of the right kidney and partial nephrectomy of the left kidney 
(for the Uremic group and sham-operation for Control animals). 
Specifically, we evaluated a variety of redox status indices, oxidative stress 
indices as well as antioxidant molecules and enzymes in blood and in two different 
types of skeletal muscle, in the fast glycolytic psoas and in the slow oxidative soleus. 
Moreover, we evaluated the effects of CKD on biochemical and hematological status. 
We also examined whether the oxidative stress markers measured in blood adequately 
reflects redox status in skeletal muscle and whether redox status in psoas muscle 
adequately depicts the redox status in soleus muscle. Moreover, it was examined if 
blood urea and creatinine levels had any possible reflection on blood and skeletal 
muscle redox status and if there is a correlation between urea and creatinine levels. 
 Regarding redox status analysis in blood, our major findings indicated that 
GSH concentration was significantly higher in the erythrocytes of the Uremic group 
compared to the Control and that there was a tendency for an increase in TBARS 
concentration in the plasma of Uremic group compared to Control. The rest of the 
redox status indices did not show any significant differences or tendencies between 
the Control and the Uremic group. 
As far as the redox status evaluation in skeletal muscle is concerned, our study 
addressed increased PC levels in skeletal muscle, by approximately 1.82 fold for 
psoas and 2.71 fold for soleus in Uremic compared to Control samples. Moreover, we 
observed significant differences between the two skeletal muscle types (psoas and 
soleus) studied. Specifically, Total protein and TAC concentrations were found to be 
decreased in soleus muscle compared to psoas in both Control and Uremic group. 
Additionally, soleus demonstrated higher levels of TBARS and PC levels as well as 
higher GSH levels, Catalase and GR-Reductase activities compared to psoas muscle 
in both the Control and Uremic group with Uremic soleus to demonstrate further 
increased GSH levels and GR-Reductase and CAT activities. 
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Additionally our study systematically examined a range of biochemical and 
hematological indices. Results indicated that there was no change in blood lipid and 
glucose profile of the Uremic group as compared to the Control group. 
However, there were significant differences in hematological parameters 
between the Control and the Uremic group. RBC, hematocrit and MCH levels were 
found to be decreased in the Uremic group and MCV had a tendency to decrease in 
the Uremic group compared to the Control group. Overall, in the Uremic group, the 
RBC, Hemoglobin, hematocrit and MCH levels were at the lower limits of 
physiological reference values. 
Finally, in the present study we observed that there was no correlation between 
the redox indices evaluated in the blood and their levels in the two different types of 
skeletal muscle (psoas, soleus) respectively. However we observed significant 
correlations in critical redox indices (PC, GSSG and CAT) between the two different 
types of skeletal muscle only in the Uremic group. Also, a tendency existed for key 
biochemical indices, such as urea and creatinine, to correlate with the blood 
antioxidant molecule (GSH) in the Uremic samples but not in the Controls. 
As far as redox status evaluation in blood is concerned, past studies suggested 
that oxidative stress is implicated in CKD pathophysiology. There is evidence that as 
the kidney function is getting worse, the redox status imbalance becomes more 
profound.  However, very limited information existed about redox changes in early 
CKD stages and whether antioxidant capacity or ROS overproduction (or both) may 
be altered. Our study tries to answer such open questions.  
There is an ambivalence with regards to GSH blood levels in human patient 
studies (having been found lower (Drai et al., 2001; Lim, Cheng, et al., 2002; 
Schettler et al., 1998) or higher (Biasioli et al., 1996; Bober et al., 2010; Stepniewska 
et al., 2006) in various HD studies). In moderately uremic pre-dialysis patients, in 
agreement to our observations, Bober et al showed higher levels of GSH in whole 
blood of CKD patients compared to age-matched healthy (Bober et al., 2010) (which 
increased further in HD patients). However, in other studies a reduction in GSH levels 
in the whole blood of CKD patients has been observed compared to controls (Annuk 
et al., 2001; Ceballos-Picot et al., 1996; Sahni et al., 2012) reflecting a depletion in 
the antioxidant reserve. Overall, the increased GSH blood levels in our study could be 
the result of an adaptive response to the uremic environment. The latter appears more 
likely in our case given the almost doubling of blood GSSG in the Uremic group 
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(Uremic levels being 1.77 fold of those of Controls) which, without reaching 
statistical significance, indicated increased levels of hydrogen peroxide or lipid 
peroxides, similarly to human studies (Annuk et al., 2001).  
Nonetheless, catalase also reduces hydrogen peroxide to water but there was no 
statistical difference in the activity of the specific antioxidant enzyme between the 
Control and the Uremic group (rather its activity tended to be lower in erythrocytes of 
the Uremic group). Based on the above, it appeared that hydrogen peroxide 
scavenging was undertaken in a greater degree by the glutathione redox cycling 
mechanism than catalase in our CKD model.  
The significant increase of GSH in uremic blood samples could also explain the 
observed, largely undisturbed, TAC and carbonylation levels of blood proteins. In our 
study animals followed the same diet, carefully designed not to tax the remaining 
kidney function, similarly to diet guidelines followed by patients, while providing 
balanced nutrients and minerals. However, dietary intakes can greatly influence GSH 
levels, and could explain the literature’s conflicting reports with regards to human 
patients’ GSH levels.   
In our work we developed our methodology (data not shown) to prevent 
artifacts during GSH and GSSG titration, with the most important one being a 5-15% 
oxidation of GSH during sample deproteination with acids. This artifact can lead to 
remarkable overestimation of GSSG (Rossi et al., 2002) and underestimation of total 
GSH. Thus we applied the thiol alkylating agent NEM at the preparatory stages to 
prevent the oxidation of GSH. In the conflicting patient studies on GSH and GSSH 
findings (Annuk et al., 2001; Bober et al., 2010; Ceballos-Picot et al., 1996; Sahni et 
al., 2012) it is not clear if such measures were always taken. Notwithstanding the 
above, it should be also noted that blood levels of GSH, as a ‘systemic’ marker, 
cannot reveal its origins. However, its increased levels in circulation confer an 
antioxidant advantage preventing or ameliorating vascular and other damage.  
The increased (but not statistically significant) plasma TBARS levels by 
approximately 1.4 fold, in Uremic compared to Control samples, point to increased 
levels of lipid peroxidation, a process where oxidants, such as free radicals, assault 
lipids and especially their membranes (Ayala et al., 2014), leading to alterations of 
cell’s quality and survival. Regarding HD patients, the large majority of studies 
reported increased TBARS levels in plasma compared to healthy individuals (Bober 
et al., 2010; Dimitrijevic et al., 2012; Guo et al., 2013; Haklar et al., 1995; Sakata et 
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al., 2008; Sommerburg et al., 1998), reflecting extensive lipid peroxidation. Taking all 
the above into consideration together with our findings, it could be concluded that 
lipid peroxidation in CKD emerges even from the early stages and is getting worse 
during the progression of the disease.  
Given that skeletal muscle contains high levels of fibrillar proteins, and that 
their turnover is quite slow, skeletal muscle becomes extremely susceptible to free 
radical oxidation with adverse functional outcomes. We observed increased protein 
carbonylation in both muscle types of our Uremic group. Our findings are in 
agreement with those reported by Lim et al (Lim, Cheng, et al., 2002) in skeletal 
muscle of uremic patients on HD. The increased levels of PC in a pre-dialysis stage of 
CKD, as it was observed in our study, could be regarded as a very interesting finding 
for the time point of protein oxidation, revealing the early emergence of oxidative 
damage to protein content. Taking into account the role of carbonyl stress in vascular 
damage (Chen et al., 2013) and the general functionality of muscle, an early 
countermeasure for protein oxidation could be of great importance for patients before 
they move into the end-stage where the negative effects on muscle status may become 
irreversible.  
Skeletal muscle is a heterogeneous tissue which consists of a large diversity of 
fiber types. This heterogeneity in muscle type composition determines distinct 
biochemical and structural characteristics which in turn are responsible for the variety 
of physiological and metabolic functions (Essen-Gustavsson et al., 1992; Pette & 
Staron, 1990). In our study we examined the redox status of two different types of 
skeletal muscle, the slow twitch soleus and the fast twitch psoas in order to observe 
their possible different response in the uremic environment. Consistently to the two 
muscle type differences in mitochondrial content, TBARS levels were higher in 
soleus muscles than psoas, irrespective of group. 
Among other pathways, muscle catabolism is mediated by TNF-α/NF-κB 
signaling which in turn is affected from endogenous ROS. TNF-α widely excites 
mitochondria ROS production, promoting TNF-α/NF-κB activation (Hennet et al., 
1993; Schulze-Osthoff et al., 1992), a process which seems to be tissue specific (Y. P. 
Li et al., 1998). Taking into consideration that soleus muscle contains a higher amount 
of mitochondria, it would be rather logical that it would be more sensitive to NF-κB 
activation and therefore, to protein loss and muscle wasting. Our findings, where 
soleus muscle exhibited lower total protein levels, seem to confirm this observation. 
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Based on the increased amount of mitochondria in slow muscles (Engel, 1970), 
it could be expected that soleus may be more exposed to ROS and their negative 
effects, but also that it may develop an appropriate antioxidant capacity to withstand 
the oxidative load. Despite the reduced TAC levels in soleus muscle in comparison 
with psoas, the increased levels GSH, CAT and CR-reductase indicate than healthy 
soleus indeed demonstrates a higher antioxidant capacity than psoas, with uremic 
soleus appearing to have likewise further upregulated its defenses.  
We observed no changes in lipid profile between the Control and the Uremic 
group to point to the development of dyslipidemia (as usually observed in human 
patients). Perhaps more time was needed for our model of uremia to develop such 
changes in Cholesterol. Furthermore, diet composition is known to influence blood 
biochemical parameters and the animals of the present study were fed the same diet 
(3.5% fat content). Thus differences in our methods and species could also contribute 
to our results. Still, the observed tendency for increased lipid peroxidation (TBARS) 
in the plasma of the Uremic compared to the Control and the tendency for a higher 
Triglycerides/HDL ratio in the Uremic group fits well with a progressive atherogenic 
development due to chronic renal insufficiency. 
 However, there were significant differences in the levels of hematological 
parameters in the Uremic group as compared to the Control group. RBC count and 
Hematocrit levels were found to be decreased in the Uremic group. The mean 
corpuscular hemoglobin or mean cell hemoglobin (MCH) was significantly lower in 
the Uremic group. MCH reflects the average mass of hemoglobin per red blood cell, 
and lower values may be linked to hypochromic anemias and microcytic RBC. The 
latter is possible as we observed a tendency for lower mean corpuscular volume or 
mean cell volume (MCV), in the Uremic group. A possible explanation for the 
aforementioned hematological disturbances could be the expected impairment in the 
erythropoietin production and other factors which influence negatively the red cell 
production in bone marrow and the red cell lifespan. Moreover, apoptosis may be 
increased and contribute to the disturbed hematological status. A higher apoptotic rate 
could be hypothesized by the higher bilirubin levels in the experimental group. 
Overall, taking into consideration the fact that Hb, Hct and MCH levels and red blood 
cell count in the Uremic group were at the lower limits of rabbit physiological values 
it is concluded that these findings constitute early signs of anemia development. As 
previously discussed, despite USA and EU guidelines for the administration of EPO 
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in pre-dialysis stage patients this approach is not so much popular since anemia 
development may not be clear in the pre-dialysis patients. Our findings of low 
hematocrit and overall disturbed hematological parameters in an animal model of pre-
dialysis CKD further verify that our model represents an (untreated) human renal 
disease condition (when EPO is not supplemented). Taken together, our observations 
and the human data, and guidelines, these findings indicate that anemia could have a 
major role in disease development and symptoms severity and should be addressed as 
early as possible. 
The present study was the first to evaluate the relationships between redox 
status indices in the blood and skeletal muscle under renal insufficiency. It is known 
that blood levels of ROS at a given time point of sampling, whether in health or 
disease, reflect the dynamic balance between ROS generation and ROS neutralization. 
The origin of the ROS (or RNS), and their levels at the point of origin cannot be 
easily surmised. If a disease state is implicated then not only the primarily suffering 
organic system could be contributing to a redox but also secondarily affected systems 
(e.g. muscle), as well as systemic inflammation and vascular stress could be 
implicated. Notably, we observed that none of the redox status indices examined in 
the two different types of skeletal muscle, was reliably reflected in the blood. Based in 
the above findings, it seems that there is no correspondence between blood and 
skeletal muscle redox status indices in CKD, demonstrating that tissue specific redox 
status changes do not cause corresponding changes that can be measured in blood.  
Moreover, it is possible that the development of uremic myopathy (and thus skeletal 
muscle’s contribution to oxidative stress) was not so advanced as to be strongly 
reflected in blood levels. We cannot exclude that in advanced CKD, PC muscle levels 
may be also reflected in blood. The increased protein carbonylation observed in our 
psoas muscle re-iterate the human observations and perhaps indicate that increased 
muscle PC levels is one of the earliest redox modifications occurring in uremic 
muscle that could presumably be reflected in blood at a later stage. Perhaps the 
upregulation of blood GSH levels observed, acted to neutralize ROS in the blood 
inhibiting our ability to trace muscle redox status in uremic muscle. This, assumption 
is strengthened by the observation for a tendency for Creatinine and Urea blood levels 
in the pool data to correlate with blood GSH. Creatinine and urea reflect kidney 
disease severity. Perhaps, if verified by further work, clinicians which use blood 
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creatinine and urea levels to monitor CKD progression could also develop threshold 
values to flag up redox disturbances. 
The two muscle types are expected, due to the known differences in oxidative 
capacity, to have a different redox profile. Significant correlations of redox status 
indices among the two types of skeletal muscle (psoas, soleus), were found only for 
the Uremic group and not for the Control group, in PC, GSSG and CAT levels 
between psoas and soleus muscle levels. This discrepancy indicated that the 
experimentally induced chronic renal insufficiency posed an appreciable redox 
challenge for skeletal muscle in the Uremic groups, whose samples presented with a 
coordinated variability in redox levels (in contrast to Control). 
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Limitations of the study 
In the current research some potential weaknesses have been recognized that 
need to be acknowledged. Firstly, a bigger number of animals could perhaps give a 
more clear aspect of the tendencies for some indices examined, perhaps also including 
a non-operated control group. However, due to the high costs of the model and ethical 
considerations this was not possible. 
Secondly the evaluation of additional indices of oxidative damage such as 8-
OH-dG for DNA oxidative damage, isoprostanes for lipid peroxidation, advanced 
glycosylation end-products (AGEs) and advanced oxidation protein products 
(AOOPs) could perhaps add a more detailed picture of the redox status. We however, 
focused on popular techniques, reliably used in our and other laboratories. 
The lack of insulin sensitivity evaluation, and technical difficulties with regards 
to blood and muscle glycogen analysis, restricted our ability to address the possibility 
of the metabolic syndrome development in early CKD. Moreover, as we did not 
measure oxidized LDL we could not strongly address atherogenicity. Last but not 
least it was not possible to measure Erythropoietin levels in our animal model.  
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6. Concluding Remarks  
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In conclusion, the results of this work demonstrate that even in the pre-dialysis stages 
of CKD there is an emergence of oxidative stress in blood and as an adaptive response 
the antioxidant defense mechanisms are upregulated in order to preserve redox status 
homeostasis. Moreover in both types of skeletal muscle (psoas, soleus) carbonyl 
formation indicates an early stimulus of muscle protein degradation. However both 
oxidative damage and antioxidant response seem to be muscle type-specific. Our 
model of CKD shows that the lipid profile in this stage of the disease development 
does not seem to be disturbed to a great extent. However, an atherogenic development 
cannot be excluded and should be addressed early on. Still, we found a severely 
disturbed hematological profile in experimental animals.  This highlights that early 
recognition of anemia, in pre-dialysis stage, could play a key role it its treatment and 
could probably delay the progression of CKD. Last but not least, it was found that 
blood levels of the redox status indices did not reflect muscle concentrations and more 
work is needed in the direction of less invasive monitoring of muscle related redox 
imbalances. 
Overall, our results highlight the need for interventions early during disease 
progression in order to protect skeletal muscle quality, maintain redox balance and 
correct anemia, and thus allow patients to reach the end-stage at the best possible 
status. 
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Future perspectives: 
 
To complement these observations future work should investigate modified 
LDLs and insulin sensitivity in order to address the possibility of the metabolic 
syndrome development in early CKD.  
Our findings should be verified in human studies. While this is difficult to 
achieve due to ethical and practical constrains perhaps opportunity sampling (e.g. 
during fistula installation) could allow for muscle sample analysis in an advanced 
CKD stage.  
Last but not least, the lack of correlation between levels of blood and muscle 
indices doesn’t preclude the possibility that other redox markers or at a different 
disease state, less invasive blood diagnostics could be developed. 
 Another issue that probably should be discussed is the presence of two 
fundamental biological processes, authophagy and inflammation, which are involved 
in both physiological and pathological conditions. It has been suggested that CKD 
occurs partly due to imbalance between the molecular mechanisms that govern 
oxidative stress, inflammation, authophagy and cell death. Mounting evidence 
suggests that both oxidative stress and autophagy are significantly involved in CKD. 
However, limited information is available for understanding signaling pathways of 
autophagy and oxidative stress. As it is known, basal levels of redox signaling and 
autophagy signaling are necessary to preserve cellular homeostasis and to trigger 
cytoprotective pathways. Changes in autophagic flux have been shown to regulate 
ROS production. Similarly, several lines of evidence suggest that free radicals act as 
upstream modulators of autophagy induction. Therefore, is believed that there exists a 
two-way interaction between oxidative stress and autophagy, but there are important 
questions that still need to be answered. The specific signals regarding the molecular 
interactions between oxidative stress and autophagy remain to be uncovered. Specific 
therapeutic strategies that can regulate both oxidative stress and autophagy signaling 
are needed to benefit patients with CKD. 
 Inflammation process is regarded as the most common outcome of oxidative 
stress. ROS directly or indirectly can elevate inflammation, and trigger the expression 
of pro-inflammatory cytokines. Although the lack of inflammation indices’ evaluation 
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in our study could be considered as a limitation, the levels of leukocytes, a clinical 
marker of systemic inflammation, were between the normal ranges in both groups 
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APPENDIX Α 
Υπεύθυνη Δήλωση 
Η κάτωθι υπογεγραμμένη Κωνσταντίνα Πουλιανίτη με ΑΕΜ 16/2011, διδακτορική  
φοιτήτρια της Σχολής Επιστήμης Φυσικής Αγωγής και Αθλητισμού του 
προγράμματος ΄Ασκηση και Υγεία 
 δηλώνω υπεύθυνα ότι αποδέχομαι τους παρακάτω όρους που αφορούν  
(α) στα πνευματικά δικαιώματα της Διδακτορικής διατριβής μου μου με τίτλο 
«Μηχανισμοί της μυϊκής λειτουργίας: Η επίδραση της ουραιμίας στη βιοχημική 
κατάσταση και την ανοχή στο οξειδωτικό στρες» 
(β) στη διαχείριση των ερευνητικών δεδομένων που θα συλλέξω στην πορεία 
εκπόνησής της: 
1. Τα πνευματικά δικαιώματα του τόμου της μεταπτυχιακής ή διδακτορικής 
διατριβής που θα προκύψει  θα ανήκουν σε μένα. Θα ακολουθήσω τις οδηγίες 
συγγραφής, εκτύπωσης και κατάθεσης αντιτύπων της διατριβής στα ανάλογα 
αποθετήρια (σε έντυπη ή/και σε ηλεκτρονική μορφή).  
2. Η διαχείριση των δεδομένων της διατριβής ανήκει από κοινού σε εμένα και 
στον/στην κύριο επιβλέποντα -ουσα καθηγητή -τρια.  
3. Οποιαδήποτε επιστημονική δημοσίευση ή ανακοίνωση (αναρτημένη ή 
προφορική), ή αναφορά που προέρχεται από το υλικό/δεδομένα της εργασίας αυτής 
θα γίνεται με συγγραφείς εμένα τον ίδιο, τον/την κύριο-α επιβλέποντα -ουσα ή/και 
άλλους ερευνητές (πχ μέλη της τριμελούς συμβουλευτικής επιτροπής, συνεργάτες 
κλπ), ανάλογα με τη συμβολή τους στην έρευνα και στη συγγραφή των ερευνητικών 
εργασιών.  
4. Η σειρά των ονομάτων στις επιστημονικές δημοσιεύσεις ή επιστημονικές 
ανακοινώσεις θα αποφασίζεται από κοινού από εμένα και τον/την κύριο -α 
επιβλέποντα -ουσα της εργασίας,  πριν αρχίσει η εκπόνησή της. Η απόφαση αυτή θα 
πιστοποιηθεί εγγράφως μεταξύ εμού και του/της κύριου-ας επιβλέποντος -ουσας. 
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Τέλος, δηλώνω ότι γνωρίζω τους κανόνες περί δεοντολογίας και περί 
λογοκλοπής και πνευματικής ιδιοκτησίας και ότι θα τους τηρώ απαρέγκλιτα 
καθ’ όλη τη διάρκεια της φοίτησης και κάλυψης των εκπαιδευτικών 
υποχρεώσεων μου που προκύπτουν από το ΠΜΣ/τμήμα και καθ’ όλη τη διάρκεια 
των διαδικασιών δημοσίευσης που θα προκύψουν μετά την ολοκλήρωση των 
σπουδών μου. 
20/10/2012 
 
H δηλούσα 
Κωνσταντίνα Πουλιανίτη  
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APPENDIX B 
 
 
Εσωτερική Επιτροπή Δεοντολογίας 
  Τρίκαλα:10/10/12  
  Αριθµ. Πρωτ.: 631 
 
Αίτηση Εξέτασης της πρότασης για διεξαγωγή Έρευνας µε τίτλο: «Μηχανισµοί της 
µυϊκής λειτουργίας: η επίδραση της ουραιµίας στην βιοχηµική κατάσταση και την ανοχή 
στο οξειδωτικό στρες» 
 
Επιστηµονικώς υπεύθυνος-η / επιβλέπων-ουσα: Δρ. Χριστίνα Καρατζαφέρη 
Ιδιότητα: Επίκουρη 
Καθηγήτρια 
Ίδρυµα: Τ.Ε.Φ.Α.Α 
Τµήµα: Πανεπιστήµιο Θεσσαλίας 
 
Κύριος ερευνητής-τρια / φοιτητής-τρια: 
Κωνσταντίνα Πουλιανίτη Πρόγραµµα 
Σπουδών: Απόκτηση διδακτορικού διπλώµατος 
Ίδρυµα: Τ.Ε.Φ.Α.Α 
Τµήµα: Πανεπιστήµιο Θεσσαλίας 
Η προτεινόµενη έρευνα θα είναι: 
Ερευνητικό πρόγραµµα X  Μεταπτυχιακή διατριβή □    Διπλωµατική εργασία □   
Διδακτορική έρευνα   Χ 
 
Τηλ. επικοινωνίας: 6975584990 
Email επικοινωνίας: poulianiti.konstantina@yahoo.gr 
 
 
 
Η Εσωτερική Επιτροπή Δεοντολογίας του Τ.Ε.Φ.Α.Α., Πανεπιστηµίου 
Θεσσαλίας µετά την υπ. Αριθµ. 2-2/10-10-2012 συνεδρίασή της εγκρίνει τη 
διεξαγωγή της προτεινόµενης έρευνας. 
O Πρόεδrος της Εσωτερικής Επιτροπής Δεοντολογίας – ΤΕΦΑΑ 
 
 Τσιόκανος Αθανάσιος Αναπλ. Καθηγητής 
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APPENDIX C 
Σύσταση τροφής κονίκλων 
D30006 and D07122101 
Low Phytoestrogen Rabbit Diet and Same With Lower Protein, Potassium, 
Calcium,Phosphorus, and Sodium 
 
 
Product # D30006 D07122101 
 gm% kcal% gm% kcal% 
Protein 17.8 22 8.9 11 
Carbohydrate 55.0 68 63.6 79 
Fat 3.5 10 3.5 10 
Total  100  100 
kcal/gm 3.23  3.21  
     
Ingredient gm kcal gm kcal 
Casein, 30 Mesh 175 700 87.5 350 
DL-Methionine 3 12 1.5 6 
     
Corn Starch 390 1560 459 1836 
MaltoDextrin 10 25 100 25 100 
Sucrose 125 500 145 580 
     
Cellulose, BW200 150 0 150 0 
Inulin 25 0 25 0 
     
Soybean Oil 35 315 35 315 
     
Mineral Mix S30003 60 0 0 0 
Mineral Mix S39102 0 0 60 0 
     
Vitamin Mix V30002 10 40 10 40 
Choline Bitartrate 2 0 2 0 
     
Sodium Bicarbonate 0 0 4 0 
     
Total 1000 3227 1004 3227 
     
gm%     
Potassium 1.0  0.25  
Calcium 0.8  0.4  
Phosphorus 0.5  0.126  
Sodium 0.2  0.2  
Chloride 0.3  0.2  
Iron 0.01  0.01  
 
                                 Formulated by E.A. Ulman, Ph.D., Research Diets, Inc., 7/9/01. 
                   Using purified ingredients, this diet matches Purina 5321.It is very low in phytoestrogens. 
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APPENDIX D 
 
 
 
 
 
 
 
 
 
 
References: (Dontas et al., 2011; Hewitt, Innes, Savory, & Wills, 1989; MediRabbit.com) 
 
Biochemical and Hematological reference 
values for New Zealand rabbits 
Total Cholesterol (mg/dl) 10-80 
HDL Cholesterol (mg/dl) 15-30 
LDL Cholesterol (mg/dl) 20-40 
Triglycerides (mg/dl) > 155 
Glucose (mg/dl) 75-140 
Bilirubin (mg/dl) <1,16 
Uric acid (mg/dl) 1-4.3 
Leykocytes (10^3/μL) 5.1-13 
Red Blood Cells (10^6/mm3) 3.8-7.9  
Hemoglobin (g/dl) 9.4-17.4 
Hematocrit (%) 26.7-47.2 
MCV (mm3) 50-75 
MCH (pg/cell) 18-24 
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APPENDIX E 
 
 
 
 
 
 
 
 
 
 
 
 
 
Redox status and Biochemical profile in a typical New 
Zealand rabbit (no intervention) analyzed in our 
laboraties. 
 mixed muscle blood 
Total Protein (mg/ml) 5,43 68,415 
Uric acid (mg/dl) 0,437 0,680 
GSH (μmol/gr protein) 3,21  
GSSG (μmol/gr protein) 0,148  
Ratio (GSH/GSSG) 22  
GR Reductase (U/gr protein) 7,482 218,269 
TAC (μmol DPPH/ml) 0,675 0,749 
CAT (U/mg protein) 24,16 328,980 
PC (nmol/mg protein) 0,167 0,625 
TBARS (nmol/ml) 3,378 5,663 
Total Cholesterol (mg/dl) 10,45 113,500 
HDL (mg/dl)  57,850 
LDL (mg/dl)  35,550 
Triglycerides (mg/dl) 172 100,5 
Glucose (mg/dl)  438,000 
Bilirubin (mg/dl)  0,170 
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